
<html lang="en"     class="pb-page"  data-request-id="1a6403cc-1ab8-4965-9b83-6b5391eebb39"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-9;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c00003;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis" /></meta><meta name="dc.Creator" content="Abraham L.  Moure" /></meta><meta name="dc.Creator" content="Gagandeep  Narula" /></meta><meta name="dc.Creator" content="Flavia  Sorrentino" /></meta><meta name="dc.Creator" content="Adama  Bojang" /></meta><meta name="dc.Creator" content="Clement K. M.  Tsui" /></meta><meta name="dc.Creator" content="Carine  Sao Emani" /></meta><meta name="dc.Creator" content="Esther  Porras-De Francisco" /></meta><meta name="dc.Creator" content="Beatriz  Díaz" /></meta><meta name="dc.Creator" content="María José  Rebollo-López" /></meta><meta name="dc.Creator" content="Pedro Alfonso  Torres-Gómez" /></meta><meta name="dc.Creator" content="Eva María  López-Román" /></meta><meta name="dc.Creator" content="Isabel  Camino" /></meta><meta name="dc.Creator" content="Patricia  Casado Castro" /></meta><meta name="dc.Creator" content="Laura  Guijarro López" /></meta><meta name="dc.Creator" content="Fátima  Ortega" /></meta><meta name="dc.Creator" content="Lluis  Ballell" /></meta><meta name="dc.Creator" content="David  Barros-Aguirre" /></meta><meta name="dc.Creator" content="Modesto  Remuiñán Blanco" /></meta><meta name="dc.Creator" content="Yossef  Av-Gay" /></meta><meta name="dc.Description" content="Screening of a GSK-proprietary library against intracellular Mycobacterium tuberculosis identified 1, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compoun..." /></meta><meta name="Description" content="Screening of a GSK-proprietary library against intracellular Mycobacterium tuberculosis identified 1, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compoun..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 10, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00003" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00003" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00003" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00003" /></link>
        
    
    

<title>MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00003" /></meta><meta property="og:title" content="MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0010.jpeg" /></meta><meta property="og:description" content="Screening of a GSK-proprietary library against intracellular Mycobacterium tuberculosis identified 1, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compound is a prodrug that is bioactivated by the mycobacterial enzyme MymA. A hit-expansion program including design, synthesis, and profiling of a defined set of analogues with optimized drug-like properties led to the identification of an emerging lead compound, displaying potency against intracellular bacteria in the low micromolar range, high in vitro solubility and permeability, and excellent microsomal stability." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00003"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00003">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00003&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00003&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00003&amp;href=/doi/10.1021/acs.jmedchem.0c00003" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4732-4748</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02164" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00007" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against <i>Mycobacterium tuberculosis</i></span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Abraham L. Moure</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abraham L. Moure</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>A.L.M.: email, <a href="/cdn-cgi/l/email-protection#02636070636a636f2c7a2c6e6d726778426571692c616d6f"><span class="__cf_email__" data-cfemail="49282b3b282128246731672526392c33092e3a22672a2624">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abraham+L.++Moure">Abraham L. Moure</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0255-1036" title="Orcid link">http://orcid.org/0000-0003-0255-1036</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gagandeep Narula</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gagandeep Narula</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine,  Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gagandeep++Narula">Gagandeep Narula</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Flavia Sorrentino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Flavia Sorrentino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Flavia++Sorrentino">Flavia Sorrentino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adama Bojang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adama Bojang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine,  Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adama++Bojang">Adama Bojang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Clement K. M. Tsui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Clement K. M. Tsui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Clement+K.+M.++Tsui">Clement K. M. Tsui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carine Sao Emani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carine Sao Emani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carine++Sao+Emani">Carine Sao Emani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Esther Porras-De Francisco</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Esther Porras-De Francisco</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Esther++Porras-De+Francisco">Esther Porras-De Francisco</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Beatriz Díaz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beatriz Díaz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beatriz++D%C3%ADaz">Beatriz Díaz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">María José Rebollo-López</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">María José Rebollo-López</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mar%C3%ADa+Jos%C3%A9++Rebollo-L%C3%B3pez">María José Rebollo-López</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pedro Alfonso Torres-Gómez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pedro Alfonso Torres-Gómez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pedro+Alfonso++Torres-G%C3%B3mez">Pedro Alfonso Torres-Gómez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eva María López-Román</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eva María López-Román</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eva+Mar%C3%ADa++L%C3%B3pez-Rom%C3%A1n">Eva María López-Román</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Isabel Camino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Isabel Camino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Isabel++Camino">Isabel Camino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patricia Casado Castro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patricia Casado Castro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Casado+Castro">Patricia Casado Castro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laura Guijarro López</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura Guijarro López</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Guijarro+L%C3%B3pez">Laura Guijarro López</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fátima Ortega</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fátima Ortega</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=F%C3%A1tima++Ortega">Fátima Ortega</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lluis Ballell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lluis Ballell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lluis++Ballell">Lluis Ballell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Barros-Aguirre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Barros-Aguirre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Barros-Aguirre">David Barros-Aguirre</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4099-0438" title="Orcid link">http://orcid.org/0000-0002-4099-0438</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Modesto Remuiñán Blanco</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Modesto Remuiñán Blanco</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Diseases of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>M.R.B.: email, <a href="/cdn-cgi/l/email-protection#0964666d6c7a7d66276b277b6c647c60676867496e7a62276a6664"><span class="__cf_email__" data-cfemail="d4b9bbb0b1a7a0bbfab6faa6b1b9a1bdbab5ba94b3a7bffab7bb">[email protected]</span>m</a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Modesto++Remui%C3%B1%C3%A1n+Blanco">Modesto Remuiñán Blanco</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yossef Av-Gay</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yossef Av-Gay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine,  Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Y.A.-G.: email, <a href="/cdn-cgi/l/email-protection#bcc5d3cfcfd5fcd1ddd5d092c9dedf92dfdd"><span class="__cf_email__" data-cfemail="fa8395898993ba979b9396d48f9899d4999b">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yossef++Av-Gay">Yossef Av-Gay</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9547-0237" title="Orcid link">http://orcid.org/0000-0002-9547-0237</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00003&amp;href=/doi/10.1021%2Facs.jmedchem.0c00003" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4732–4748</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 10, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 January 2020</li><li><span class="item_label"><b>Published</b> online</span>10 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00003" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00003</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00003"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1060</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00003" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Abraham&quot;,&quot;last_name&quot;:&quot;L. Moure&quot;},{&quot;first_name&quot;:&quot;Gagandeep&quot;,&quot;last_name&quot;:&quot;Narula&quot;},{&quot;first_name&quot;:&quot;Flavia&quot;,&quot;last_name&quot;:&quot;Sorrentino&quot;},{&quot;first_name&quot;:&quot;Adama&quot;,&quot;last_name&quot;:&quot;Bojang&quot;},{&quot;first_name&quot;:&quot;Clement&quot;,&quot;last_name&quot;:&quot;K. M. Tsui&quot;},{&quot;first_name&quot;:&quot;Carine&quot;,&quot;last_name&quot;:&quot;Sao Emani&quot;},{&quot;first_name&quot;:&quot;Esther&quot;,&quot;last_name&quot;:&quot;Porras-De Francisco&quot;},{&quot;first_name&quot;:&quot;Beatriz&quot;,&quot;last_name&quot;:&quot;Díaz&quot;},{&quot;first_name&quot;:&quot;María&quot;,&quot;last_name&quot;:&quot;José Rebollo-López&quot;},{&quot;first_name&quot;:&quot;Pedro&quot;,&quot;last_name&quot;:&quot;Alfonso Torres-Gómez&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;María López-Román&quot;},{&quot;first_name&quot;:&quot;Isabel&quot;,&quot;last_name&quot;:&quot;Camino&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Casado Castro&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Guijarro López&quot;},{&quot;first_name&quot;:&quot;Fátima&quot;,&quot;last_name&quot;:&quot;Ortega&quot;},{&quot;first_name&quot;:&quot;Lluis&quot;,&quot;last_name&quot;:&quot;Ballell&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Barros-Aguirre&quot;},{&quot;first_name&quot;:&quot;Modesto&quot;,&quot;last_name&quot;:&quot;Remuiñán Blanco&quot;},{&quot;first_name&quot;:&quot;Yossef&quot;,&quot;last_name&quot;:&quot;Av-Gay&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4732-4748&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00003&quot;},&quot;abstract&quot;:&quot;Screening of a GSK-proprietary library against intracellular Mycobacterium tuberculosis identified 1, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compound is a prodrug that is bioactivated by the mycobacterial enzyme MymA. A hit-expansion program including design, synthesis, and profiling of a defined set of analogues with optimized drug-like properties led to the identification of an emerging lead compound, displaying potency against intracellular bacteria in the low micromolar range, high in vitro solubility and permeability, and excellent microsomal stability.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00003&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00003" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00003&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00003" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00003&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00003" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00003&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00003&amp;href=/doi/10.1021/acs.jmedchem.0c00003" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00003" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00003" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00003%26sid%3Dliteratum%253Aachs%26pmid%3D32275415%26genre%3Darticle%26aulast%3DMoure%26date%3D2020%26atitle%3DMymA%2BBioactivated%2BThioalkylbenzoxazole%2BProdrug%2BFamily%2BActive%2Bagainst%2BMycobacterium%2Btuberculosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D9%26spage%3D4732%26epage%3D4748%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291214" title="Bacteria">Bacteria</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290769" title="Suspensions">Suspensions</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/jmcmar.2020.63.issue-9/20200514/jmcmar.2020.63.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00003&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Screening of a GSK-proprietary library against intracellular <i>Mycobacterium tuberculosis</i> identified <b>1</b>, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compound is a prodrug that is bioactivated by the mycobacterial enzyme MymA. A hit-expansion program including design, synthesis, and profiling of a defined set of analogues with optimized drug-like properties led to the identification of an emerging lead compound, displaying potency against intracellular bacteria in the low micromolar range, high in vitro solubility and permeability, and excellent microsomal stability.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Tuberculosis (TB), an airborne disease whose main causative agent in humans is <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>), is currently considered the leading cause of death among communicable diseases. It is estimated that 10 million people worldwide developed active infection in 2018, with an estimated 1.5 million deaths during the same period.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The current treatment for drug-susceptible TB consists of a cocktail of four drugs for an overall period of 6 months with curation rates above 80%.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Treatment length and strong side effects caused by less-than-optimal chemotherapy have led to poor patient adherence and high default rates, strongly contributing to the emergence of multidrug-resistant (MDR-TB) and extensively drug resistant (XDR-TB) strains. Treatment options for this group of infected individuals show a moderate to low success rate (54% and 30% for MDR and XDR, respectively) and involve an even lengthier chemical treatment with stronger side effects, causing very low treatment compliance rates.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This vicious circle has been exacerbated by reduced investment in innovative therapies against TB during the second half of the past century, with a 40 years drought in regulatory approvals until bedaquiline and delamanid were approved as therapeutic agents against strains refractory to first-line drugs.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> Despite the recent boost experienced in TB drug development from public and private enterprises, a shorter duration treatment, with far less side effects and with a novel pharmacological effect to overcome antibiotic resistance, is yet to be achieved.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Antibacterial drug discovery heavily relied on whole-cell screening as a source for new antibiotics, a strategy only partially abandoned by the advent of target-based drug discovery. However, target-based approaches for discovering novel chemical entities has shown a poor performance in the antibacterial area, and therefore the scientific community is revisiting cell-based strategies.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> Phenotypic screening against <i>Mtb</i> have been historically carried out in liquid media under conditions optimized for bacterial growth. However, the dynamic environment bacteria encounter during the different stages of the disease and the metabolic adaptation of mycobacteria to the environmental pressure in the host has increased criticism regarding the suitability of such screenings.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> As an alternative, screening in <i>Mtb</i>-infected macrophages re-creates the natural environment bacteria encounter during macrophage infection and allows for bacterial metabolic adaptation inside the host cell. This model also accounts for compound permeability, active uptake, and/or efflux events within the host cell. It could be also used as a platform for identifying compounds that interfere and disrupt essential interactions in the host–guest interplay required for <i>Mtb</i> pathogenesis or even compounds that solely act as enhancers of the host immune response.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We have recently developed an intracellular high-throughput screening (HTS) against <i>Mtb</i>-infected THP-1 macrophage-like cells.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Using our approach, we have screened two GSK-proprietary libraries and identified a set of active, diverse chemical entities (undisclosed results). In this study, we present the biological profiling of the intracellular hit <b>1</b>, along with our attempts to elucidate the compound’s mode of action. We demonstrate that <b>1</b> behaves as a prodrug that is bioactivated by the mycobacterial FAD-containing monooxygenase MymA (enconded by the gene <i>mymA</i>, <i>Rv3083</i>). We also disclose the results of our medicinal chemistry program including the design, synthesis, and profiling of a set of active analogues with optimized drug-like properties.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Identification and Profiling of <b>1</b></h3><div class="NLM_p">Two GSK proprietary libraries (>80K compounds) were selected for high-throughput screening in <i>Mtb</i> infected THP-1 human-like macrophages using our intracellular assay.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><b>1</b>, a 2-(thioalkyl)benzoxazole derivative, was identified as a hit with a high potential for further progression based on its activity profile and chemical tractability. The compound showed an intracellular IC<sub>90</sub> value of 2.8 μM (0.9 μg/mL) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). It also presented activity in the extracellular assay (MIC = 10 μM). The compound displayed an acceptable property forecast index (PFI) value for a nonoptimized hit (PFI = 7.63),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> as well as excellent aqueous solubility and suboptimal solubility in fasted state simulated intestinal fluid (FaSSIF). <b>1</b> was inactive against a predefined panel of Gram-positive, Gram-negative bacteria, and other mycobacterial species, highlighting its specificity against <i>M. tuberculosis</i> (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Supporting Information, Table S1</a>), and presented a safe cytotoxicity profile in both HepG2 and THP-1 cell viability assays. Primary hepatocytes, which represent a model for metabolic toxicity,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> were also tested with <b>1</b> showing no signs of cytotoxicity at concentrations up to 100 μM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Profiling Details of Hit <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0003.gif" alt="" id="gr3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Mean value of <i>n</i> ≥ 2 experiments. In parentheses: value in μg/mL.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">HepG2: human caucasian hepatocyte carcinoma cell line.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">THP-1: human monocytic leukemia cell line.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">PFI: property forecast index, PFI = (ChromlogD<sub>7.4</sub>) + (no. of aromatic rings).</p></div></div><div></div></div><div class="NLM_p last"><b>1</b> was profiled against a predefined panel comprising a bundle of enzymes, transporters, receptors, and ion channels regulating key functions in humans (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Table S2</a>), showing a remarkable absence of off-target interactions in these targets.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The combined data indicate that <b>1</b> likely targets <i>Mtb</i> selectively and that its activity does not arise from a nonspecific cytotoxic event in the infected macrophage. We then moved on into screening compound <b>1</b> in an in vivo mice model of acute infection. Intratracheal H37Rv-infected C57BL/6 mice were treated with 200 mg/kg of <b>1</b> once per day for a time course of 8 days. Mice were codosed with CYP inhibitor 1-aminobenzotriazole (ABT, 50 mg kg<sup>–1</sup> day<sup>–1</sup>) to avoid rapid systemic clearance (vide infra).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Unfortunately, <b>1</b> did not display a statistically significant reduction of mycobacterial load in lung in our assay when compared to control specimens.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro DMPK-tox Assessment of <b>1</b></h3><div class="NLM_p">Metabolic stability of <b>1</b> in human and mouse liver microsomes was assessed. The results displayed a high metabolic turnover, with in vitro intrinsic clearance (Cl<sub>i</sub>) values of 5.8 and 131.5 mL/(min·g<sub>tissue</sub>) respectively. To gain an insight into the poor metabolic stability observed, we submitted <b>1</b> to an in silico predictive tool indicating the most likely site of metabolism caused by human liver enzymes. The sulfur atom was displayed as the most reactive moiety in the structure, with S-oxidation and S-dealkylation being the predicted metabolic transformations with the highest score (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Figure S1</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">Examples of metabolically labile structures featuring a alkylthio(hetero)aryl moiety from the literature indicated that upon S-oxidation, this structural motif could behave as a potential source of chemically reactive metabolites.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Reduced glutathione (GSH) is the most common trapping agent used for detection of chemically reactive metabolites in vitro.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compound <b>1</b> was incubated with human liver microsomes in the presence of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) and GSH. LCMS/MS analysis of the samples did not detect the presence of GSH-conjugates, suggesting that <b>1</b> is not susceptible of generating chemically reactive metabolites upon metabolization. Literature reports also indicated that molecules likely to generate reactive metabolites showed a positive correlation with the irreversible inhibition of the CYP family of enzymes.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> We tested the ability of compound <b>1</b> to irreversibly bind to the CYP3A4 isoform in a metabolism-dependent inhibition assay. <b>1</b> did not inhibit CYP3A4 activity, showing pIC<sub>50</sub> < 4.4 independent of the preincubation of the enzyme with <b>1</b> and with or without the presence of the cofactor. In light of the observed results, we suggest that neither the compound nor its metabolites behave as an irreversible inhibitor of CYP enzymes (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Tables S3 and S4</a>).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Mycobacterial-Mediated Bioactivation of <b>1</b></h3><div class="NLM_p">S-oxidation of sulfur-containing compounds is a well-studied mechanism of bioactivation inside mycobacteria. Approved drugs like ethionamide (ETH), isoxyl, and thiacetazone and more recent examples of investigational drugs behave as prodrugs that undergo bioactivation inside mycobacteria. <i>Mtb</i> flavin monooxigenases exemplified by EthA and MymA are the best studied activators of ETH.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> These literature precedents, together with the likely event of sulfur oxidative metabolism predicted by the in silico site of metabolism tool, led us to believe that <b>1</b> could behave as an antimycobacterial prodrug. The bioactivity of compound <b>1</b> was compared to a panel of previously described <i>ethA</i> and <i>mymA</i> mutant strains.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> As seen in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <i>mymA</i> mutants show increased resistance to <b>1</b>, while the <i>ethA</i> mutants demonstrate the same MIC values as the parental strain, H37Rv, suggesting that <b>1</b> is bioactivated by MymA.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Activity of <b>1</b> against a Panel of <i>mymA</i> and <i>ethA</i> Mutans Strains<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0004.gif" alt="" id="gr4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cross resistance of mutants to <b>1</b> was determined using the Alamar Blue resazurin assay. WT H37Rv is the parental strain. 2-RM1 is an <i>ethA</i> frameshift mutant, and 3-RM1 is a <i>mymA</i> operon deletion mutant. Rv3083::Tn is a transposon insertion mutant in <i>mymA</i> gene, and SG2 is an <i>ethA</i> and <i>mymA</i> double mutant.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Mtb Mutant Resistant to Compound <b>1</b> Is Mapped to mymA</h3><div class="NLM_p last">We selected mutants resistant to compound <b>1</b> by growing an <i>Mtb</i> H37Rv strain in the presence of 5 times the MIC concentration. One single resistant colony was isolated and confirmed to be resistant to compound <b>1</b> up to concentration of 38 μM. Whole genome sequencing (WGS) identified two single nucleotide polymorphism sites (SNPs) in this mutant when compared to its parental strain, an insertion (indel) of adenine nucleotide at position 382 of the <i>mym</i>A gene causing a frame shift, and a change of cytosine to thymidine at position 16 of the sugI gene (<i>Rv3331</i>) with a gained stop codon in this gene. Gene specific PCR sequence analysis of the mutated strain confirmed the insertion of the adenine nucleotide at position 382 of <i>mym</i>A and that the <i>eth</i>A gene remained intact, confirming that resistance to compound <b>1</b> is attributed to a single insertion mutation in <i>mymA</i>.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Hit Optimization of Compound <b>1</b></h3><div class="NLM_p">Three defined areas were identified for chemical modification around compound <b>1</b>: the heterocyclic scaffold (R1), the pyrrolidineamide moiety (R2) and the central linker containing the S-alkyl chain (R3) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Initial structure–activity relationhsip (SAR) efforts were directed toward (a) understanding the impact of discrete structural changes in the intracellular bioactivity and (b) assessing and mitigating microsomal stability across the family of new designed compounds.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural modifications around the hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00003&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Modifications on the <i>S</i>-Alkyl Chain</h4><div class="NLM_p">Replacing the sulfur atom or moving it across the chain had a negative impact on activity (compounds <b>2</b>–<b>5</b>; <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Sulfinyl and sulfonyl analogues were also synthesized and tested (compounds <b>1a</b> and <b>1b</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Figure S2</a>). Unfortunately, both showed rapid decomposition in aqueous solution, precluding compound profiling. Increasing the steric hindrance around the sulfur was well tolerated (compound <b>6</b>), although clearance values showed no improvement. Alkyl chain elongation was tolerated (compound <b>8</b>), whereas a reduction in chain length by one carbon was deleterious for activity (compound <b>7</b>). In line with this result, elimination of the alkyl chain (compound <b>9</b>) rendered the compound inactive.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Modifications of the <i>S</i>-Alkyl Chain</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0005.gif" alt="" id="gr5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Mean value of <i>n</i> ≥ 2 experiments. In parentheses: value in μg/mL.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">In vitro intrinsic microsomal clearance.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">PFI: property forecast index, PFI = (ChromlogD<sub>7.4</sub>) + (no. of aromatic rings).</p></div></div><div></div></div></div><div id="sec2_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Modifications of the Heterocyclic Scaffold</h4><div class="NLM_p">Placing the chlorine substituent in different positions around the benzoxazole moiety showed similar levels of intracellular activity (compounds <b>11</b> and <b>12</b>; <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) except when the substitution was next to the nitrogen atom (compound <b>10</b>). Chlorine replacement by other small functional groups with different size and electronic properties displayed potency levels in the same order of magnitude (compounds <b>13</b>–<b>16</b>). However, a larger morpholine group was detrimental for activity (compound <b>17</b>). The difluorosubstituted analogue <b>18</b> was equally active. The structural modifications described above showed no significant improvement in the in vitro metabolic stability profile of the molecule except in the case of compound <b>17</b>. Replacing the benzoxazole bicycle by a benzothiazole, a benzimidazole, or a phenyl-substituted oxazole (compounds <b>19</b>–<b>22)</b> rendered the molecule poorly active or inactive. A 3,4-dimethyloxazole was also nonactive, although it showed a remarkable improvement in metabolic stability (compound <b>23</b>). This improvement could be attributed to the stark reduction in lipophilicity observed when compared to the other tested analogues (a similar trend is observed between compounds <b>13</b>–<b>16</b> and <b>17</b>), suggesting a potential strategy for reduction of high metabolic turnover in the series (vide infra).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Nitrogen substitution in different positions of the benzoxazole ring led to nonactive derivatives (compound <b>24</b>–<b>26</b>), although there was a significant improvement in intrinsic clearance. This finding is interesting when compared to the profile of the active, unsubstituted benzoxazole <b>14</b>. While it could be implied that the nitrogen lone pair might have a negative interaction in the active site (and thus the lack of potency), we hypothesize that the introduction of a nitrogen atom in the benzoxazole renders the structure more electrodeficient and therefore the sulfur atom is less likely to be oxidized, precluding the bioactivation of the prodrug.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Modifications of the Heterocyclic Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0006.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Mean value of <i>n</i> ≥ 2 experiments. In parentheses: value in μg/mL. Cli is in vitro intrinsic microsomal clearance.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">PFI: property forecast index, PFI = (ChromlogD<sub>7.4</sub>) + (no. of aromatic rings).</p></div></div><div></div></div></div><div id="sec2_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Modifications of the Pyrrolidineamide</h4><div class="NLM_p">Methyl-substituted pyrrolidine (compounds <b>27</b> and <b>28</b>; <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) showed similar levels of potency only when substituted at the β position, whereas α substitution rendered the molecule poorly active. A difluoro-substituted pyrrolidine analog was equally potent (compound <b>29</b>). Moving the carbonyl group inside the pyrrolidine cycle or replacing this moiety by a cyclic sulfonamide displayed potency levels in the same order of magnitude (compouns <b>30</b> and <b>31</b>). However, the absence of the carbonyl group in either the pyrrolidine or the alkyl chain led to a substantial decrease in activity (compound <b>32</b>). Ring contraction was deleterious for activity, whereas replacement of pyrrolidine by a piperidine ring showed no impact in activity (compounds <b>33</b> and <b>34</b>). Tertiary acyclic amides were also tolerated although activity was dependent on the substituent size (compounds <b>35</b> and <b>36</b>). On the other hand, secondary acyclic amides were virtually inactive independent of the size of the substituent directly attached to the nitrogen atom (compounds <b>37</b> and <b>38</b>). Metabolic stability values across this subset of analogues suggested a direct correlation with lipophilicity. Following this underlying trend, polar six-membered ring replacements were devised and tested. A morpholine or <i>N</i>-(methyl)piperazine analogue displayed a lower metabolic turnover albeit lower activity levels (compounds <b>39</b> and <b>40</b>). The thiomorpholine dioxide analog displayed the best in vitro clearance profile across the series, although it turned out to be inactive (compound <b>41</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Modifications of the Pyrrolidineamide Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0007.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Mean value of <i>n</i> ≥ 2 experiments. In parentheses: value in μg/mL.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">In vitro intrinsic microsomal clearance.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">PFI: property forecast index, PFI = (ChromlogD<sub>7.4</sub>) + (no. of aromatic rings).</p></div><div class="footnote" id="t5fn6"><sup><sup>d</sup></sup><p class="last">Cyclopentyl group.</p></div></div><div></div></div></div><div id="sec2_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Identification of Structure–Property Trends</h4><div class="NLM_p">The SAR generated around <b>1</b> suggested an underlying correlation between intrinsic clearance and compound lipophilicity. This trend was easily spotted when Cl<sub>i</sub> data were plotted against measured PFI for the full set of analogues (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Two different areas were clearly identified: a region for compounds with PFI ≤ 6.5, where Cli values in human microsomes remained in most of the cases below 2 mL/(min·g<sub>tissue</sub>), and compounds with PFI > 6.5, for which clearance values showed a broad, random distribution. The data set was also color-coded, setting up a spectrum of color ranging from green to orange for compounds with an intracellular IC<sub>50</sub> in the range of 0.1 μM to 10 μM and from orange to red for compounds with activity in the range of >10 μM to 50 μM. The colored notation for activity brought up another emerging trend between bioactivity and PFI, with potency decaying as we move from high to low PFI compounds. Our attention was focused on compounds with PFI ≤ 6.5 and Cl<sub>i</sub> < 2 mL/(min·g<sub>tissue</sub>). Analogues with structural modifications that affect the electron density around the sulfur atom (compounds <b>23</b>–<b>26</b>) and those where the sulfur atom was replaced or moved (compounds <b>2</b>, <b>4</b>, and <b>5</b>) were deemed less interesting for further exploration as lack of activity was likely to be caused by low bacterial bioactivation turnover. On the other hand, compounds <b>32</b> and <b>39</b>–<b>41</b> showed a remarkable improvement in metabolic stability by just carrying out a pyrrolidine modification strategy, a position unlikely to affect the electronic density around the sulfur atom. More important, these compounds were not inactive and were susceptible of chemical modification to improve potency. Among all, compound <b>41</b> was the only one showing a stark improvement in both human and mouse microsomes (0.42 and 2.3 mL/(min·g<sub>tissue</sub>), respectively).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Human Cl<sub>i</sub> vs measured PFI scatter plot: <i>X</i>-axis, measured PFI; <i>Y</i>-axis, human in vitro microsomal clearance. Numbers for each spot corresponds to compound numbers in the SAR tables. Color coding is as follows: green to orange is for compounds with an intracellular IC<sub>50</sub> in the range of 0.1–10 μM; orange to red is for compounds with IC<sub>50</sub> > 10–50 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00003&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An exploratory, focused SAR around the thiomorpholine dioxide ring on compound <b>41</b> was carried out aiming to identify analogues with potency improvement (compounds <b>42</b>–<b>47</b>; <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). All the compounds designed showed a promising in vitro metabolic stability profile. Among them, compound <b>46</b> displayed the best intrinsic clearance values (hCl<sub>i</sub> = 0.4 mL/(min·g<sub>tissue</sub>), mCl<sub>i</sub>= 0.6 mL/(min·g<sub>tissue</sub>)), along with a remarkable increase in activity as compared to <b>41</b> (<b>46</b>, IC<sub>90</sub> = 7.7 μM; <b>41</b>, IC<sub>90</sub> > 50 μM). To further decrease the PFI, the fluoro derivatives for compounds <b>41</b> and <b>46</b> were also synthesized and tested (compounds <b>48</b> and <b>49</b>). Both compounds showed a slight improvement in microsomal stability, but unfortunately, they turned out to be inactive.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Refined, Exploratory SAR around the Analogue <b>41</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0008.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Mean value of <i>n</i> ≥ 2 experiments. In parentheses: value in μg/mL.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">In vitro intrinsic microsomal clearance.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">PFI: property forecast index, PFI = (ChromlogD<sub>7.4</sub>) + (no. of aromatic rings).</p></div></div><div></div></div><div class="NLM_p">Overall, the structure–activity relationship generated around the hit <b>1</b> revealed key structural features accounting for the activity along with the identification of a suboptimal metabolic stability profile in the family. In-depth analysis of property trends across the set of compounds followed by a synthesis of a refined set of analogues led to the identification of <b>46</b>, an optimized analogue displaying an intracellular activity in the same order of magnitude as <b>1</b>, absence of cytotoxicity, improved solubility and lipophilicity profile, good permeability, and optimal metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Comparative Profile for Compound <b>1</b> and Optimized Analogue <b>46</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0009.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">In parentheses: value in μg/mL.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">PFI: property forecast index, PFI = (ChromlogD<sub>7.4</sub>) + (no. of aromatic rings).</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">FaSSIF: fasted state simulated intestinal fluid.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">In vitro intrinsic clearance.</p></div></div><div></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A 2-(thioalkyl)benzoxazole derivative (<b>1</b>) was identified in a high throughput intracellular screening campaign against <i>Mtb</i>-infected THP-1 cells. The displayed bioactivity profile along with the acceptable drug-like properties of the compound, the absence of relevant safety flags, and its chemical tractability made the hit attractive for further investigation. We have demonstrated that <b>1</b> is a prodrug and that the mycobacterial monoxygenase MymA is key in its bioactivation pathway. A comprehensive hit optimization campaign led to the discovery of a sweet spot in the chemical space where analogues showed an optimal balance of bioactivity and drug-like properties, as exemplified by analogue <b>46</b>. Further exploration of this chemical space to identify more potent analogues to progress to in vivo efficacy studies is currently underway along with efforts to fully elucidate the mechanism of action of this family of compounds.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All starting materials were purchased from commercial sources and used as received. Solvents were dried using a commercial solvent purification system and stored under nitrogen. All final compounds were characterized by <sup>1</sup>H NMR spectroscopy and LCMS. <sup>1</sup>H NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer at 293 K using residual signal of deuterated solvent as internal reference; chemical shifts for protons are reported in a parts per million. Final compounds showed a purity of ≥95%. Purity was determined by HPLC (Acquity UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm, ammonium acetate 25 mM + 10% acetonitrile at pH 6.6/acetonitrile) at 35 °C. Preparative HPLC was carried out using Waters XBridge prep OBD C18 5 μm, 19 mm × 150 mm column. Positive ion mass spectra (HRMS, high resolution mass spectroscopy) was acquired using a QSTAR Elite (AB Sciex Instruments) mass spectrometer, equipped with a turbospray source, over a mass range of 250–700, with a scan time of 1 s. Compounds <b>7</b>, <b>9</b>, <b>31</b>, <b>34</b>, <b>36</b>, <b>37</b>, and <b>39</b> were available in the GSK compound collection, and therefore their synthesis was not required. The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents. All animal studies were ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> In Vitro Activity Assay</h3><div class="NLM_p last">The measurement of the minimum inhibitory concentration (MIC) was performed in 96-well flat-bottom polystyrene microtiter plates (Costar ref 3599). Ten 2-fold drug dilutions in neat DMSO starting at 80 μM were performed, lines A–H and rows 1–10 of the plate layout. Moxifloxacin was used as a control curve; eight 2-fold dilutions of moxifloxacin starting at 2 μg/mL were prepared (row 11, lines A–H). Neat DMSO was added to row 12 (wells A–D) as growth control, and rifampicin (1 μg/mL) was added in column 12 (wells E–H) as blank control in order to calculate the <i>Z</i>′ value (cutoff <i>Z</i>′ ≥ 0.4). The inoculum was standardized to 1 × 10<sup>7</sup> CFUs/mL by measuring the optical density (OD) at 600 nm (OD = 0.125) and diluted 1:100 in Middlebrook 7H9 medium (Difco, ref 90003-876) supplied with 10% ADC (Difco, ref 90000-420) and 0,025% tyloxapol (Sigma T0307-50G) to produce the final inoculum of H37Rv strain (ATCC25618). 200 μL of this inoculum was added to the entire plate. The plates were incubated at 37 °C for 6 days. A resazurin solution was prepared by dissolving one tablet of resazurin (Fisher Scientific ref R/0040/79) in 30 mL of sterile phosphate buffered saline. Of this solution, an amount of 25 μL was added to each well. The plates were incubated at 37 °C for 48 additional hours, and fluorescence was measured (Spectramax M5, Molecular Devices; ex 530 nm, em 590 nm, cutoff 570 nm). MIC value is considered as the minimum concentration of compound that completely inhibits visible growth of the organism as detected by the reduction of resazurin (blue wells).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Intracellular Assay</h3><div class="NLM_p">The intracellular assay was performed as previously described with minor modifications.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> THP-1 cells (ATCC TIB-202) grown in RPMI-1640 medium (Sigma R5886) supplemented with 10% fetal bovine serum (FBS South American (CE), source Gibco 10270), 1 mM sodium pyruvate (Sigma S8636), and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine (Sigma G2150) were incubated at 37 °C, 5% CO<sub>2</sub> and 95% humidity. THP-1 cells were treated according to GSK policies for management of human biological samples.</div><div class="NLM_p"><i>Preparation of M. tuberculosis Single Cell Suspensions.</i> A single cell suspension of Mtb H37Rv pATB45luc was prepared prior to infection. 25 mL of bacterial culture grown to log phase in Middlebrook 7H9 medium (Difco, ref 90003-876) supplied with 10% ADC (Difco, ref 90000-420) and 0.025% tyloxapol (Sigma T0307-50G) was centrifuged at 2860<i>g</i> for 10 min. Hygromicin (Sigma CAS no. 31282-04-9) was added to the assay at the final concentration of 0.1 mg/mL (stock in water filtered at 200 mg/mL). After removal of the supernatant, cell clumps were dispersed by vigorously shaking with sterile 4 mm solid glass beads (Sigma) for 2 min. Dispersed cells were then resuspended in 10 mL of RPMI medium and left to decant for 5 min at room temperature. Cells were then centrifuged at 402<i>g</i> for 5 min. Supernatant was collected, and pellet was resuspended in RPMI culture medium. Mtb OD culture was measured at OD600. OD mL-L was converted to CFU mL-L considering that 0.1 OD is equal to approximately 10<sup>8</sup> CFU mL-L.</div><div class="NLM_p"><i>Infection of THP-1 Cells with Mtb and Incubation with Compounds.</i> 3 × 10<sup>8</sup> THP-1 cells were simultaneously differentiated with phorbol myristate acetate (PMA, 40 ng mL-1, Sigma) and infected with a single cell suspension of Mtb H37Rv-pATB45luc in a roller bottle at a MOI 1:10. Cells were put in a roller bottle apparatus for 4 h at 37 °C at 1.5 rpm. After incubation, infected cells were washed six times by centrifugation at 400<i>g</i> for 5 min and resuspended in fresh RPMI medium to remove extracellular bacilli. In the last wash, previous to plate seeding, infected macrophages were resuspended in RPMI medium supplemented with 10% fetal bovine serum (Hyclone), 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and pyruvate. After this step, cells were filtered with a 40 μm Falcon cell strainer to remove cell clumps and obtain single cell suspension. Finally, adjust cell density to 2 × 10<sup>5</sup> cells/mL and seed the plates. An amount of 50 μL of this cell suspension (typically 10 000 cells per well) was dispensed into the wells of 384-well plates (white, flat bottom, Greiner 781075). Prior to addition of the cell suspension, the screening compounds (250 nL) were dispensed into the plates and the top concentration (50 uM) was dispensed in wells 1 and 13. 1:3 serial dilutions were performed from 1 to 12 and from 13 to 24. Plates were allowed to incubate at 37 °C at 80% relative humidity for 5 days under 5% CO<sub>2</sub>. Luciferase activity, proportional to bacterial load, was determined by using the BrightGlo luciferase assay system (Promega, Madison, WI, E2650) according to the manufacturer’s protocol. Resultant luminescence was measured in an Envision multilabel plate reader (PerkinElmer) using the 384-plate Ultra Sensitive luminescence mode, with a measurement time of 200 ms per well.</div><div class="NLM_p last"><i>Data Analysis.</i> Every assay plate contained a column of negative controls with DMSO (Sigma W387520) which correspond to 100% bacterial growth (control 1, column 6) and a column of positive controls in which 100% inhibition of cell growth was reached by adding 5 μM rifampicin (column 18, control 2). These controls were used to monitor assay quality through determination of <i>Z</i>′ (<i>Z</i>′ should be higher than 0.4). % inhibition was calculated as % inhibition = 100 × [(data – control1)/(control2 – control1)]. IC<sub>50</sub> and IC<sub>90</sub> were calculated using nonlinear regression curve fit ActivityBase software.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> THP-1 Cytotoxicity Assay</h3><div class="NLM_p last">THP-1 cells (ATCC TIB-202) grown in RPMI-1640 medium (Sigma R5886) supplemented with 10% fetal bovine serum (FBS South American (CE), source Gibco 10270), 1 mM sodium pyruvate (Sigma S8636), and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine (Sigma G2150) were incubated at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. Then the cells were harvested by centrifugation (350<i>g</i>) for 5 min at room temperature and resuspended in growth medium supplied with 10% FBS and counted using a cell counter (NucleoconterNC100, Chemometec). THP-1 cells were treated according to GSK policies for management of human biological samples. A suspension with 5 × 10<sup>5</sup> cells/mL was prepared using the same medium specification, and PMA (Sigma P1585) was added to the cells in a final concentration of 40 μg/mL. Cells were incubated at 37 °C and left to differentiate for 4 h. Then, cells were washed with complete medium and centrifuged at specific parameters, and cell density was adjusted to 2 × 10<sup>5</sup> cells/mL. In order to quantify the cells, in an Eppendorf tube prepare a dilution of the cells in RPMI medium (1:10 or 1:100) so that the solution does not appear turbid anymore. Use the NucleocounterNC100 (Chemometec) to quantify the amount of cells. An amount of 50 μL of this suspension (10 000 cells/well) of differentiated cells was transferred to each well of sterile white 384-well microplates with clear bottom (Greiner 781095). Those plates already contained 250 nL of antitubercular compounds. The top concentration (50 μM) was dispensed in wells 1 and 13. 1:3 serial dilutions were performed from 1 to 12 and from 13 to 24. Every assay plate contained a column of negative controls with DMSO (Sigma W387520) which correspond to 100% bacterial growth (control 1, column 6) and a column of positive controls in which 100% inhibition of cell growth was reached by adding 5 μM doxorubicin (Sigma D1515) (column 18, control 2). These controls were used to monitor assay quality through determination of <i>Z</i>′ (<i>Z</i>′ should be higher than 4). Hygromicin (Sigma CAS no. 31282-04-9) was added to the assay at the final concentration of 0.1 mg/mL (stock in water filtered at 200 mg/mL). The compounds were assayed in duplicate. The plate was then incubated for 5 days at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. Luminescence is measured after 5 days of incubation using the ATPLite 1Step kit (PerkinElmer 6016739). Briefly, 25 μL of reconstituted substrate solution of an ATP monitoring assay kit was added to each well. Then the plate was shaken for 1 min (incubation needs to be in the dark) and the luminescence was measured using EnVision multilabel reader (PerkinElmer), using measurement time of 0.1 s. The Tox50 value corresponds to the concentration of the compound necessary to inhibit 50% of cell growth and was calculated using nonlinear regression curve fit of GraphPad Prism version 6.07. % inhibition was calculated as % inhibition = 100 × [(data – control1)/(control2 – control1)].</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> HepG2 Cytotoxicity Assay</h3><div class="NLM_p last">HepG2 cells were cultured using Eagle’s MEM supplemented with 10% heat-inactivated FBS, 1% NEAA, and 1% penicillin/streptomycin. Prior to addition of the cell suspension, an amount of 250 nL of test compounds per well was predispensed in TC-treated black clear-bottomed 384-well plates (Greiner, catalog no. 781091) with an Echo 555 instrument. After that, 25 μL of HepG2 (ATCC HB-8065) cells (∼3000 cells/well) grown to confluency in Eagle’s MEM supplemented with 10% heat-inactivated FBS, 1% NEAA, and 1% pencillin/streptomycin were added to each well with the reagent dispenser. Plates were allowed to incubate at 37 °C with 20% O<sub>2</sub> and 5% CO<sub>2</sub> for 48 h. After the incubation period (48 h), the plates were equilibrated to room temperature before proceeding to develop the luminescent signal. ATP levels measured with CellTiter Glo kit (Promega) were used as cell viability readout. Then 25 μL of CellTiter Glo substrate dissolved in the buffer was added to each well. Plates were incubated at room temperature for 10 min for stabilization of luminescence signal and read on View Lux with excitation and emission filters of 613 and 655 nm, respectively.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Cytotoxicity in Cryopreserved Hepatocytes</h3><div class="NLM_p last">Cryopreserved human hepatocytes are plated on 96-well collagen coated plates. After 24 h the cells are dosed with test compound and incubated for 72 h, with the dosing solutions replaced every 24 h throughout the dosing period. One hour prior to the end of the incubation period, the cells are loaded with MTT [yellow; 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2<i>H</i>-tetrazolium bromide] and the plates are dried and resolubilized using DMSO. The plates are then scanned using the Sunrise plate reader (Tecan). The % cell viability relative to vehicle control for each concentration was estimated, with graphical representation of the dose–response curve.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Gene Identification in Mutant</h3><div class="NLM_p last">High fidelity enzyme KOD polymerase (Novagen) was used to amplify the genes encoding for MymA (<i>Rv3083</i>) and EthA (<i>Rv3854c</i>) from DNA obtained from the mutant resistant to compound <b>1</b> and its parental strain. <i>Eth</i>A primers, with restriction sites (underlined), were <b>ethA-F</b><u class="uu">AAGCTT</u>AGAAGGAGAAGTACCGATGACCGAGCACCTCGA and <b>ethA-R</b> GC<u class="uu">GTTAAC</u>CTAAACCCCCACCGGGGCAG, and <i>mym</i>A primers were <b>mymA-F</b><u class="uu">AAGCTT</u>AGAAGGAGAAGTACCGATGAACCAGCATTTCGACGT and <b>mymA-R</b> GC<u class="uu">GTTAAC</u>TCAGGCCGCCGCGTGGTCTTG. The PCR products were purified and sequenced, and the resulting data were aligned against the wild-type’s sequence. Alignment was performed using Sequencher (version 5.4.6) and DNAMAN (version 4.1)</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> ChromlogD Assay</h3><div class="NLM_p last">The chromatographic hydrophobicity index (CHI) values are measured using reversed phase HPLC column (50 mm × 2 mm, 3 μm Gemini NX C18, Phenomenex, U.K.) with fast acetonitrile gradient at starting mobile phase at pH 2, 7.4, and 10.5. CHI values are derived directly from the gradient retention times by using a calibration line obtained for standard compounds. The CHI value approximates to the volume % organic concentration when the compound elutes. CHI is linearly transformed into ChromlogD by least-squares fitting of experimental CHI values to calculated log <i>P</i> (ClogP) values for over 20K research compounds using the following formula: ChromlogD = 0.0857CHI – 2.00. The average error of the assay is ±3 CHI units or ±0.25 ChromlogD.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Kinetic aqueous solubility assay</h3><div class="NLM_p last">The aqueous solubility of test compounds were measured using an in-house method utilizing quantification via chemiluminescent nitrogen detection (CLND) or charged aerosol detector (CAD): a 5 μL of 10 mM DMSO stock solution was diluted to 100 μL with pH 7.4 phosphate buffered saline and equilibrated for 1 h at rt and filtered through Millipore Multiscreen HTS-PCF filter plates (MSSL BPC). The eluent is quantified by suitably calibrated flow injection CLND (or CAD). This assay has a dynamic range between the lower detection limit of 1 and 500 μM, governed by the protocol’s 1:20 dilution into pH 7.4 phosphate buffer solution from nominal 10 mM DMSO stock.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> FaSSIF Solubility Assay</h3><div class="NLM_p last">Solubility of test compounds in fasted simulated intestinal fluid (FaSSIF) was determined at pH 6.5 after 4 h equilibration at rt. An amount of 1 mL of FaSSIF buffer (3 mM sodium taurocholate, 0.75 mM lecithin in sodium phosphate buffer at pH 6.5) was added to manually weighed 1 mg of solid compound in a 2 mL HPLC autosampler vial. The resulting suspension is shaken at 900 rpm for 4 h at rt and then transferred to a Multiscreen HTS, 96-well solubility filter plate. The residual solid was removed by filtration. The supernatant solution was quantified by HPLC–UV using single-point calibration of a known concentration of the compound in DMSO. The dynamic range of the assay was 1–1000 μg/mL.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Artifical Membrane Permeability (AMP) Assay</h3><div class="NLM_p last">A 8% <span class="smallcaps smallerCapital">l</span>-α-phosphatidylcholine (EPC) in 1% cholesterol decane solution and a 1.8% EPC in cholesterol decane solution were prepared. The lipid solution was then aliquoted into 4 mL capped vials, sealed with parafilm, and stored in −20 °C freezer. The lipid solution was then transferred from 4 mL vial into 96-well half area plate (130 μL/well) for daily assay usage. An additional 50 mM phosphate buffer with 0.5% encapsin, pH at 7.4, was prepared. The assay was run by the Biomek FX and Biomek software. The assay procedure is written under the Biomek software. For one batch assay, it can test two 96-well sample plates with at least one standard on each sample plate. The total assay time was about 4 h. An amount of 3.5 μL of lipid solution was added to the filter plate, shaken for 12 s, and an amount of 250 μL of buffer was added to the donor side and 100 μL to the receiver side. The assay plate was shaken for 45 min before adding the compounds. The test compounds (2.5 μL) were added to the donor side. The assay was run as replicates: Assay plates 1 and 2 tested the sample plate 1; assay plates 3 and 4 tested the sample plate 2. The assay plates were then incubated and shaken for 3 h at room temperature. The assay samples were transferred to the HPLC analysis plates, and an amount of 100 μL of receiver solution was aspirated and transferred to the receiver for analysis. Similarly, another 100 μL from the donor solution was transferred to the donor analysis plate. Compound concentration was measured by HPLC at different time-points.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Stability in Microsomes</h3><div class="NLM_p last">Intrinsic clearance (Cli) values were determined in mouse and human liver microsomes. Test compounds (final concentration 0.5 μM) were incubated at 37 °C for 45 min in 50 mM potassium phosphate buffer (pH 7.4) containing 0.5 mg of microsomal protein/mL. The reaction was started by addition of cofactor NADPH. At 0, 5, 15, 30, and 45 min, an aliquot (100 μL) was taken, quenched with acetonitrile containing an appropriate internal standard, centrifuged, and analyzed by LCMS/MS. The intrinsic clearance was determined from the following equation: Cli = <i>k</i> × (mL of incubation/mg of microsomal protein) × (mg of microsomal protein/g o fliver), where <i>k</i> is the turnover rate constant of the ln(% remaining compound) vs time regression and mg of microsomal protein/g of liver is 48.0 and 39.7 for mouse and human, respectively.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> GSH Trapping Experiment</h3><div class="NLM_p last">The test agent (25 μM) was incubated in duplicate with pooled human liver microsomes (HLMs, protein concentration = 1 mg/mL) at 37 °C. The reaction contained microsomal protein in 100 mM potassium phosphate, 1 mM reduced glutathione, 2 mM NADPH, and 3 mM MgCl<sub>2</sub> (pH 7.4). Control incubation was performed for each test agent where 100 mM phosphate buffer was added instead of NADPH to detect non-NADPH dependent formation of reactive metabolites, reactive degradants in the test agent, and experimental artifacts. After 60 min incubation, an aliquot was removed from each experimental and control reaction and mixed with an equal volume of ice-cold acetonitrile. Stopped reactions were incubated for at least 10 min at −20 °C, and an additional volume of water was added. The samples were centrifuged to remove precipitated protein, and the supernatants were analyzed by LCMS/MS.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> In Vivo Efficacy Assay</h3><div class="NLM_p last">Specific pathogen-free, 8- to 10-week-old female C57BL/6 mice were purchased from Envigo Laboratories and were allowed to acclimate for 1 week. The experimental design for the acute assay has been previously described.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In brief, mice were intratracheally infected with 100 000 CFU/mouse of H37Rv <i>Mtb</i>. Compounds were administered for 8 consecutive days, once per day, starting 1 day after infection. Lungs were harvested 24 h after the last administration. All lung lobes are aseptically removed, homogenized, and frozen. Homogenates are plated in 10% OADC-7H11 medium for 18 days at 37 °C in the presence of 0.4% activated charcoal. The viable CFU were converted to logarithms, which were then evaluated by one-way analysis of variance, followed by multiple-comparison analysis of variance by Dunnett’s posttest (GraphPad Prism software program). Differences were considered significant at the 95% level of confidence. All animal studies are ethically reviewed and carried out in accordance with European Directive 2010/63/EU and the GSK Policy on the Care, Welfare and Treatment of Animals.</div></div><div id="sec4_13_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Synthesis of Compounds <b>1</b>–<b>49</b>. 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>1</b>)</h3><div class="NLM_p last">Commercially available compound. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.76 (d, <i>J</i> = 2.3 Hz, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.35 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 3.50 (t, <i>J</i> = 6.3 Hz, 2H), 3.36 (t, <i>J</i> = 6.6 Hz, 2H), 3.30 (t, <i>J</i> = 6.6 Hz, 2H), 2.84 (t, <i>J</i> = 6.8 Hz, 2H), 1.70–1.92 (m, 4H). LCMS: [M + H<sup>+</sup> = 311]. Purity was determined as >95% by HPLC (252 nm). Retention time (Rt): 1.29 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Preparation of Compounds <b>1a</b> and <b>1b</b>. 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)sulfinyl)-1-(pyrrolidin-1-yl)propan-1-one (<b>1a</b>)</h3><div class="NLM_p last">MCPBA (224 mg, 1.0 mmol) was added to a suspension of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (350 mg, 1.11 mmol) in dichloromethane (DCM) at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. Upon completion of the reaction monitored by LCMS, an aqueous saturated solution of K<sub>2</sub>CO<sub>3</sub> was added to the mixture. The organic phase was separated, dried over MgSO4, filtered and the solvent removed affording a white solid. (Several attempts to purify the compound on silica gel at this stage were unsuccessful due to the intrinsic low stability of the compound, leading in all cases to decomposition.) The resulting crude was triturated with <i>tert</i>-butyl methyl ether (TBME) and then filtered. The isolated solid was dissolved in 4 mL of ethanol and left for 2 days until crystals were observed. Filtration of such crystals and trituration with TBME afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)sulfinyl)-1-(pyrrolidin-1-yl)propan-1-one (<b>1a</b>) as a white solid (15.2 mg, 4% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.03–8.08 (m, 1H), 7.94 (d, <i>J</i> = 8.8 Hz, 1H), 7.55–7.64 (m, 1H), 3.67–3.77 (m, 1H), 3.49–3.59 (m, 1H), 3.39 (t, <i>J</i> = 7.1 Hz, 2H), 3.06–3.23 (m, 2H), 2.79 (t, <i>J</i> = 6.6 Hz, 2H), 1.80–1.93 (m, 2H), 1.73 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>3</sub>SNa [M + Na]<sup>+</sup>, calcd, 349.0384; found, 349.0369. Purity was determined as >93% by HPLC (251 nm). Rt: 1.02 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)sulfonyl)-1-(pyrrolidin-1-yl)propan-1-one (<b>1b</b>)</h3><div class="NLM_p last">MCPBA (704 mg, 3.14 mmol) was added to a suspension of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (470 mg, 1.50 mmol) in DCM at 0 °C. The reaction mixture was allowed to reach rt and then left stirring for 2 h. Upon completion of the reaction monitored by LCMS, an aqueous solution of sodium metabisulfite (2 M) was added to the mixture. The organic phase was separated, dried over MgSO4, filtered and the solvent removed under vacuum. The corresponding crude was dry loaded onto silica and quickly purified by flash chromatography (50% to 100% ethyl acetate/cyclohexanes). The selected fractions were combined and the solvent was removed to afford 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)sulfonyl)-1-(pyrrolidin-1-yl)propan-1-one (<b>1b</b>) as a white solid (140 mg, 27% yield). Note: Partial decomposition was observed upon chromatography on silica gel, hence the low yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.17 (d, <i>J</i> = 2.0 Hz, 1H), 8.01 (d, <i>J</i> = 8.8 Hz, 1H), 7.72 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 3.97 (t, <i>J</i> = 6.8 Hz, 2H), 3.39 (t, <i>J</i> = 6.8 Hz, 2H), 3.05 (t, <i>J</i> = 6.8 Hz, 2H), 2.86 (t, <i>J</i> = 6.6 Hz, 2H), 1.81–1.90 (m, 2H), 1.67–1.76 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> = 343; [M + H]<sup>+</sup>. Purity was determined as >95% by HPLC (249 nm). Rt: 1.12 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-(5-Chlorobenzo[<i>d</i>]oxazol-2-yl)-1-(pyrrolidin-1-yl)butan-1-one (<b>2</b>)</h3><div class="NLM_p">2-Amino-4-chlorophenol (150 mg, 0.99 mmol), glutaric acid (397 mg, 2.98 mmol), and polyphosphoric acid (2405 mg, 9.93 mmol) were mixed in a vial. The vial was sealed and the mixture heated under vigorous stirring to 180 °C overnight. Upon completion monitored by LCMS, the reaction mixture was poured into a mixture of ice/water and then ethyl acetate was added. The organic phase was separated and the aqueous phase extracted 3 times with ethyl acetate. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and the solvent was removed. The resulting crude was dry loaded onto silica and purified by flash chromatography (50–100% ethyl acetate/cyclohexanes). The selected fractions were combined and the solvent removed, affording 4-(5-chlorobenzo[<i>d</i>]oxazol-2-yl)butanoic acid as a yellow solid (374 mg, 78% yield, isolated as a 50% w/w mixture with glutaric acid). The product was used as a such in the next step. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.80 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.8 Hz, 1H), 7.40 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 2.98 (t, <i>J</i> = 7.5 Hz, 2H), 2.38 (t, <i>J</i> = 7.3 Hz, 2H), 2.02 (q, <i>J</i> = 7.3 Hz, 2H). Glutaric acid signals: δ = 12.08 (s, 4H), 2.24 (t, <i>J</i> = 7.5 Hz, 8H), 1.70 (quin, <i>J</i> = 7.4 Hz, 4H). MS (ESI): <i>m</i>/<i>z</i> = 240, 242; [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed.</div><div class="NLM_p last">Propylphosphonic acid anhydride (T3P, 1.56 mL, 2.34 mmol) was added to a solution of 4-(5-chlorobenzo[<i>d</i>]oxazol-2-yl)butanoic acid (374 mg, 0.78 mmol, 50% w/w mixture with glutaric acid), pyrrolidine (168 mg, 2.34 mmol), and Et<sub>3</sub>N (394 mg, 3.90 mmol) in dichloromethane. The solution was then stirred at rt for 1 h. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was then purified by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution). The selected fractions were combined and the solvent was removed under vacuum to afford 4-(5-chlorobenzo[<i>d</i>]oxazol-2-yl)-1-(pyrrolidin-1-yl)butan-1-one (<b>2</b>) as a white solid (92.1 mg, 40% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.79 (d, <i>J</i> = 2.3 Hz, 1H), 7.71 (d, <i>J</i> = 8.8 Hz, 1H), 7.40 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.35 (t, <i>J</i> = 6.8 Hz, 2H), 3.25 (t, <i>J</i> = 6.8 Hz, 2H), 2.99 (t, <i>J</i> = 7.3 Hz, 2H), 2.37 (t, <i>J</i> = 7.2 Hz, 2H), 2.03 (quin, <i>J</i> = 7.3 Hz, 2H), 1.81–1.91 (m, 2H), 1.69–1.79 (m, 2H). HRMS (ESI) for C<sub>15</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd, 293.1057; found, 293.1053. Purity was determined as >95% by HPLC (235 nm). Rt: 1.12 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)amino)-1-(pyrrolidin-1-yl)propan-1-one (<b>3</b>)</h3><div class="NLM_p">Et<sub>3</sub>N (399 mg, 2.37 mmol) was added to a solution of β-alanine ethyl ester hydrochloride (175.2 mg, 1.03 mmol) in anhydrous dichloromethane at rt. The mixture was stirred for 10 min, and then 2,5-dichlorobenzooxazole (150 mg, 0.79 mmol) was added. The resulting mixture was stirred at rt for 1 h. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum, affording a white solid (200 mg, 84% yield). <sup>1</sup>H NMR (chloroform-<i>d</i>, 400 MHz): δ = 7.33 (d, <i>J</i> = 2.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.3 Hz, 1H), 7.01 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 5.49–5.66 (m, 1H), 4.19 (q, <i>J</i> = 7.1 Hz, 2H), 3.76 (q, <i>J</i> = 6.1 Hz, 2H), 2.72 (t, <i>J</i> = 6.1 Hz, 2H), 1.28 (t, <i>J</i> = 7.1 Hz, 3H). MS (ESI): <i>m</i>/<i>z</i> = 269, 271; [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed.</div><div class="NLM_p last">Ethyl 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)amino)propanoate (200 mg, 0.67 mmol) was dissolved in a 1:1 mixture of THF/water (6 mL), and then LiOH monohydrate (93.7 mg, 2.01 mmol) was added. The mixture was stirred at rt overnight. Upon completion of the reaction monitored by LCMS, the mixture was acidified with 1 N HCl and ethyl acetate was added. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum, affording a white solid (176 mg, 98% yield) that was used as a such in the next step. The solid was dissolved in dichloromethane, and Et<sub>3</sub>N (166 mg, 1.65 mmol) and pyrrolidine (61.4 mg, 0.86 mmol) were added. Then, the mixture cooled down to 0 °C and propylphosphonic acid anhydride (0.658 mL, 0.99 mmol) was added to the reaction mixture. The resultant solution was stirred at rt for 2 h. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum affording a brown crude. The crude was dry loaded onto silica and purified by flash chromatography (0% to 100% 3:1 ethyl acetate/EtOH). The selected fractions were combined and the solvent removed affording 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)amino)-1-(pyrrolidin-1-yl)propan-1-one (<b>3</b>) as a white solid (120 mg, 61% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.14 (t, <i>J</i> = 5.7 Hz, 1H), 7.34 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (d, <i>J</i> = 2.3 Hz, 1H), 6.99 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 3.52 (q, <i>J</i> = 6.6 Hz, 2H), 3.37 (t, <i>J</i> = 6.7 Hz, 2H), 3.28 (t, <i>J</i> = 6.8 Hz, 2H), 2.59 (t, <i>J</i> = 6.8 Hz, 2H), 1.81–1.90 (m, 2H), 1.70–1.80 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>2</sub>Na [M + Na]<sup>+</sup>, calcd, 316.0823; found, 316.0827. Purity was determined as >95% by HPLC (289 nm). Rt: 1.06 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)(methyl)amino)-1-(pyrrolidin-1-yl)propan-1-one (<b>4</b>)</h3><div class="NLM_p last">Iodomethane (36.2 mg, 0.25 mmol) was added to a solution of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)amino)-1-(pyrrolidin-1-yl)propan-1-one (50 mg, 0.17 mmol) and K<sub>2</sub>CO<sub>3</sub> (58.8 mg, 0.42 mmol) in dimethylformamide (5 mL). The reaction mixture was heated up to 50 °C for 2 h. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum affording a brown crude. The crude was dry loaded onto silica and purified by flash chromatography (10% to 70% 3:1 ethyl acetate/cyclohexanes). The selected fractions were combined and the solvent was removed affording 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)(methyl)amino)-1-(pyrrolidin-1-yl)propan-1-one (<b>4</b>) as a pale yellow oil (40.3 mg, 77% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.40 (d, <i>J</i> = 8.6 Hz, 1H), 7.30 (d, <i>J</i> = 2.3 Hz, 1H), 7.00 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 3.72 (t, <i>J</i> = 7.2 Hz, 2H), 3.39 (t, <i>J</i> = 6.7 Hz, 2H), 3.26 (t, <i>J</i> = 6.8 Hz, 2H), 3.14 (s, 3H), 2.65 (t, <i>J</i> = 7.2 Hz, 2H), 1.80–1.89 (m, 2H), 1.70–1.80 (m, 2H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2</sub>Na [M + Na]<sup>+</sup>, calcd, 330.0980; found, 330.0993. Purity was determined as >95% by HPLC (254 nm). Rt: 1.12 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2-(((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)methyl)thio)-1-(pyrrolidin-1-yl)ethenone (<b>5</b>)</h3><div class="NLM_p">A suspension of 5-chloro-2-(chloromethyl)-1,3-benzoxazole (70 mg, 0.34 mmol), thioglycolic acid (41.5 mg, 0.45 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (225.8 mg, 0.69 mmol) in acetonitrile (5 mL) was stirred at 100 °C for 1 h in a microwave reactor. Upon completion of the reaction monitored by LCMS, to the sample was added acetic acid and the solvent was removed under vacuum. The resulting solid was triturated with TBME to afford a pale brown solid (62.3 mg, 56% yield, isolated as a 3:1 w/w mixture with thioglycolic acid). The product was used as such in the next step. <sup>1</sup>H NMR (chloroform-<i>d</i>, 400 MHz): δ = 7.71 (d, <i>J</i> = 2.0 Hz, 1H), 7.47 (d, <i>J</i> = 8.6 Hz, 1H), 7.35 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 4.13 (s, 2H), 3.44 (s, 2H). Thioglycolic acid signals: δ = 3.32 (d, <i>J</i> = 8.3 Hz, 2H), 2.04 (t, <i>J</i> = 8.6 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> = 258, 260; [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed.</div><div class="NLM_p last">The brown solid was dissolved in dichloromethane, and Et<sub>3</sub>N (60.5 mg, 0.60 mmol) and pyrrolidine (20.6 mg, 0.29 mmol) were added. Then, the mixture was cooled down to 0 °C and propylphosphonic acid anhydride (0.239 mL, 0.36 mmol) was added to the reaction mixture. The resultant solution was stirred at rt for 2 h. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum affording a brown crude that was purified by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution). The selected fractions were combined and the solvent was removed affording 2-(((5-chlorobenzo[<i>d</i>]oxazol-2-yl)methyl)thio)-1-(pyrrolidin-1-yl)ethenone (<b>5</b>) as a white solid (22.6 mg, 30% yield). <sup>1</sup>H NMR (chloroform-<i>d</i>, 400 MHz): δ = 7.68 (d, <i>J</i> = 2.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.6 Hz, 1H), 7.32 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 4.11 (s, 2H), 3.42–3.52 (m, 6H), 1.98 (quin, <i>J</i> = 6.6 Hz, 2H), 1.87 (quin, <i>J</i> = 6.6 Hz, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>16</sub>ClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, calcd, 311.0616; found, 311.0615. Purity was determined as >95% by HPLC (238 nm). Rt: 1.17 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 4-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)butan-1-one (<b>8</b>)</h3><div class="NLM_p last">A suspension of 5-chloro-2-mercaptobenzoxazole (150 mg, 0.80 mmol), 4-chloro-1-(pyrrolidin-1-yl)butan-1-one (202.8 mg, 1.04 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (526.6 mg, 1.60 mmol) in acetonitrile (5 mL) was stirred at 100 °C for 1 h in a microwave reactor. Upon completion of the reaction monitored by LCMS, the sample was filtered and the crude purified by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution). The selected fractions were combined and the solvent was evaporated affording 4-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)butan-1-one (<b>8</b>) as an oil (105 mg, 40% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.75 (d, <i>J</i> = 2.3 Hz, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.33–3.41 (m, 4H), 3.26 (t, <i>J</i> = 6.8 Hz, 2H), 2.41 (t, <i>J</i> = 7.1 Hz, 2H), 2.01 (quin, <i>J</i> = 7.2 Hz, 2H), 1.79–1.89 (m, 2H), 1.69–1.79 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> = 325; [M + H]<sup>+</sup>. Purity was determined as >95% by HPLC (252 nm). Rt: 1.24 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> General Procedure for the Synthesis of Compounds <b>10</b>–<b>16</b> and <b>18</b>–<b>26</b></h3><div class="NLM_p">Et<sub>3</sub>N (22.81 mmol, 2307 mg) was added to a solution of 3-chloropropionic acid (9.12 mmol, 1000 mg) and pyrrolidine (10.95 mmol, 786 mg) in dichloromethane (50 mL) at rt. Then, the mixture was cooled down to 0 °C and propylphosphonic acid anhydride (50% in ethyl acetate, 13.68 mmol, 9.12 mL) was added to the reaction mixture. The resultant solution was stirred at rt overnight. Upon completion of the reaction by TLC, water was added and the organic phase separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed. The crude was dry loaded onto silica and purified by flash chromatography (50% to100% ethyl acetate/cyclohexanes). The selected fractions were combined and the solvent was removed affording 3-chloro-1-(pyrrolidin-1-yl)propan-1-one as a colorless oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 3.78 (t, <i>J</i> = 6.5 Hz, 2H), 3.40 (t, <i>J</i> = 6.8 Hz, 2H), 3.28 (t, <i>J</i> = 6.8 Hz, 2H), 2.74 (t, <i>J</i> = 6.5 Hz, 2H), 1.86 (quin, <i>J</i> = 6.8 Hz, 2H), 1.76 (quin, <i>J</i> = 6.8 Hz, 2H). MS (ESI): <i>m</i>/<i>z</i> = 162, 164; [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed.</div><div class="NLM_p last">A suspension of the corresponding mercaptoheteroarene (1 equiv), 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (1.3 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (2.0 equiv) in acetonitrile was stirred at 100 °C for 1 h in a microwave reactor. Upon completion by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was then dry loaded onto silica and purified by flash chromatography or alternatively dissolved in DMSO (1.0–1.5 mL) and purified by preparative HPLC. The selected fractions were combined and the solvent was removed under vacuum to afford the desired compound.</div></div><div id="sec4_13_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-((4-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>10</b>)</h3><div class="NLM_p last">Using the general procedure described above, the reaction of 4-chlorobenzo[<i>d</i>]oxazole-2-thiol (88 mg, 0.47 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (109.6 mg, 0.61 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((4-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>10</b>) as a white solid (86.2 mg, 58% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.64 (dd, <i>J</i> = 8.2, 0.9 Hz, 1H), 7.43 (dd, <i>J</i> = 8.0, 0.9 Hz, 1H), 7.32 (t, <i>J</i> = 8.1 Hz, 1H), 3.53 (t, <i>J</i> = 6.6 Hz, 2H), 3.40 (t, <i>J</i> = 6.7 Hz, 2H), 3.30 (t, <i>J</i> = 6.8 Hz, 2H), 2.86 (t, <i>J</i> = 6.7 Hz, 2H), 1.82–1.90 (m, 2H), 1.71–1.81 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 333.0435; found, 333.0436. Purity was determined as >95% by HPLC (256 nm). Rt: 1.20 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-((6-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>11</b>)</h3><div class="NLM_p last">Using the general procedure described above, the reaction of 6-chlorobenzo[<i>d</i>]oxazole-2-thiol (50 mg, 0.27 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (62 mg, 0.35 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((6-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>11</b>) as a white solid (24.5 mg, 29% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 7.85 (d, <i>J</i> = 2.0 Hz, 1H), 7.65 (d, <i>J</i> = 8.5 Hz, 1H), 7.39 (dd, <i>J</i> = 2.0, 8.6 Hz, 1H), 3.49 (t, <i>J</i> = 6.6 Hz, 2H), 3.36 (t, <i>J</i> = 6.6 Hz, 2H), 3.29 (t, <i>J</i> = 6.7 Hz, 2H), 2.84 (t, <i>J</i> = 6.6 Hz, 2H), 1.85 (quin, <i>J</i> = 6.7 Hz, 2H), 1.76 (quin, <i>J</i> = 6.8 Hz, 2H).). MS (ESI): <i>m</i>/<i>z</i> = 311; 313 [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed. Purity was determined as >95% by HPLC (254 nm). Rt: 1.23 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-((7-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>12</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 7-chlorobenzo[<i>d</i>]oxazole-2-thiol (50 mg, 0.27 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (62 mg, 0.35 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((7-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>12</b>) as a white solid (35.5 mg, 42% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 7.63 (dd, <i>J</i> = 1.0, 7.8 Hz, 1H), 7.42 (dd, <i>J</i> = 1.0, 7.9 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 3.51 (t, <i>J</i> = 6.6 Hz, 2H), 3.37 (t, <i>J</i> = 6.6 Hz, 2H), 3.30 (t, <i>J</i> = 6.7 Hz, 2H), 2.85 (t, <i>J</i> = 6.5 Hz, 2H), 1.85 (quin, <i>J</i> = 6.6 Hz, 2H), 1.76 (quin, <i>J</i> = 6.6 Hz, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>16</sub>ClN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 311.0621; found, 311.0621 Purity was determined as >95% by HPLC (280 nm). Rt: 1.22 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-((5-Fluorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>13</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5-fluorobenzoxazole-2-thiol (50 mg, 0.29 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (68.3 mg, 0.38 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>13</b>) as a white solid (64.2 mg, 74% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.67 (dd, <i>J</i> = 8.8, 4.3 Hz, 1H), 7.54 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 7.11–7.21 (m, 1H), 3.49 (t, <i>J</i> = 6.7 Hz, 2H), 3.36 (t, <i>J</i> = 6.8 Hz, 2H), 3.29 (t, <i>J</i> = 6.8 Hz, 2H), 2.84 (t, <i>J</i> = 6.7 Hz, 2H), 1.85 (quin, <i>J</i> = 6.2 Hz, 2H), 1.76 (quin, <i>J</i> = 6.4 Hz, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 295.0911; found, 295.0922. Purity was determined as >95% by HPLC (285 nm). Rt: 1.14 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-(Benzo[<i>d</i>]oxazol-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>14</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 2-mercaptobenzoxazole (50 mg, 0.33 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (76.4 mg, 0.43 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-(benzo[<i>d</i>]oxazol-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>14</b>) as a white solid (11.4 mg, 12% yield). <sup>1</sup>H NMR (chloroform-<i>d</i>, 400 MHz): δ = 7.57–7.62 (m, 1H), 7.42–7.47 (m, 1H), 7.21–7.32 (m, 2H), 3.62 (t, <i>J</i> = 6.7 Hz, 2H), 3.51 (t, <i>J</i> = 6.8 Hz, 2H), 3.40 (t, <i>J</i> = 6.7 Hz, 2H), 2.90 (t, <i>J</i> = 6.7 Hz, 2H), 1.91–2.00 (m, 2H), 1.83–1.91 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 277.1005; found, 277.1006. Purity was determined as >95% by HPLC (279 nm). Rt: 1.11 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-((5-Methylbenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>15</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5-methylbenzo[<i>d</i>]oxazole-2-thiol (90 mg, 0.54 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (125.9 mg, 0.70 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-methylbenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>15</b>) as a white solid (41.2 mg, 26% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.44 (br. s, 1H), 7.11 (d, <i>J</i> = 8.1 Hz, 1H), 3.48 (t, <i>J</i> = 6.6 Hz, 2H), 3.36 (t, <i>J</i> = 6.7 Hz, 2H), 3.29 (t, <i>J</i> = 6.8 Hz, 2H), 2.82 (t, <i>J</i> = 6.7 Hz, 2H), 2.40 (s, 3H), 1.70–1.91 (m, 4H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 313.0981; found, 313.0995. Purity was determined as >95% by HPLC (251 nm). Rt: 1.19 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-((5-Methoxybenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>16</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5-methoxybenzoxazole-2-thiol (100 mg, 0.54 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (124.9 mg, 0.70 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution, Xbdrige column) afforded 3-((5-methoxybenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>16</b>) as a white solid (78 mg, 47% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.52 (d, <i>J</i> = 8.8 Hz, 1H), 7.22 (d, <i>J</i> = 2.5 Hz, 1H), 6.87 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 3.79 (s, 3H), 3.48 (t, <i>J</i> = 6.7 Hz, 2H), 3.36 (t, <i>J</i> = 6.8 Hz, 2H), 3.30 (t, <i>J</i> = 6.6 Hz, 2H), 2.83 (t, <i>J</i> = 6.7 Hz, 2H), 1.81–1.89 (m, 2H), 1.72–1.80 (m, 2H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>SNa [M + Na]<sup>+</sup>, calcd, 329.0930; found, 329.0928. Purity was determined as >95% by HPLC (253 nm). Rt: 1.13 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 3-((5,6-Difluorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>18</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5,6-difluorobenzo[<i>d</i>]oxazole-2-thiol (95 mg, 0.46 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (106 mg, 0.59 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5,6-difluorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>18</b>) as a white solid (35.7 mg, 25% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.97 (dd, <i>J</i> = 9.9, 7.1 Hz, 1H), 7.83 (dd, <i>J</i> = 10.4, 7.6 Hz, 1H), 3.49 (t, <i>J</i> = 6.6 Hz, 2H), 3.36 (t, <i>J</i> = 6.7 Hz, 2H), 3.29 (t, <i>J</i> = 6.8 Hz, 2H), 2.83 (t, <i>J</i> = 6.6 Hz, 2H), 1.81–1.90 (m, 2H), 1.71–1.80 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>15</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 313.0817; found, 313.0825. Purity was determined as 95% by HPLC (287 nm). Rt: 1.23 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 3-((5-Chlorobenzo[<i>d</i>]thiazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>19</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5-chloro-2-mercaptobenzothiazole (50 mg, 0.25 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (57.3 mg, 0.32 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]thiazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>19</b>) as a white solid (16.2 mg, 20% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.92–7.97 (m, 1H), 7.38–7.45 (m, 1H), 3.54 (t, <i>J</i> = 6.7 Hz, 2H), 3.37 (t, <i>J</i> = 6.8 Hz, 2H), 3.30 (t, <i>J</i> = 6.6 Hz, 2H), 2.82 (t, <i>J</i> = 6.8 Hz, 2H), 1.71–1.92 (m, 4H). HRMS (ESI) for C<sub>14</sub>H<sub>16</sub>ClN<sub>2</sub>OS<sub>2</sub> [M + H]<sup>+</sup>, calcd, 327.0387; found, 327.0395. Purity was determined as >95% by HPLC (235 nm). Rt: 1.28 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3-((5-Chloro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>20</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5-chloro-1<i>H</i>-benzo[<i>d</i>]imidazole-2-thiol (50 mg, 0.27 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (62.3 mg, 0.35 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chloro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>20</b>) as a white solid (13.8 mg, 16% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 12.69 (br. s, 1H), 7.32–7.59 (m, 2H), 7.12 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.45 (t, <i>J</i> = 6.6 Hz, 2H), 3.34 (t, <i>J</i> = 6.6 Hz, 2H), 3.29 (t, <i>J</i> = 6.8 Hz, 3H), 2.76 (t, <i>J</i> = 6.9 Hz, 2H), 1.79–1.88 (m, 2H), 1.71–1.79 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>17</sub>ClN<sub>3</sub>OS [M + H]<sup>+</sup>, calcd, 310.0775; found, 310.0787. Purity was determined as >95% by HPLC (293 nm). Rt: 1.04 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3-((4-Phenyloxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>21</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 4-phenyloxazole-2-thiol (150 mg, 0.68 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (146 mg, 0.81 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((4-phenyloxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>21</b>) as a white solid (62.4 mg, 29% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.64 (s, 1H), 7.70–7.78 (m, 2H), 7.39–7.47 (m, 2H), 7.28–7.36 (m, 1H), 3.35–3.45 (m, 4H), 3.29 (t, <i>J</i> = 6.8 Hz, 2H), 2.79 (t, <i>J</i> = 6.8 Hz, 2H), 1.81–1.90 (m, 2H), 1.71–1.80 (m, 2H). HRMS (ESI) for C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 303.1162; found, 303.1174. Purity was determined as 95% by HPLC (257 nm). Rt: 1.17 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3-((5-Phenyloxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>22</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 5-phenyloxazole-2-thiol (80 mg, 0.45 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (96.4 mg, 0.54 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-phenyloxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>22</b>) as a white solid (31.4 mg, 23% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.71 (s, 1H), 7.63–7.68 (m, 2H), 7.43–7.50 (m, 2H), 7.32–7.39 (m, 1H), 3.34–3.44 (m, 4H), 3.29 (t, <i>J</i> = 6.8 Hz, 2H), 2.78 (t, <i>J</i> = 6.8 Hz, 2H), 1.85 (quin, <i>J</i> = 6.4 Hz, 2H), 1.76 (quin, <i>J</i> = 6.3 Hz, 2H). HRMS (ESI) for C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 303.1162; found, 303.1171. Purity was determined as = 95% by HPLC (291 nm). Rt: 1.15 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3-((4,5-Dimethyloxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>23</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 4,5-dimethyloxazole-2-thiol (40 mg, 0.31 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (71.6 mg, 0.40 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((4,5-dimethyloxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>23</b>) as a pale orange oil (28.9 mg, 36% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 3.74–3.86 (m, 2H), 3.34 (t, <i>J</i> = 6.6 Hz, 2H), 3.26 (t, <i>J</i> = 6.8 Hz, 2H), 2.53–2.58 (m, 2H), 2.08 (s, 3H), 2.05 (s, 3H), 1.84 (quin, <i>J</i> = 6.6 Hz, 2H), 1.75 (quin, <i>J</i> = 6.7 Hz, 2H). MS (ESI): <i>m</i>/<i>z</i> = 255; [M + H]<sup>+</sup>. Purity was determined as >95% by HPLC (250 nm). Rt: 0.93 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3-(Oxazolo[4,5-<i>b</i>]pyridin-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>24</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of oxazolo[4,5-<i>b</i>]pyridine-2-thiol (150 mg, 0.49 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (115.1 mg, 0.64 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-(oxazolo[4,5-<i>b</i>]pyridin-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>24</b>) as a white solid (30.2 mg, 22% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.43 (dd, <i>J</i> = 5.1, 1.5 Hz, 1H), 8.07 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.34 (dd, <i>J</i> = 8.1, 5.1 Hz, 1H), 3.54 (t, <i>J</i> = 6.7 Hz, 2H), 3.37 (t, <i>J</i> = 6.7 Hz, 2H), 3.30 (t, <i>J</i> = 6.8 Hz, 2H), 2.87 (t, <i>J</i> = 6.6 Hz, 2H), 1.71–1.92 (m, 4H). HRMS (ESI) for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 300.0777; found, 300.0786. Purity was determined as >95% by HPLC (298 nm). Rt: 0.95 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-(Oxazolo[4,5-<i>c</i>]pyridin-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>25</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of oxazolo[4,5-<i>c</i>]pyridine-2-thiol (200 mg, 1.18 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (275.9 mg, 1.54 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-(oxazolo[4,5-<i>c</i>]pyridin-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>25</b>) as a white solid (53.8 mg, 16% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.94 (d, <i>J</i> = 0.8 Hz, 1H), 8.49 (d, <i>J</i> = 5.3 Hz, 1H), 7.76 (dd, <i>J</i> = 5.6, 0.8 Hz, 1H), 3.53 (t, <i>J</i> = 6.7 Hz, 2H), 3.36 (t, <i>J</i> = 6.7 Hz, 2H), 3.30 (t, <i>J</i> = 6.8 Hz, 2H), 2.86 (t, <i>J</i> = 6.6 Hz, 2H), 1.70–1.90 (m, 4H). HRMS (ESI) for C<sub>13</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 278.0958; found, 278.0963. Purity was determined as 95% by HPLC (210 nm). Rt: 0.93 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 3-(Oxazolo[5,4-<i>c</i>]pyridin-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>26</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of oxazolo[5,4-<i>c</i>]pyridine-2-thiol (150 mg, 0.49 mmol) with 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (115.1 mg, 0.64 mmol) followed by purification by preparative HPLC (20% to 80% MeCN/1% ammonium bicarbonate solution) afforded 3-(oxazolo[5,4-<i>c</i>]pyridin-2-ylthio)-1-(pyrrolidin-1-yl)propan-1-one (<b>26</b>) as a yellow solid (16.2 mg, 12% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.95 (d, <i>J</i> = 0.8 Hz, 1H), 8.49 (d, <i>J</i> = 5.3 Hz, 1H), 7.71 (dd, <i>J</i> = 5.1, 0.8 Hz, 1H), 3.54 (t, <i>J</i> = 6.6 Hz, 2H), 3.37 (t, <i>J</i> = 6.6 Hz, 2H), 2.86 (t, <i>J</i> = 6.8 Hz, 2H), 1.81–1.90 (m, 2H), 1.72–1.80 (m, 2H). HRMS (ESI) for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 300.0777; found, 300.0784. Purity was determined as >95% by HPLC (274 nm). Rt: 0.92 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3-((5-Morpholinobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>17</b>)</h3><div class="NLM_p last">CS<sub>2</sub> (247 mg, 4.87 mmol) was added to a solution of 2-amino-4-morpholinophenol (239 mg, 1.22 mmol) and KOH (276 mg, 4.87 mmol) in EtOH (10 mL). The vial was then sealed and the mixture heated up to 100 °C for 3 h. Upon completion of the reaction monitored by LCMS, the solution was acidified with HCl (4 M in dioxane), the solvent removed under vacuum, and the crude triturated with dichloromethane and filtered, affording a brown solid (258 mg, 80% yield). The crude was dissolved in acetonitrile (3 mL), and then 3-chloro-1-(pyrrolidin-1-yl)propan-1-one (222 mg, 1.24 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (626 mg, 1.90 mmol) were added. The vial was sealed and heated up to 100 °C for 1 h in a microwave reactor. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum affording a brown crude that was purified on silica gel by flash chromatography (50% to 100% ethyl acetate/cyclohexanes). The selected fractions were combined and the solvent was removed affording 3-((5-morpholinobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)propan-1-one (<b>17</b>) as a pale brown solid (16.2 mg, 5% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): = 7.47 (d, <i>J</i> = 9.1 Hz, 1H), 7.17 (d, <i>J</i> = 2.3 Hz, 1H), 6.95 (dd, <i>J</i> = 9.1, 2.5 Hz, 1H), 3.69–3.80 (m, 4H), 3.47 (t, <i>J</i> = 6.7 Hz, 2H), 3.36 (t, <i>J</i> = 6.8 Hz, 2H), 3.29 (t, <i>J</i> = 6.6 Hz, 2H), 3.05–3. δ13 (m, 4H), 2.82 (t, <i>J</i> = 6.7 Hz, 2H), 1.71–1.90 (m, 4H). MS (ESI): <i>m</i>/<i>z</i> = 362; [M + H]<sup>+</sup>. Purity was determined as >95% by HPLC (236 nm). Rt: 1.06 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> General Procedure for the Synthesis of Compounds <b>6</b>, <b>27</b>–<b>29</b>, <b>33</b>, <b>35</b>, <b>38</b>, and <b>40</b>–<b>47</b></h3><div class="NLM_p">3-Chloropropionic acid (6.93 mmol, 760 mg, or the equivalent 3-chlorobutanoic acid when required) was added to a suspension of 5-chlorobenzo[<i>d</i>]oxazole-2-thiol (5.33 mmol, 1000 mg) and Cs<sub>2</sub>CO<sub>3</sub> (10.67 mmol, 3510 mg) in acetonitrile (10 mL). The resulting mixture was stirred at 100 °C for 1 h in a microwave reactor. Upon completion of the reaction by LCMS, the solution was partitioned between water and dichloromethane. The aqueous phase was then acidified with HCl (1 M aqueous solution). The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was triturated with cyclohexanes and then dried, affording 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid as a pale pink solid (1260 mg, 82% yield). The solid was used as a such without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ = 12.52 (br. s., 1H), 7.78 (d, <i>J</i> = 2.02 Hz, 1H), 7.69 (d, <i>J</i> = 8.70 Hz, 1H), 7.37 (dd, <i>J</i> = 2.15, 8.72 Hz, 1H), 3.48 (t, <i>J</i> = 6.82 Hz, 2H), 2.83 (t, <i>J</i> = 6.82 Hz, 2H). MS (ESI): <i>m</i>/<i>z</i> = 258, 260; [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed.</div><div class="NLM_p last">Propylphosphonic acid anhydride (T3P, 1.5 equiv) was added to a solution of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (1 equiv), the corresponding amine (1.2 equiv), and Et<sub>3</sub>N (2.5 equiv) in dichloromethane. The solution was then stirred at rt overnight. Upon completion of the reaction by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was then dry loaded onto silica and purified by flash chromatography or alternatively dissolved in DMSO (1.0–1.5 mL) and purified by preparative HPLC. The selected fractions were combined and the solvent was removed under vacuum to afford the desired compound.</div></div><div id="sec4_13_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)butan-1-one (<b>6</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)butanoic acid (139 mg, 0.51 mmol) with pyrrolidine (44.2 mg, 0.61 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(pyrrolidin-1-yl)butan-1-one (<b>6</b>) as a white solid (46.2 mg, 28% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.78 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 4.22–4.33 (m, 1H), 3.40 (t, <i>J</i> = 6.8 Hz, 2H), 3.29 (t, <i>J</i> = 6.6 Hz, 2H), 2.91 (dd, <i>J</i> = 16.4, 5.3 Hz, 1H), 2.76 (dd, <i>J</i> = 16.7, 7.1 Hz, 1H), 1.82–1.91 (m, 2H), 1.71–1.81 (m, 2H), 1.53 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 325.0772; found, 325.0785. Purity was determined as >95% by HPLC (289 nm). Rt: 1.27 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (±)-3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(2-methylpyrrolidin-1-yl)propan-1-one (<b>27</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70 mg, 0.27 mmol) with 2-methylpyrrolidine (27.7 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded (±)-3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(2-methylpyrrolidin-1-yl)propan-1-one (<b>27</b>) as an orange oil (52.1 mg, 59% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 80 °C): δ = 7.69 (d, <i>J</i> = 2.3 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.33 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.97–4.13 (m, 1H), 3.54 (t, <i>J</i> = 6.8 Hz, 2H), 3.32–3.48 (m, 2H), 2.76–2.89 (m, 2H), 1.75–2.02 (m, 3H), 1.47–1.67 (m, 1H), 1.13 (d, <i>J</i> = 6.3 Hz, 3H). HRMS (ESI) for C<sub>15</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 325.0777; found, 325.0776. Purity was determined as >95% by HPLC (288 nm). Rt: 1.29 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(3-methylpyrrolidin-1-yl)propan-1-one (<b>28</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70.0 mg, 0.27 mmol) with 3-methylpyrrolidine hydrochloride (39.6 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(3-methylpyrrolidin-1-yl)propan-1-one (<b>28</b>) as a white solid (46.7 mg, 53% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.77 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.36 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.42–3.61 (m, 4H), 3.16–3.38 (m, 1H), 2.74–2.94 (m, 3H), 2.09–2.30 (m, 1H), 1.87–2.04 (m, 1H), 1.32–1.56 (m, 1H), 1.00 (dd, <i>J</i> = 6.6, 1.0 Hz, 3H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 325.0772; found, 325.0783. Purity was determined as >95% by HPLC (252 nm). Rt: 1.29 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(3,3-difluoropyrrolidin-1-yl)propan-1-one (<b>29</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70.0 mg, 0.27 mmol) with 3,3-difluoropyrrolidine (39.6 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(3,3-difluoropyrrolidin-1-yl)propan-1-one (<b>29</b>) as a white solid (55.4 mg, 59% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.75–7.78 (m, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.91 (t, <i>J</i> = 13.1 Hz, 1H), 3.63–3.77 (m, 2H), 3.46–3.56 (m, 3H), 2.87 (dt, <i>J</i> = 19.3, 6.7 Hz, 2H), 2.31–2.47 (m, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>13</sub>ClF<sub>2</sub>N<sub>2</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 369.0247; found, 369.0256. Purity was determined as >95% by HPLC (252 nm). Rt: 1.24 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 1-(Azetidin-1-yl)-3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propan-1-one (<b>33</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70 mg, 0.27 mmol) with azetidine hydrochloride (30.50 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 1-(azetidin-1-yl)-3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propan-1-one (<b>33</b>) as a white solid (10.2 mg, 12% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.57 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 4.34 (t, <i>J</i> = 7.1 Hz, 2H), 4.06 (t, <i>J</i> = 7.6 Hz, 2H), 3.80 (t, <i>J</i> = 7.7 Hz, 2H), 2.61 (t, <i>J</i> = 6.9 Hz, 2H), 2.14 (quin, <i>J</i> = 7.7 Hz, 2H). HRMS (ESI) for C<sub>13</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 297.0464; found, 297.0461. Purity was determined as >95% by HPLC (261 nm). Rt: 1.11 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>,<i>N</i>-diethylpropanamide (<b>35</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70 mg, 0.27 mmol) with diethylamine (24.1 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>,<i>N</i>-diethylpropanamide (<b>35</b>) as a colorless oil (47.8 mg, 56% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.73–7.78 (m, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.35 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 3.50 (t, <i>J</i> = 6.6 Hz, 2H), 3.23–3.30 (m, 4H), 2.90 (t, <i>J</i> = 6.7 Hz, 2H), 0.98–1.11 (m, 6H). HRMS (ESI) for C<sub>14</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 313.0777; found, 313.0775. Purity was determined as >95% by HPLC (288 nm). Rt: 1.29 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-cyclopentylpropanamide (<b>38</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (60.0 mg, 0.23 mmol) with cyclopentamine (23.8 mg, 0.28 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-cyclopentylpropanamide (<b>38</b>) as a white solid (12.1 mg, 16% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.92 (d, <i>J</i> = 7.1 Hz, 1H), 7.77 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.99 (sxt, <i>J</i> = 7.1 Hz, 1H), 3.48 (t, <i>J</i> = 6.8 Hz, 2H), 2.63 (t, <i>J</i> = 6.8 Hz, 2H), 1.72–1.84 (m, 2H), 1.54–1.66 (m, 2H), 1.42–1.54 (m, 2H), 1.27–1.40 (m, 2H). HRMS (ESI) for C<sub>15</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 347.0591; found, 347.0582. Purity was determined as >95% by HPLC (288 nm). Rt: 1.25 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(4-methylpiperazin-1-yl)propan-1-one (<b>40</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (60 mg, 0.23 mmol) with <i>N</i>-methylpiperazine (27.9 mg, 0.28 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(4-methylpiperazin-1-yl)propan-1-one (<b>40</b>) as a white solid (43.7 mg, 55% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.76 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.35 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.43–3.53 (m, 4H), 3.36–3.42 (m, 2H), 2.91 (t, <i>J</i> = 6.6 Hz, 2H), 2.20–2.30 (m, 4H), 2.16 (s, 3H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, calcd, 340.0886; found, 340.0885. Purity was determined as >95% by HPLC (288 nm). Rt: 1.11 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(1,1-dioxidothiomorpholino)propan-1-one (<b>41</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (50 mg, 0.19 mmol) with thiomorpholine 1,1-dioxide (31.5 mg, 0.23 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(1,1-dioxidothiomorpholino)propan-1-one (<b>41</b>) as a white solid (50.7 mg, 70% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.77 (d, <i>J</i> = 2.3 Hz, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.80–3.94 (m, 4H), 3.51 (t, <i>J</i> = 6.7 Hz, 2H), 3.21–3.28 (m, 2H), 3.06–3.14 (m, 2H), 3.02 (t, <i>J</i> = 6.7 Hz, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup>, calcd, 375.0240; found, 375.0235. Purity was determined as >95% by HPLC (288 nm). Rt: 1.11 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(1,1-dioxidothiazolidin-3-yl)propan-1-one (<b>42</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (90.0 mg, 0.35 mmol) with thiazolidine-1,1-dioxide (51.3 mg, 0.41 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(1,1-dioxidothiazolidin-3-yl)propan-1-one (<b>42</b>) as a white solid (8.0 mg, 6% yield). <sup>1</sup>H NMR (chloroform-<i>d</i>, 400 MHz): δ = 7.54–7.61 (m, 1H), 7.37 (d, <i>J</i> = 8.6 Hz, 1H), 7.24 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 4.56 (s, 1H), 4.50 (s, 1H), 4.17 (t, <i>J</i> = 7.2 Hz, 1H), 4.06 (t, <i>J</i> = 6.9 Hz, 1H), 3.53–3.63 (m, 2H), 3.37 (t, <i>J</i> = 7.1 Hz, 1H), 3.29 (t, <i>J</i> = 7.2 Hz, 1H), 3.03 (t, <i>J</i> = 6.6 Hz, 1H), 2.95 (t, <i>J</i> = 6.7 Hz, 1H). HRMS (ESI) for C<sub>13</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>4</sub>S<sub>2</sub>Na [M + Na]<sup>+</sup>, calcd, 382.9897; found, 382.9879. Purity was determined as >95% by HPLC (252 nm). Rt: 1.17 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(4-(methylsulfonyl)piperidin-1-yl)propan-1-one (<b>43</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70.0 mg, 0.27 mmol) with 1-(methylsulfonyl)piperidine (53.7 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(4-(methylsulfonyl)piperidin-1-yl)propan-1-one (<b>43</b>) as a white solid (52.0 mg, 48% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.76 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.35 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 4.42–4.62 (m, 1H), 3.91–4.04 (m, 1H), 3.50 (t, <i>J</i> = 6.6 Hz, 2H), 3.32–3.39 (m, 1H), 2.88–3.10 (m, 6H), 2.56–2.69 (m, 1H), 1.98–2.07 (m, 2H), 1.49–1.61 (m, 1H), 1.33–1.49 (m, 1H). HRMS (ESI) for C<sub>16</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>4</sub>S<sub>2</sub>Na [M + Na]<sup>+</sup>, calcd, 425.0367; found, 425.0359. Purity was determined as >95% by HPLC (252 nm). Rt: 1.14 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(4-(methylsulfonyl)piperazin-1-yl)propan-1-one (<b>44</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (70.0 mg, 0.27 mmol) with 1-(methylsulfonyl)piperazine (54.1 mg, 0.32 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(4-(methylsulfonyl)piperazin-1-yl)propan-1-one (<b>44</b>) as a white solid (34.1 mg, 31% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.77 (d, <i>J</i> = 2.3 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.36 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.47–3.62 (m, 6H), 3.05–3.16 (m, 4H), 2.95 (t, <i>J</i> = 6.7 Hz, 2H), 2.88 (s, 3H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub>Na [M + Na]<sup>+</sup>, calcd, 426.0319; found, 426.0327. Purity was determined as >95% by HPLC (252 nm). Rt: 1.19 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> (±)3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(3-(methylsulfonyl)pyrrolidin-1-yl)propan-1-one (<b>45</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (80.0 mg, 0.31 mmol) with 3-(methylsulfonyl)pyrrolidine (56.1 mg, 0.37 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded (±)3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-1-(3-(methylsulfonyl)pyrrolidin-1-yl)propan-1-one (<b>45</b>) as a white solid (72.9 mg, 60% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.77 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.91–4.07 (m, 1H), 3.75–3.87 (m, 1H), 3.67–3.73 (m, 1H), 3.54–3.63 (m, 1H), 3.47–3.53 (m, 3H), 3.04 (s, 3H), 2.83–2.95 (m, 2H), 2.27–2.36 (m, 1H), 2.19–2.27 (m, 1H). HRMS (ESI) for C<sub>15</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup>, calcd, 389.0391; found, 389.0390. Purity was determined as >95% by HPLC (252 nm). Rt: 1.11 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-(1,1-dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-<i>N</i>-methylpropanamide (<b>46</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (80.0 mg, 0.31 mmol) with 4-(methylamino)tetrahydro-2<i>H</i>-thiopyran 1,1-dioxide (60.4 mg, 0.37 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-(1,1-dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-<i>N</i>-methylpropanamide (<b>46</b>) as a white solid (49.0 mg, 36% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.76 (d, <i>J</i> = 1.7 Hz, 1H), 7.64–7.71 (m, 1H), 7.30–7.42 (m, 1H), 4.48–4.75 (m, 0.6H), 3.95–4.28 (m, 0.4H), 3.47–3.59 (m, 2H), 3.32–3.44 (m, 2H), 2.97–3.13 (m, 3H), 2.92 (t, J = 6.5 Hz, 1H), 2.82 (s, 1.7H), 2.73 (s, 1.3H), 2.06–2.28 (m, 2H), 1.74–2.02 (m, 2H). The split signals coalesce when running a VT-NMR in DMSO-<i>d</i><sub>6</sub> at 80 °C. MS (ESI): <i>m</i>/<i>z</i> = 403; 405 [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed. Purity was determined as >95% by HPLC (252 nm). Rt: 1.16 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 3-((5-Chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-(1,1-dioxidotetrahydrothiophen-3-yl)-<i>N</i>-methylpropanamide (<b>47</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (80.0 mg, 0.31 mmol) with 3-(methylamino)tetrahydrothiophene 1,1-dioxide (56.1 mg, 0.37 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-(1,1-dioxidotetrahydrothiophen-3-yl)-<i>N</i>-methylpropanamide (<b>47</b>) as a white solid (43.0 mg, 36% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.69 (d, <i>J</i> = 2.3 Hz, 1H), 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.33 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 4.77–5.29 (m, 1H), 3.54 (t, <i>J</i> = 6.8 Hz, 2H), 3.23–3.36 (m, 2H), 3.06–3.18 (m, 2H), 2.93–3.00 (m, 2H), 2.89 (br s, 3H), 2.14–2.35 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> = 389; 391 [M + H]<sup>+</sup>, 1 × Cl isotopic pattern observed. Purity was determined as >95% by HPLC (289 nm). Rt: 1.18 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> General Procedure for the Synthesis of Compounds <b>48</b> and <b>49</b></h3><div class="NLM_p last">3-Chloropropionic acid (2.28 mmol, 250 mg) was added to a suspension of 5-fluorobenzo[<i>d</i>]oxazole-2-thiol (1.78 mmol, 300 mg) and Cs<sub>2</sub>CO<sub>3</sub> (3.51 mmol, 1155 mg) in acetonitrile (5 mL). The resulting mixture was stirred at 100 °C for 1 h in a microwave reactor. Upon completion of the reaction by LCMS, the solution was partitioned between water and dichloromethane. The aqueous phase was then acidified with HCl (1 M aqueous solution). The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was triturated with cyclohexanes and then dried, affording an off-white solid (406 mg, 95% yield). The solid was used as such without further purification. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 12.47 (br s, 1H), 7.68 (dd, <i>J</i> = 9.0, 4.4 Hz, 1H), 7.56 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 7.14–7.21 (m, 1H), 3.48 (t, <i>J</i> = 6.8 Hz, 2H), 2.84 (t, <i>J</i> = 6.8 Hz, 2H).</div></div><div id="sec4_13_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 1-(1,1-Dioxidothiomorpholino)-3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)propan-1-one (<b>48</b>)</h3><div class="NLM_p last">Propylphosphonic acid anhydride (T3P, 0.356 mL, 0.53 mmol) was added to a solution of 3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (100 mg, 0.41 mmol), thiomorpholine 1,1-dioxide (67.9 mg, 0.49 mmol), and Et<sub>3</sub>N (103.8 mg, 1.03 mmol) in dichloromethane (2 mL). The solution was then stirred at rt for 2 h. Upon completion of the reaction by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was then purified by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution). The selected fractions were combined and the solvent was removed affording 1-(1,1-dioxidothiomorpholino)-3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)propan-1-one (<b>48</b>) as a white solid (52.0 mg, 35% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.67 (dd, <i>J</i> = 8.8, 4.3 Hz, 1H), 7.54 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 7.17 (td, <i>J</i> = 9.2, 2.8 Hz, 1H), 3.78–3.94 (m, 4H), 3.51 (t, <i>J</i> = 6.6 Hz, 2H), 3.21–3.27 (m, 2H), 3.06–3.13 (m, 2H), 3.02 (t, <i>J</i> = 6.6 Hz, 2H). HRMS (ESI) for C<sub>14</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [M + H]<sup>+</sup>, calcd, 359.0530; found, 359.0528. Purity was determined as >95% by HPLC (284 nm). Rt: 1.06 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>N</i>-(1,1-Dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-methylpropanamide (<b>49</b>)</h3><div class="NLM_p last">By use of the general procedure described above, the reaction of 3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)propanoic acid (80.0 mg, 0.33 mmol) with 4-(methylamino)tetrahydro-2<i>H</i>-thiopyran 1,1-dioxide (65.6 mg, 0.39 mmol) followed by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded <i>N</i>-(1,1-dioxidotetrahydro-2<i>H</i>-thiopyran-4-yl)-3-((5-fluorobenzo[<i>d</i>]oxazol-2-yl)thio)-<i>N</i>-methylpropanamide (<b>49</b>) as a white solid (52.0 mg, 41% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz, 80 °C): δ = 7.62 (dd, <i>J</i> = 8.8, 4.3 Hz, 1H), 7.45 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 7.14 (dd, <i>J</i> = 9.1, 2.5 Hz, 1H), 3.55 (t, <i>J</i> = 6.8 Hz, 2H), 3.28–3.42 (m, 2H), 2.97–3.09 (m, 5H), 2.81 (br s, 3H), 2.14–2.29 (m, 2H), 1.83–1.96 (m, 2H). HRMS (ESI) for C<sub>16</sub>H<sub>19</sub>FN<sub>2</sub>O<sub>4</sub>S<sub>2</sub>, [M + H]<sup>+</sup>, calcd, 409.0663; found, 409.0674. Purity was determined as >95% by HPLC (284 nm). Rt: 1.07 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Synthesis of Compounds <b>30</b> and <b>32</b></h3><div class="NLM_p last">1-(3-Hydroxypropyl)-2-pyrrolidinone (60 mg, 0.41 mmol) and 5-chloro-2-mercaptobenzoxazole (93.3 mg, 0.50 mmol) were dissolved in dichloromethane (10 mL). Then PPh<sub>3</sub> (222.4 mg, 0.83 mmol) was added followed by the dropwise addition of DIAD (0.125 mL, 0.62 mmol). The resultant solution was stirred at rt overnight. Upon completion of the reaction monitored by LCMS, the solution was partitioned between water and dichloromethane. The organic phase was separated, dried over MgSO<sub>4</sub>, filtered and the solvent removed under vacuum. The resulting crude was then purified by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution). The selected fractions were combined and the solvent was removed under vacuum to afford 1-(3-((5-chlorobenzo[<i>d</i>]oxazol-2-yl)thio)propyl)pyrrolidin-2-one (<b>30</b>) as a yellow oil (88.4 mg, 68% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.76 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.22–3.39 (m, 6H), 2.22 (t, <i>J</i> = 8.1 Hz, 2H), 1.89–2.02 (m, 4H). HRMS (ESI) for C<sub>14</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup>, calcd, 333.0435; found, 333.0437. Purity was determined as >95% by HPLC (288 nm). Rt: 1.18 min (Acquity UPLC BEH C18).</div></div><div id="sec4_13_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 5-Chloro-2-((3-(pyrrolidin-1-yl)propyl)thio)benzo[<i>d</i>]oxazole (<b>32</b>)</h3><div class="NLM_p last">By use of the Mitsunobu procedure described above, the reaction of 3-(pyrrolidin-1-yl)propan-1-ol (80 mg, 0.61 mmol) with 5-chloro-2-mercaptobenzoxazole (137.9 mg, 0.74 mmol) followed by purification by preparative HPLC (30% to 100% MeCN/1% ammonium bicarbonate solution) afforded 5-chloro-2-((3-(pyrrolidin-1-yl)propyl)thio)benzo[<i>d</i>]oxazole (<b>32</b>) as a white solid (79.2 mg, 42% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.75 (d, <i>J</i> = 2.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.6 Hz, 1H), 7.35 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 3.36 (t, <i>J</i> = 7.2 Hz, 2H), 2.38–2.46 (m, 4H), 1.94 (quin, <i>J</i> = 7.0 Hz, 2H), 1.62–1.71 (m, 4H). HRMS (ESI) for C<sub>14</sub>H<sub>18</sub>ClN<sub>2</sub>OS [M + H]<sup>+</sup>, calcd, 297.0823; found, 297.0832. Purity was determined as >95% by HPLC (287 nm). Rt: 1.05 min (Acquity UPLC BEH C18).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00003" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00003?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00003</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings with associated biochemical and biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Safety report, antimicrobial panel results, virtual site of metabolism prediction, GSH trapping experiments, and CYP450 inhibition assay for compound <b>1</b> as well as additional biochemical and biological data for compounds <b>2</b>–<b>49</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_001.csv">jm0c00003_si_001.csv (4.04 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf">jm0c00003_si_002.pdf (456.62 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00003" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abraham L. Moure</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine, 
     and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0255-1036" title="Orcid link">http://orcid.org/0000-0003-0255-1036</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5c3d3e2e3d343d3172247230332c39261c3b2f37723f3331"><span class="__cf_email__" data-cfemail="7a1b18081b121b1754025416150a1f003a1d091154191517">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Modesto Remuiñán Blanco</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3e53515a5b4d4a51105c104c5b534b57505f507e594d55105d5153"><span class="__cf_email__" data-cfemail="deb3b1babbadaab1f0bcf0acbbb3abb7b0bfb09eb9adb5f0bdb1b3">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yossef Av-Gay</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine, 
    Department of Microbiology
and Immunology, 
     and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9547-0237" title="Orcid link">http://orcid.org/0000-0002-9547-0237</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2b52445858426b464a4247055e494805484a"><span class="__cf_email__" data-cfemail="60190f131309200d01090c4e1502034e0301">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gagandeep Narula</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine, 
    Department of Microbiology
and Immunology, 
     and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Flavia Sorrentino</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine, 
     and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adama Bojang</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine, 
    Department of Microbiology
and Immunology, 
     and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clement K. M. Tsui</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carine Sao Emani</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine and , , University of British
Columbia, Vancouver, British Columbia V6T 1Z3, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Esther Porras-De Francisco</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beatriz Díaz</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">María José Rebollo-López</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pedro Alfonso Torres-Gómez</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva María López-Román</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Isabel Camino</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Casado Castro</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Guijarro López</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fátima Ortega</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lluis Ballell</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Barros-Aguirre</span> - <span class="hlFld-Affiliation affiliation">Diseases
of the Developing World (DDW), Global Health Catalyst, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4099-0438" title="Orcid link">http://orcid.org/0000-0002-4099-0438</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Funding for this research was provided by the Tres Cantos Open Lab Foundation (Project Code TC188) and the European Uniońs Seventh Framework Programme (Grant Agreement No. 291799<i>)</i> to A.L.M. and the Canadian Institute of Health Research Grant PJT-148646 to Y.A.-G. MymA and ethA strains were kindly donated by D. Hung and her team at the Broad Institute. We thank Virginia Pichler for testing compound <b>1</b> against different mycobacteria species. We gratefully acknowledge the inspiring scientific discussions with Joseph Chao, Xingji Zheng, and the GSK DDW staff as well as the support provided by the TCOLF operations team during all the stages of the project.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">aminobenzotriazole</p></td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">artificial membrane permeability</p></td></tr><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony forming unit</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetics</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EI</td><td class="NLM_def"><p class="first last">electron impact</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">ETH</td><td class="NLM_def"><p class="first last">ethionamide</p></td></tr><tr><td class="NLM_term">FAD</td><td class="NLM_def"><p class="first last">flavin-adenine dinucleotide</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectroscopy</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">MCPBA</td><td class="NLM_def"><p class="first last">meta-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistant</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimal inhibitory concentration</p></td></tr><tr><td class="NLM_term">Mtb</td><td class="NLM_def"><p class="first last"><i>Mycobacterium tuberculosis</i></p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">OD</td><td class="NLM_def"><p class="first last">optical density</p></td></tr><tr><td class="NLM_term">PCR</td><td class="NLM_def"><p class="first last">polymerase chain reaction</p></td></tr><tr><td class="NLM_term">PFI</td><td class="NLM_def"><p class="first last">property forecast index</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SNP</td><td class="NLM_def"><p class="first last">single nucleotide polymorphism</p></td></tr><tr><td class="NLM_term">TB</td><td class="NLM_def"><p class="first last">tuberculosis</p></td></tr><tr><td class="NLM_term">TBME</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl methyl ether</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">UPLC</td><td class="NLM_def"><p class="first last">ultrahigh pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">WGS</td><td class="NLM_def"><p class="first last">whole genome sequencing</p></td></tr><tr><td class="NLM_term">XDR</td><td class="NLM_def"><p class="first last">extensively drug resistant</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65360" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65360" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Global
Tuberculosis Report 2019</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global%0ATuberculosis+Report+2019%3B+World+Health+Organization%3A+Geneva%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%250ATuberculosis%2520Report%25202019%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span> <i>WHO
Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+WHO%0ATreatment+Guidelines+for+Drug-Resistant+Tuberculosis%2C+2016+Update%3B+World+Health+Organization%3A+Geneva%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWHO%250ATreatment%2520Guidelines%2520for%2520Drug-Resistant%2520Tuberculosis%252C%25202016%2520Update%26pub%3DWorld%2520Health%2520Organization%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span> <i>The
Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis.
Interim Policy Guidance</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The%0AUse+of+Delamanid+in+the+Treatment+of+Multidrug-Resistant+Tuberculosis.%0AInterim+Policy+Guidance%3B+World+Health+Organization%3A+Geneva%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%250AUse%2520of%2520Delamanid%2520in%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Tuberculosis.%250AInterim%2520Policy%2520Guidance%26pub%3DWorld%2520Health%2520Organization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span> <i>The
Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis:
Interim Policy Guidance</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The%0AUse+of+Bedaquiline+in+the+Treatment+of+Multidrug-Resistant+Tuberculosis%3A%0AInterim+Policy+Guidance%3B+World+Health+Organization%3A+Geneva%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%250AUse%2520of%2520Bedaquiline%2520in%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Tuberculosis%253A%250AInterim%2520Policy%2520Guidance%26pub%3DWorld%2520Health%2520Organization%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoagland, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">New agents for the treatment of drug-resistant mycobacterium tuberculosis</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2Fj.addr.2016.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27151308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2016&pages=55-72&author=D.+T.+Hoaglandauthor=J.+Liuauthor=R.+B.+Leeauthor=R.+E.+Lee&title=New+agents+for+the+treatment+of+drug-resistant+mycobacterium+tuberculosis&doi=10.1016%2Fj.addr.2016.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New agents for the treatment of drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Hoagland, Daniel T.; Liu, Jiuyu; Lee, Robin B.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-72</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inadequate dosing and incomplete treatment regimens, coupled with the ability of the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have fueled the rise of multidrug-resistant tuberculosis (MDR-TB).  Treatment of MDR-TB infections is a major clin. challenge that has few viable or effective solns.; therefore patients face a poor prognosis and years of treatment.  This review focuses on emerging drug classes that have the potential for treating MDR-TB and highlights their particular strengths as leads including their mode of action, in vivo efficacy, and key medicinal chem. properties.  Examples include the newly approved drugs bedaquiline and delaminid, and other agents in clin. and late preclin. development pipeline for the treatment of MDR-TB.  Herein, we discuss the challenges to developing drugs to treat tuberculosis and how the field has adapted to these difficulties, with an emphasis on drug discovery approaches that might produce more effective agents and treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBEswjNcHj27Vg90H21EOLACvtfcHk0liSGbGebnjWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D&md5=7c8ca15b9b493cceaf3d51d93b9afcec</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHoagland%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DNew%2520agents%2520for%2520the%2520treatment%2520of%2520drug-resistant%2520mycobacterium%2520tuberculosis%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D102%26spage%3D55%26epage%3D72%26doi%3D10.1016%2Fj.addr.2016.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divangahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehme, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis</span>. <i>Nature Reviews Disease Primers</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">16076</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2016.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrdp.2016.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27784885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=16076&author=M.+Paiauthor=M.+A.+Behrauthor=D.+Dowdyauthor=K.+Dhedaauthor=M.+Divangahiauthor=C.+C.+Boehmeauthor=A.+Ginsbergauthor=S.+Swaminathanauthor=M.+Spigelmanauthor=H.+Getahunauthor=D.+Menziesauthor=M.+Raviglione&title=Tuberculosis&doi=10.1038%2Fnrdp.2016.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis</span></div><div class="casAuthors">Pai Madhukar; Behr Marcel A; Divangahi Maziar; Menzies Dick; Pai Madhukar; Dowdy David; Dheda Keertan; Boehme Catharina C; Ginsberg Ann; Swaminathan Soumya; Spigelman Melvin; Getahun Haileyesus; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16076</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex.  Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body.  Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss.  Only active pulmonary TB is contagious.  In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings.  Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests.  Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens.  Although the Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic.  Thus, efforts are underway to develop newer vaccines with improved efficacy.  New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkhlsQg_ocTUPI-fCgwosgfW6udTcc2eaYIujJN9z8dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D&md5=b2170e953514895635d3d13d8deefa24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2016.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2016.76%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DM.%26aulast%3DBehr%26aufirst%3DM.%2BA.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DDivangahi%26aufirst%3DM.%26aulast%3DBoehme%26aufirst%3DC.%2BC.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DSpigelman%26aufirst%3DM.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DMenzies%26aufirst%3DD.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DTuberculosis%26jtitle%3DNature%2520Reviews%2520Disease%2520Primers%26date%3D2016%26volume%3D2%26spage%3D16076%26doi%3D10.1038%2Fnrdp.2016.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">The challenge of new drug discovery for tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1038/nature09657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnature09657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21270886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=483-490&author=A.+Koulauthor=E.+Arnoultauthor=N.+Lounisauthor=J.+Guillemontauthor=K.+Andries&title=The+challenge+of+new+drug+discovery+for+tuberculosis&doi=10.1038%2Fnature09657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The challenge of new drug discovery for tuberculosis</span></div><div class="casAuthors">Koul, Anil; Arnoult, Eric; Lounis, Nacer; Guillemont, Jerome; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7331</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) is more prevalent in the world today than at any other time in human history.  Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance.  A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clin. development of new drugs.  The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new mol. scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control.  Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host.  In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9J_uIM64vSrVg90H21EOLACvtfcHk0lgz0dArYoqQ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D&md5=2c70f07fc0c88727f6b20d35f0c85695</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature09657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09657%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DThe%2520challenge%2520of%2520new%2520drug%2520discovery%2520for%2520tuberculosis%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D483%26epage%3D490%26doi%3D10.1038%2Fnature09657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payne, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwynn, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span> <span> </span><span class="NLM_article-title">Drugs for bad bugs: confronting the challenges of antibacterial discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1038/nrd2201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrd2201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=17159923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=29&author=D.+J.+Payneauthor=M.+N.+Gwynnauthor=D.+J.+Holmesauthor=D.+L.+Pompliano&title=Drugs+for+bad+bugs%3A+confronting+the+challenges+of+antibacterial+discovery&doi=10.1038%2Fnrd2201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs for bad bugs: confronting the challenges of antibacterial discovery</span></div><div class="casAuthors">Payne, David J.; Gwynn, Michael N.; Holmes, David J.; Pompliano, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-40</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets.  Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action.  Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH1tM2BSZbWLVg90H21EOLACvtfcHk0lgz0dArYoqQ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfM&md5=18100253f9868af578ea621ab98a5c86</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2201%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DD.%2BJ.%26aulast%3DGwynn%26aufirst%3DM.%2BN.%26aulast%3DHolmes%26aufirst%3DD.%2BJ.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26atitle%3DDrugs%2520for%2520bad%2520bugs%253A%2520confronting%2520the%2520challenges%2520of%2520antibacterial%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D29%26doi%3D10.1038%2Fnrd2201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, N. S.</span></span> <span> </span><span class="NLM_article-title">Hit generation in TB drug discovery: from genome to granuloma</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1887</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00602</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00602" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=1887-1916&author=T.+Yuanauthor=N.+S.+Sampson&title=Hit+generation+in+TB+drug+discovery%3A+from+genome+to+granuloma&doi=10.1021%2Facs.chemrev.7b00602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Hit Generation in TB Drug Discovery: From Genome to Granuloma</span></div><div class="casAuthors">Yuan, Tianao; Sampson, Nicole S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1887-1916</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB epidemic.  Recent efforts have focused on the development of whole-cell screening assays because biochem., target-based inhibitor screens during the last two decades have not delivered new TB drugs.  Mycobacterium tuberculosis (Mtb), the causative agent of TB, encounters diverse microenvironments and can be found in a variety of metabolic states in the human host.  Due to the complexity and heterogeneity of Mtb infection, no single model can fully recapitulate the in vivo conditions in which Mtb is found in TB patients, and there is no single "std." screening condition to generate hit compds. for TB drug development.  However, current screening assays have become more sophisticated as researchers attempt to mirror the complexity of TB disease in the lab.  In this review, we describe efforts using surrogates and engineered strains of Mtb to focus screens on specific targets.  We explain model culture systems ranging from carbon starvation to hypoxia, and combinations thereof, designed to represent the microenvironment which Mtb encounters in the human body.  We outline ongoing efforts to model Mtb infection in the lung granuloma.  We assess these different models, their ability to generate hit compds., and needs for further TB drug development, to provide direction for future TB drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzrykH7_zp77Vg90H21EOLACvtfcHk0lgz0dArYoqQ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCksr4%253D&md5=8ab51150e2eaeeb672ea666afb64ebf9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00602%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DSampson%26aufirst%3DN.%2BS.%26atitle%3DHit%2520generation%2520in%2520TB%2520drug%2520discovery%253A%2520from%2520genome%2520to%2520granuloma%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26spage%3D1887%26epage%3D1916%26doi%3D10.1021%2Facs.chemrev.7b00602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span> <span> </span><span class="NLM_article-title">The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">159</span>, <span class="refDoi"> DOI: 10.1038/nrmicro3200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrmicro3200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=24487820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Sntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=159&author=V.+Dartois&title=The+path+of+anti-tuberculosis+drugs%3A+from+blood+to+lesions+to+mycobacterial+cells&doi=10.1038%2Fnrmicro3200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells</span></div><div class="casAuthors">Dartois, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">159-167</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets.  However, most currently used anti-tuberculosis drugs were introduced into clin. use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies.  In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technol. could be used to design optimized multidrug regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_pBYMx4IImbVg90H21EOLACvtfcHk0limHiGAlw6t0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Sntrs%253D&md5=fc2208aa14e3e937b230d0a7ae78940a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro3200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro3200%26sid%3Dliteratum%253Aachs%26aulast%3DDartois%26aufirst%3DV.%26atitle%3DThe%2520path%2520of%2520anti-tuberculosis%2520drugs%253A%2520from%2520blood%2520to%2520lesions%2520to%2520mycobacterial%2520cells%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2014%26volume%3D12%26spage%3D159%26doi%3D10.1038%2Fnrmicro3200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prideaux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Via, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarathy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  Iii</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span> <span> </span><span class="NLM_article-title">The association between sterilizing activity and drug distribution into tuberculosis lesions</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1038/nm.3937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnm.3937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=26343800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1223-1227&author=B.+Prideauxauthor=L.+E.+Viaauthor=M.+D.+Zimmermanauthor=S.+Eumauthor=J.+Sarathyauthor=P.+O%E2%80%99Brienauthor=C.+Chenauthor=F.+Kayaauthor=D.+M.+Weinerauthor=P.-Y.+Chenauthor=T.+Songauthor=M.+Leeauthor=T.+S.+Shimauthor=J.+S.+Choauthor=W.+Kimauthor=S.+N.+Choauthor=K.+N.+Olivierauthor=C.+E.+Barryauthor=V.+Dartois&title=The+association+between+sterilizing+activity+and+drug+distribution+into+tuberculosis+lesions&doi=10.1038%2Fnm.3937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The association between sterilizing activity and drug distribution into tuberculosis lesions</span></div><div class="casAuthors">Prideaux, Brendan; Via, Laura E.; Zimmerman, Matthew D.; Eum, Seokyong; Sarathy, Jansy; O'Brien, Paul; Chen, Chao; Kaya, Firat; Weiner, Danielle M.; Chen, Pei-Yu; Song, Taeksun; Lee, Myungsun; Shim, Tae Sun; Cho, Jeong Su; Kim, Wooshik; Cho, Sang Nae; Olivier, Kenneth N.; Barry, Clifton E., III; Dartois, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1223-1227</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Finding new treatment-shortening antibiotics to improve cure rates and curb the alarming emergence of drug resistance is the major objective of tuberculosis (TB) drug development.  Using a matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging suite in a biosafety containment facility, we show that the key sterilizing drugs rifampicin and pyrazinamide efficiently penetrate the sites of TB infection in lung lesions.  Rifampicin even accumulates in necrotic caseum, a crit. lesion site where persisting tubercle bacilli reside.  In contrast, moxifloxacin, which is active in vitro against a subpopulation of Mycobacterium tuberculosis that persists in specific niches under drug pressure and has achieved treatment shortening in mice, does not diffuse well in caseum, concordant with its failure to shorten therapy in recent clin. trials.  We suggest that such differential spatial distribution and kinetics of accumulation in lesions may create temporal and spatial windows of monotherapy in specific niches, allowing the gradual development of multidrug-resistant TB.  We propose an alternative working model to prioritize new antibiotic regimens based on quant. and spatial distribution of TB drugs in the major lesion types found in human lungs.  The finding that lesion penetration may contribute to treatment outcome has wide implications for TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0jbKV6VoIrVg90H21EOLACvtfcHk0limHiGAlw6t0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbnF&md5=b57f73461e02f4ee62ebf8e7579c4361</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm.3937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3937%26sid%3Dliteratum%253Aachs%26aulast%3DPrideaux%26aufirst%3DB.%26aulast%3DVia%26aufirst%3DL.%2BE.%26aulast%3DZimmerman%26aufirst%3DM.%2BD.%26aulast%3DEum%26aufirst%3DS.%26aulast%3DSarathy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKaya%26aufirst%3DF.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DP.-Y.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DShim%26aufirst%3DT.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DCho%26aufirst%3DS.%2BN.%26aulast%3DOlivier%26aufirst%3DK.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DDartois%26aufirst%3DV.%26atitle%3DThe%2520association%2520between%2520sterilizing%2520activity%2520and%2520drug%2520distribution%2520into%2520tuberculosis%2520lesions%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D1223%26epage%3D1227%26doi%3D10.1038%2Fnm.3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Av-Gay, Y.</span></span> <span> </span><span class="NLM_article-title">New era of TB drug discovery and its impact on disease management</span>. <i>Curr. Treat. Options Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1007/s40506-016-0098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1007%2Fs40506-016-0098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=299-310&author=X.+Zhengauthor=Y.+Av-Gay&title=New+era+of+TB+drug+discovery+and+its+impact+on+disease+management&doi=10.1007%2Fs40506-016-0098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs40506-016-0098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40506-016-0098-0%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DAv-Gay%26aufirst%3DY.%26atitle%3DNew%2520era%2520of%2520TB%2520drug%2520discovery%2520and%2520its%2520impact%2520on%2520disease%2520management%26jtitle%3DCurr.%2520Treat.%2520Options%2520Infect.%2520Dis.%26date%3D2016%26volume%3D8%26spage%3D299%26epage%3D310%26doi%3D10.1007%2Fs40506-016-0098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez del Rio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presa Matilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres Gomez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Hoyos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez Herran, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza Losana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Av-Gay, Y.</span></span> <span> </span><span class="NLM_article-title">Development of an intracellular screen for new compounds able to inhibit mycobacterium tuberculosis growth in human macrophages</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1128/AAC.01920-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1128%2FAAC.01920-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=26503663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=640-645&author=F.+Sorrentinoauthor=R.+Gonzalez+del+Rioauthor=X.+Zhengauthor=J.+Presa+Matillaauthor=P.+Torres+Gomezauthor=M.+Martinez+Hoyosauthor=M.+E.+Perez+Herranauthor=A.+Mendoza+Losanaauthor=Y.+Av-Gay&title=Development+of+an+intracellular+screen+for+new+compounds+able+to+inhibit+mycobacterium+tuberculosis+growth+in+human+macrophages&doi=10.1128%2FAAC.01920-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages</span></div><div class="casAuthors">Sorrentino, Flavia; Gonzalez del Rio, Ruben; Zheng, Xingji; Matilla, Jesus Presa; Gomez, Pedro Torres; Hoyos, Maria Martinez; Herran, Maria Esther Perez; Losana, Alfonso Mendoza; Av-Gay, Yossef</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">640-645</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Here we describe the development and validation of an intracellular high-throughput screening assay for finding new antituberculosis compds. active in human macrophages.  The assay consists of a luciferase-based primary identification assay, followed by a green fluorescent protein-based secondary profiling assay.  Std. tuberculosis drugs and 158 previously recognized active antimycobacterial compds. were used to evaluate assay robustness.  Data show that the assay developed is a short and valuable tool for the discovery of new antimycobacterial compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE2XIe5jevhLVg90H21EOLACvtfcHk0limHiGAlw6t0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nF&md5=4ed12b5a9996d37db7a8d023ccabd48a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.01920-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01920-15%26sid%3Dliteratum%253Aachs%26aulast%3DSorrentino%26aufirst%3DF.%26aulast%3DGonzalez%2Bdel%2BRio%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DPresa%2BMatilla%26aufirst%3DJ.%26aulast%3DTorres%2BGomez%26aufirst%3DP.%26aulast%3DMartinez%2BHoyos%26aufirst%3DM.%26aulast%3DPerez%2BHerran%26aufirst%3DM.%2BE.%26aulast%3DMendoza%2BLosana%26aufirst%3DA.%26aulast%3DAv-Gay%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520an%2520intracellular%2520screen%2520for%2520new%2520compounds%2520able%2520to%2520inhibit%2520mycobacterium%2520tuberculosis%2520growth%2520in%2520human%2520macrophages%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D640%26epage%3D645%26doi%3D10.1128%2FAAC.01920-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.+S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lgUO2XAO4xMsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkening, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, A.</span></span> <span> </span><span class="NLM_article-title">Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1124/dmd.31.8.1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.31.8.1035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=12867492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVOlsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1035-1042&author=S.+Wilkeningauthor=F.+Stahlauthor=A.+Bader&title=Comparison+of+primary+human+hepatocytes+and+hepatoma+cell+line+HepG2+with+regard+to+their+biotransformation+properties&doi=10.1124%2Fdmd.31.8.1035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of primary human hepatocytes and hepatoma cell line HEPG2 with regard to their biotransformation properties</span></div><div class="casAuthors">Wilkening, Stefan; Stahl, Frank; Bader, Augustinus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1035-1042</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cultures of primary hepatocytes and hepatoma cell line HepG2 are frequently used in in vitro models for human biotransformation studies.  In this study, we characterized and compared the capacity of these model systems to indicate the presence of different classes of promutagens.  Genotoxic sensitivity, enzyme activity, and gene expression were monitored in response to treatment with food promutagens benzo[a]pyrene, dimethylnitrosamine (DMN), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).  DNA damage could be detected reliably with the comet assay in primary human hepatocytes, which were maintained in sandwich culture.  All three promutagens caused DNA damage in primary cells, but in HepG2 no genotoxic effects of DMN and PhIP could be detected.  We supposed that the lack of specific enzymes accounts for their inability to process these promutagens.  Therefore, we quantified the expression of a broad range of genes coding for drug-metabolizing enzymes with real-time reverse transcription-polymerase chain reaction.  The genes code for cytochromes P 450 and, in addn., for a series of important phase II enzymes.  The expression level of these genes in human hepatocytes was similar to those previously reported for human liver samples.  On the other hand, expression levels in HepG2 differed significantly from that in human.  Activity and expression, esp. of phase I enzymes, were demonstrated to be extremely low in HepG2 cells.  Up-regulation of specific genes by test substances was similar in both cell types.  In conclusion, human hepatocytes are the preferred model for biotransformation in human liver, whereas HepG2 cells may be useful to study regulation of drug-metabolizing enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Qp8poi_lTbVg90H21EOLACvtfcHk0lgUO2XAO4xMsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVOlsLc%253D&md5=95037777c25df8b976f1b6ef4a40cac1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.8.1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.8.1035%26sid%3Dliteratum%253Aachs%26aulast%3DWilkening%26aufirst%3DS.%26aulast%3DStahl%26aufirst%3DF.%26aulast%3DBader%26aufirst%3DA.%26atitle%3DComparison%2520of%2520primary%2520human%2520hepatocytes%2520and%2520hepatoma%2520cell%2520line%2520HepG2%2520with%2520regard%2520to%2520their%2520biotransformation%2520properties%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1035%26epage%3D1042%26doi%3D10.1124%2Fdmd.31.8.1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="note"><p class="first last">See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Supporting Information</a> for more details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osaki, H.</span></span> <span> </span><span class="NLM_article-title">In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1002/bdd.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1002%2Fbdd.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27379984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2ls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=373-378&author=A.+Watanabeauthor=K.+Mayumiauthor=K.+Nishimuraauthor=H.+Osaki&title=In+vivo+use+of+the+CYP+inhibitor+1-aminobenzotriazole+to+increase+long-term+exposure+in+mice&doi=10.1002%2Fbdd.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice</span></div><div class="casAuthors">Watanabe, Ayahisa; Mayumi, Kei; Nishimura, Kyohei; Osaki, Hiromi</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">373-378</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">1-Aminobenzotriazole (ABT) is a well-known in vivo nonspecific inhibitor of cytochrome P 450 (CYP) enzymes.  An effective dosing regimen of ABT for a multiple-administration study is needed to conduct pharmacol. studies for proof-of-concept, although it has been established for single-administration study, to characterize the pharmacokinetics of drug candidates.  This study demonstrated a suitable dosing vehicle of ABT for continuous administration and increased exposure to antipyrine, which is a nonspecific probe of CYP, using ABT for a long period in mice.  The dosing vehicle of ABT was 0.5% (w/v) hydroxypropyl methylcellulose and 0.5% (vol./vol.) Tween 80 in N,N-dimethylacetamide/20% hydroxypropyl-β-cyclodextrin aq. soln. (2:8, vol./vol.) based on the duration of apparent soly.  After implantation of an ALZET osmotic pump with ABT, the plasma concns. of ABT were maintained at more than 4.1 μg/mL over 336 h.  Compared with the vehicle group, the CLtot of antipyrine with ABT decreased to approx. one-fourth, and the BA of antipyrine with ABT increased up to 3-fold.  In addn., the enhancement of exposure of antipyrine by ABT was maintained over the 336 h.  The body wt., food consumption and hematol. parameters of mice did not change with ABT administration for 16 days.  These findings demonstrated that pretreatment of ABT can increase long-term exposure using continuous administration with the ALZET osmotic pump in mice with no overt toxicity.  It is concluded that the in vivo use of 1-aminobenzotriazole can be applied to pharmacol. studies for proof-of-concept, thus contributing to the selection of drug candidates at an early drug discovery stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH20CYqLyXE7Vg90H21EOLACvtfcHk0lgUO2XAO4xMsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2ls7rL&md5=691b76090f9936b301ac70a911bdaae5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2020%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DMayumi%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DK.%26aulast%3DOsaki%26aufirst%3DH.%26atitle%3DIn%2520vivo%2520use%2520of%2520the%2520CYP%2520inhibitor%25201-aminobenzotriazole%2520to%2520increase%2520long-term%2520exposure%2520in%2520mice%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2016%26volume%3D37%26spage%3D373%26epage%3D378%26doi%3D10.1002%2Fbdd.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span> <i>MetaSite</i>, version <span class="NLM_edition">6.0</span>; <span class="NLM_publisher-name">Molecular Discovery
Ltd.</span>; <a href="http://www.moldiscovery.com/software/metasite/" class="extLink">http://www.moldiscovery.com/software/metasite/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MetaSite%2C+version+6.0%3B+Molecular+Discovery%0ALtd.%3B+http%3A%2F%2Fwww.moldiscovery.com%2Fsoftware%2Fmetasite%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMetaSite%26pub%3DMolecular%2520Discovery%250ALtd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.-Z.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of 2-(Alkylthio)-1,3,4-Thiadiazoles and 2-(Alkylthio)-1,3-Benzothiazoles</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2770</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1021/tx3003998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx3003998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=2770-2779&author=Y.+Yangauthor=F.+Qiuauthor=J.+L.+Josephsauthor=W.+G.+Humphreysauthor=Y.-Z.+Shu&title=Bioactivation+of+2-%28Alkylthio%29-1%2C3%2C4-Thiadiazoles+and+2-%28Alkylthio%29-1%2C3-Benzothiazoles&doi=10.1021%2Ftx3003998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of 2-(Alkylthio)-1,3,4-Thiadiazoles and 2-(Alkylthio)-1,3-Benzothiazoles</span></div><div class="casAuthors">Yang, Yanou; Qiu, Feng; Josephs, Jonathan L.; Humphreys, W. Griffith; Shu, Yue-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2770-2779</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Certain functional groups/structural motifs are known to generate chem. reactive metabolites that can covalently modify essential cellular macromols. and, therefore, have the potential to disrupt biol. function and elicit idiosyncratic adverse drug reactions.  In this report, we describe the bioactivation of 5-substituted 2-(alkylthio)-1,3,4-thiadiazoles and 2-(alkylthio)-1,3-benzothiazoles, which can be added to the growing list of structural alerts.  When 5-substituted 2-(methylthio)-1,3,4-thiadiazoles and 2-(methylthio)-1,3-benzothiazole were incubated with pooled human liver microsomes in the presence of NADPH and GSH, unusual GSH adducts were formed.  Characterization of these GSH adducts by high-resoln. mass spectrometry indicated the replacement of the methylthio- group by GSH, and NMR expts. ascertained the proposed structures.  On the basis of the metabolic profile change in incubation samples with/without GSH, we proposed that the GSH adduct formation involved two steps: (1) enzymic oxidn. of the alkylthio- group to form sulfoxide and sulfone and (2) nucleophilic displacement of the formed sulfoxide and sulfone by GSH.  The proposed mechanism was confirmed by the formation of the same GSH adduct from the incubation of synthetically prepd. sulfoxide and sulfone compds. in buffer.  We found the sulfur oxidn. step was significantly inhibited (80-100%) by preincubation with 1-aminobenzotriazole but was much less affected by thermo-inactivation (0-45%), suggesting that the sulfoxidn. step is primarily catalyzed by cytochrome P450s and not by flavin monooxygenases.  We also investigated the presence of this bioactivation pathway in more than a dozen compds. contg. 2-(alkylthio)-1,3,4-thiadiazole and 2-(alkylthio)-1,3-benzothiazoles.  The common GSH adduct formation pathway demonstrated by current studies raises a new structural alert and potential liability in drug safety when 2-alkylthio derivs. of 1,3-benzothiazoles and 1,3,4-thiadiazoles are incorporated in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfJPsqwoIqbVg90H21EOLACvtfcHk0lhARA2C4SB4dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrvI&md5=c78efd64b32baf4f65be8fe5b8cd0c09</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx3003998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx3003998%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DF.%26aulast%3DJosephs%26aufirst%3DJ.%2BL.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DShu%26aufirst%3DY.-Z.%26atitle%3DBioactivation%2520of%25202-%2528Alkylthio%2529-1%252C3%252C4-Thiadiazoles%2520and%25202-%2528Alkylthio%2529-1%252C3-Benzothiazoles%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D2770%26epage%3D2779%26doi%3D10.1021%2Ftx3003998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Demonstration of the innate electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1470</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.052183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.113.052183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=23653442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1470-1479&author=H.+Engauthor=R.+Sharmaauthor=T.+S.+McDonaldauthor=D.+J.+Edmondsauthor=J.-P.+Fortinauthor=X.+Liauthor=B.+D.+Stevensauthor=D.+A.+Griffithauthor=C.+Limberakisauthor=W.+M.+Nolteauthor=D.+A.+Priceauthor=M.+Jacksonauthor=A.+S.+Kalgutkar&title=Demonstration+of+the+innate+electrophilicity+of+4-%283-%28Benzyloxy%29phenyl%29-2-%28ethylsulfinyl%29-6-%28trifluoromethyl%29pyrimidine+%28BETP%29%2C+a+small-molecule+positive+allosteric+modulator+of+the+glucagon-like+peptide-1+receptor&doi=10.1124%2Fdmd.113.052183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of the innate electrophilicity of 4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor</span></div><div class="casAuthors">Eng, Heather; Sharma, Raman; McDonald, Thomas S.; Edmonds, David J.; Fortin, Jean-Philippe; Li, Xianping; Stevens, Benjamin D.; Griffith, David A.; Limberakis, Chris; Nolte, Whitney M.; Price, David A.; Jackson, Margaret; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1470-1479</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP) represents a novel small-mol. activator of the glucagon-like peptide-1 receptor (GLP-1R), and exhibits glucose-dependent insulin secretion in rats following i.v. (but not oral) administration.  To explore the quant. pharmacol. assocd. with GLP-1R agonism in preclin. species, the in vivo pharmacokinetics of BETP were examd. in rats after i.v. and oral dosing.  Failure to detect BETP in circulation after oral administration of a 10-mg/kg dose in rats was consistent with the lack of an insulinotropic effect of orally administered BETP in this species.  Likewise, systemic concns. of BETP in the rat upon i.v. administration (1 mg/kg) were minimal (and sporadic).  In vitro incubations in bovine serum albumin, plasma, and liver microsomes from rodents and humans indicated a facile degrdn. of BETP.  Failure to detect metabolites in plasma and liver microsomal incubations in the absence of NADP was suggestive of a covalent interaction between BETP and a protein amino acid residue(s) in these matrixes.  Incubations of BETP with glutathione (GSH) in buffer revealed a rapid nucleophilic displacement of the ethylsulfoxide functionality by GSH to yield adduct M1, which indicated that BETP was intrinsically electrophilic.  The structure of M1 was unambiguously identified by comparison of its chromatog. and mass spectral properties with an authentic std.  The GSH conjugate of BETP was also characterized in NADPH- and GSH-supplemented liver microsomes and in plasma samples from the pharmacokinetic studies.  Unlike BETP, M1 was inactive as an allosteric modulator of the GLP-1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDfkt1MNLwnLVg90H21EOLACvtfcHk0lhARA2C4SB4dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjs7rK&md5=5394320704df49224ad4d28f1605c3f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.052183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.052183%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DH.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DMcDonald%26aufirst%3DT.%2BS.%26aulast%3DEdmonds%26aufirst%3DD.%2BJ.%26aulast%3DFortin%26aufirst%3DJ.-P.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DNolte%26aufirst%3DW.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDemonstration%2520of%2520the%2520innate%2520electrophilicity%2520of%25204-%25283-%2528Benzyloxy%2529phenyl%2529-2-%2528ethylsulfinyl%2529-6-%2528trifluoromethyl%2529pyrimidine%2520%2528BETP%2529%252C%2520a%2520small-molecule%2520positive%2520allosteric%2520modulator%2520of%2520the%2520glucagon-like%2520peptide-1%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D1470%26epage%3D1479%26doi%3D10.1124%2Fdmd.113.052183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.051839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.113.051839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=23610086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1375-1388&author=A.+S.+Kalgutkarauthor=T.+F.+Ryderauthor=G.+S.+Walkerauthor=S.+T.+M.+Orrauthor=S.+Cabralauthor=T.+C.+Goosenauthor=K.+Laphamauthor=H.+Eng&title=Reactive+metabolite+trapping+studies+on+imidazo-+and+2-methylimidazo%5B2%2C1-b%5Dthiazole-based+inverse+agonists+of+the+ghrelin+receptor&doi=10.1124%2Fdmd.113.051839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor</span></div><div class="casAuthors">Kalgutkar, Amit S.; Ryder, Tim F.; Walker, Gregory S.; Orr, Suvi T. M.; Cabral, Shawn; Goosen, Theunis C.; Lapham, Kimberly; Eng, Heather</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1375-1388</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The current study examd. the bioactivation potential of ghrelin receptor inverse agonists, 1-2-2-chloro-4-2H-1,2,3-triazol-2-yl benzyl-2,7-diazaspiro 3.5 nonan-7-yl-2-imidazo 2,1-b thiazol-6-yl ethanone (1) and 1-2-2-chloro-4-2H-1,2,3-triazol-2-yl benzyl-2,7-diazaspiro 3.5 nonan-7-yl-2-2-methylimidazo 2,1-b thiazol-6-yl ethanone (2), contg. a fused imidazo 2,1-b thiazole motif in the core structure.  Both compds. underwent oxidative metab. in NADPH- and glutathione-supplemented human liver microsomes to yield glutathione conjugates, which was consistent with their bioactivation to reactive species.  Mass spectral fragmentation and NMR anal. indicated that the site of attachment of the glutathionyl moiety in the thiol conjugates was on the thiazole ring within the bicycle.  Two glutathione conjugates were discerned with the imidazo 2,1-b thiazole deriv. 1.  One adduct was derived from the Michael addn. of glutathione to a putative S-oxide metabolite of 1, whereas, the second adduct was formed via the reaction of a second glutathione mol. with the initial glutathione-S-oxide adduct.  In the case of the 2-methylimidazo 2,1-b thiazole analog 2, glutathione conjugation occurred via an oxidative desulfation mechanism, possibly involving thiazole ring epoxidn. as the rate-limiting step.  Addnl. insights into the mechanism were obtained via 18O exchange and trapping studies with potassium cyanide.  The mechanistic insights into the bioactivation pathways of 1 and 2 allowed the deployment of a rational chem. intervention strategy that involved replacement of the thiazole ring with a 1,2,4-thiadiazole group to yield 2-2-chloro-4-2H-1,2,3-triazol-2-yl benzyl-2,7-diazaspiro 3.5 nonan-7-yl-2-2-methylimidazo 2,1-b 1,3,4 thiadiazol-6-yl ethanone (3).  These structural changes not only abrogated the bioactivation liability but also retained the attractive pharmacol. attributes of the prototype agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMoyDkpHUNgbVg90H21EOLACvtfcHk0lhARA2C4SB4dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajsbfI&md5=7d48d089b0cffbafbdbed4746f700367</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.051839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.051839%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DRyder%26aufirst%3DT.%2BF.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DCabral%26aufirst%3DS.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DEng%26aufirst%3DH.%26atitle%3DReactive%2520metabolite%2520trapping%2520studies%2520on%2520imidazo-%2520and%25202-methylimidazo%255B2%252C1-b%255Dthiazole-based%2520inverse%2520agonists%2520of%2520the%2520ghrelin%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D1375%26epage%3D1388%26doi%3D10.1124%2Fdmd.113.051839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverty, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Managing the challenge of chemically reactive metabolites in drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1038/nrd3408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+P.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+challenge+of+chemically+reactive+metabolites+in+drug+development&doi=10.1038%2Fnrd3408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0lh-6x3EK0NvMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520challenge%2520of%2520chemically%2520reactive%2520metabolites%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D292%26epage%3D306%26doi%3D10.1038%2Fnrd3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyaji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiosakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okudaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.039180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.111.039180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21467212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1247-1254&author=S.+Nakayamaauthor=H.+Takakusaauthor=A.+Watanabeauthor=Y.+Miyajiauthor=W.+Suzukiauthor=D.+Sugiyamaauthor=K.+Shiosakaiauthor=K.+Hondaauthor=N.+Okudairaauthor=T.+Izumiauthor=O.+Okazaki&title=Combination+of+GSH+trapping+and+time-dependent+inhibition+assays+as+a+predictive+method+of+drugs+generating+highly+reactive+metabolites&doi=10.1124%2Fdmd.111.039180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites</span></div><div class="casAuthors">Nakayama, Shintaro; Takakusa, Hideo; Watanabe, Akiko; Miyaji, Yoshihiro; Suzuki, Wataru; Sugiyama, Daisuke; Shiosakai, Kazuhito; Honda, Kokichi; Okudaira, Noriko; Izumi, Takashi; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1247-1254</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions.  Because the CB assay is of low throughput and costly, a qual. trapping assay using agents such as [35S]GSH is often performed in the early stages of drug discovery.  However, trapping methods alone cannot replace the CB assay.  We hypothesized that the time-dependent inhibition (TDI) assay might be complementary to the [35S]GSH trapping assay in detecting RMs.  We performed CB assays, [35S]GSH trapping assays, and TDI assays for 42 structurally diverse compds.  First, we showed that the [35S]GSH trapping assay alone does not correlate with the extent of CB.  Four compds. that the [35S]GSH trapping assay failed to detect but that showed high extent of CB were inactivators of the enzyme in the TDI assay.  There was a tendency for compds. judged as pos. in the TDI assay to show a high degree of CB irresp. of the result of the [35S]GSH trapping assay.  Finally, to combine parameters from the two assays, we introduced intrinsic clearance to describe the formation of RMs (CLint, RMs).  The Spearman rank correlation coeff. between the extent of CB and CLint, RMs was 0.77 (p < 0.0001), which was better than that for the formation rates of [35S]GSH adducts.  Therefore, we demonstrated that a combination of the [35S]GSH trapping and TDI assays is an effective method for detecting compds. potentially capable of generating highly reactive metabolites in the early stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojK-Hmy3WcnLVg90H21EOLACvtfcHk0lh-6x3EK0NvMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWksbY%253D&md5=93bb4dbc29ca3fa2d3d545a72b97ec30</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.039180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.039180%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DMiyaji%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DW.%26aulast%3DSugiyama%26aufirst%3DD.%26aulast%3DShiosakai%26aufirst%3DK.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DIzumi%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DCombination%2520of%2520GSH%2520trapping%2520and%2520time-dependent%2520inhibition%2520assays%2520as%2520a%2520predictive%2520method%2520of%2520drugs%2520generating%2520highly%2520reactive%2520metabolites%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1247%26epage%3D1254%26doi%3D10.1124%2Fdmd.111.039180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeBarber, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">Ethionamide activation and sensitivity in multidrug-resistant mycobacterium tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">9677</span>– <span class="NLM_lpage">9682</span>, <span class="refDoi"> DOI: 10.1073/pnas.97.17.9677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1073%2Fpnas.97.17.9677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10944230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVent7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=9677-9682&author=A.+E.+DeBarberauthor=K.+Mdluliauthor=M.+Bosmanauthor=L.-G.+Bekkerauthor=C.+E.+Barry&title=Ethionamide+activation+and+sensitivity+in+multidrug-resistant+mycobacterium+tuberculosis&doi=10.1073%2Fpnas.97.17.9677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">DeBarber, Andrea E.; Mdluli, Khisimuzi; Bosman, Marlein; Bekker, Linda-Gail; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9677-9682</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ethionamide (ETA) is an important component of second-line therapy for the treatment of multidrug-resistant tuberculosis.  Synthesis of radiolabeled ETA and an examn. of drug metabolites formed by whole cells of Mycobacterium tuberculosis (MTb) have allowed the authors to demonstrate that ETA is activated by S-oxidn. before interacting with its cellular target.  ETA is metabolized by MTb to a 4-pyridylmethanol product remarkably similar in structure to that formed by the activation of isoniazid by the catalase-peroxidase KatG.  The authors demonstrated that overprodn. of Rv3855 (EtaR), a putative regulatory protein from MTb, confers ETA resistance whereas overprodn. of an adjacent, clustered monooxygenase (Rv3854c, EtaA) confers ETA hypersensitivity.  Prodn. of EtaA appears to be neg. regulated by EtaR and correlates directly with [14C]ETA metab., suggesting that EtaA is the activating enzyme responsible for thioamide oxidn. and subsequent toxicity.  Coding sequence mutations in EtaA were found in 11 of 11 multidrug-resistant MTb patient isolates from Cape Town, South Africa.  These isolates showed broad cross-resistance to thiocarbonyl contg. drugs including ETA, thiacetazone, and thiocarlide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNeMx28-Vc_bVg90H21EOLACvtfcHk0lhku9KA1MT1xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVent7s%253D&md5=3c024cae0889dd21ea67117fc1284f58</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.17.9677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.17.9677%26sid%3Dliteratum%253Aachs%26aulast%3DDeBarber%26aufirst%3DA.%2BE.%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DBosman%26aufirst%3DM.%26aulast%3DBekker%26aufirst%3DL.-G.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DEthionamide%2520activation%2520and%2520sensitivity%2520in%2520multidrug-resistant%2520mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D9677%26epage%3D9682%26doi%3D10.1073%2Fpnas.97.17.9677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alahari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratraud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowruth, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1128/AAC.01063-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1128%2FAAC.01063-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=17220416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=1055-1063&author=L.+G.+Doverauthor=A.+Alahariauthor=P.+Gratraudauthor=J.+M.+Gomesauthor=V.+Bhowruthauthor=R.+C.+Reynoldsauthor=G.+S.+Besraauthor=L.+Kremer&title=EthA%2C+a+common+activator+of+thiocarbamide-containing+drugs+acting+on+different+mycobacterial+targets&doi=10.1128%2FAAC.01063-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span></div><div class="casAuthors">Dover, Lynn G.; Alahari, Anuradha; Gratraud, Paul; Gomes, Jessica M.; Bhowruth, Veemal; Reynolds, Robert C.; Besra, Gurdyal S.; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1055-1063</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets.  Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogs that do not require such processes.  Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species.  These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metab. of ISO.  Interestingly, biochem. anal. of [14C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets.  This report is also the first description of the mol. mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries.  Altogether, the results suggest that EthA is a common activator of thiocarbamide-contg. drugs.  The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems assocd. with clin. thiocarbamide use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_R6VIHikw7Vg90H21EOLACvtfcHk0liih6wpNxL-AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D&md5=e41cb13b90a0031fb69473bd1379c51a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.01063-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01063-06%26sid%3Dliteratum%253Aachs%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DAlahari%26aufirst%3DA.%26aulast%3DGratraud%26aufirst%3DP.%26aulast%3DGomes%26aufirst%3DJ.%2BM.%26aulast%3DBhowruth%26aufirst%3DV.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DEthA%252C%2520a%2520common%2520activator%2520of%2520thiocarbamide-containing%2520drugs%2520acting%2520on%2520different%2520mycobacterial%2520targets%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D1055%26epage%3D1063%26doi%3D10.1128%2FAAC.01063-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellington, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvis, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wivagg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazyanskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nietupski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haseley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span> <span> </span><span class="NLM_article-title">Baeyer-Villiger monooxygenases EthA and MymA are required for activation of replicating and non-replicating mycobacterium tuberculosis inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2Fj.chembiol.2016.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27321573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWnsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=666-677&author=S.+S.+Grantauthor=S.+Wellingtonauthor=T.+Kawateauthor=C.+A.+Desjardinsauthor=M.+R.+Silvisauthor=C.+Wivaggauthor=M.+Thompsonauthor=K.+Gordonauthor=E.+Kazyanskayaauthor=R.+Nietupskiauthor=N.+Haseleyauthor=N.+Iwaseauthor=A.+M.+Earlauthor=M.+Fitzgeraldauthor=D.+T.+Hung&title=Baeyer-Villiger+monooxygenases+EthA+and+MymA+are+required+for+activation+of+replicating+and+non-replicating+mycobacterium+tuberculosis+inhibitors&doi=10.1016%2Fj.chembiol.2016.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors</span></div><div class="casAuthors">Grant, Sarah Schmidt; Wellington, Samantha; Kawate, Tomohiko; Desjardins, Christopher A.; Silvis, Melanie R.; Wivagg, Carl; Thompson, Matthew; Gordon, Katherine; Kazyanskaya, Edward; Nietupski, Raymond; Haseley, Nathan; Iwase, Noriaki; Earl, Ashlee M.; Fitzgerald, Michael; Hung, Deborah T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">666-677</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Successful treatment of Mycobacterium tuberculosis infection typically requires a complex regimen administered over ≥6 mo.  Interestingly, many of the antibiotics used to treat M. tuberculosis are prodrugs that require intracellular activation.  Here, we describe 3 small mols., active against both replicating and non-replicating M. tuberculosis, that require activation by Baeyer-Villiger monooxygenases (BVMOs).  Two mols. require BVMO EthA (Rv3854c) for activation and the 3rd mol. requires the BVMO MymA (Rv3083).  While EthA is known to activate the antitubercular drug ethionamide, this is the 1st description of MymA as an activating enzyme of a prodrug.  Furthermore, we found that MymA also plays a role in activating ethionamide, with loss of MymA function resulting in ethionamide-resistant M. tuberculosis.  These findings suggest overlap in function and specificity of the BVMOs in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIuztoncp3ybVg90H21EOLACvtfcHk0liih6wpNxL-AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWnsbzO&md5=d4403e9912b1dd7eb89d39d8b7825ba3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%2BS.%26aulast%3DWellington%26aufirst%3DS.%26aulast%3DKawate%26aufirst%3DT.%26aulast%3DDesjardins%26aufirst%3DC.%2BA.%26aulast%3DSilvis%26aufirst%3DM.%2BR.%26aulast%3DWivagg%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DKazyanskaya%26aufirst%3DE.%26aulast%3DNietupski%26aufirst%3DR.%26aulast%3DHaseley%26aufirst%3DN.%26aulast%3DIwase%26aufirst%3DN.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DHung%26aufirst%3DD.%2BT.%26atitle%3DBaeyer-Villiger%2520monooxygenases%2520EthA%2520and%2520MymA%2520are%2520required%2520for%2520activation%2520of%2520replicating%2520and%2520non-replicating%2520mycobacterium%2520tuberculosis%2520inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D666%26epage%3D677%26doi%3D10.1016%2Fj.chembiol.2016.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">The library of mutant strains was kindly donated by the group of Dr. Deborah Hung. For details about the strains, see ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">An extended table with extracellular MIC, HepG2 tox, and aqueous solubility data for all the analogues synthesized is included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, D. F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span> <span> </span><span class="NLM_article-title">Compound lipophilicity for substrate binding to human P450s in drug metabolism</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03115-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2FS1359-6446%2804%2903115-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=15183161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1ert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=530-537&author=D.+F.+V.+Lewisauthor=M.+N.+Jacobsauthor=M.+Dickins&title=Compound+lipophilicity+for+substrate+binding+to+human+P450s+in+drug+metabolism&doi=10.1016%2FS1359-6446%2804%2903115-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Compound lipophilicity for substrate binding to human P450s in drug metabolism</span></div><div class="casAuthors">Lewis, David F. V.; Jacobs, Miriam N.; Dickins, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">530-537</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Compd. lipophilicity is of key importance to P 450 binding affinity and enzyme selectivity.  Here, lipophilicity is discussed with ref. to the human drug-metabolizing P 450 enzymes of families CYP1, CYP2 and CYP3.  From an extensive compilation of log P values for P 450 substrates, and by anal. of relationships between partitioning energy and substrate-binding free energy, the relevance of lipophilicity and other factors pertaining to P 450 binding affinity is explained, leading to the formulation of lipophilicity relationships within substrates of each human P 450 enzyme involved in drug metab.  Furthermore, log P values for P 450 substrates appear to represent markers for enzyme selectivity.  Together with the important roles of hydrogen bonding and π-π stacking interaction energies, the desolvation of the P 450 active site makes a major contribution to the overall substrate-binding energy and, consequently, a good agreement with exptl. information is reported based on this anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-r8ssl6ll_bVg90H21EOLACvtfcHk0liih6wpNxL-AQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1ert78%253D&md5=ae4f0a09265af25b77b505a1a47bbd0d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903115-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903115-0%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BF.%2BV.%26aulast%3DJacobs%26aufirst%3DM.%2BN.%26aulast%3DDickins%26aufirst%3DM.%26atitle%3DCompound%2520lipophilicity%2520for%2520substrate%2520binding%2520to%2520human%2520P450s%2520in%2520drug%2520metabolism%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D530%26epage%3D537%26doi%3D10.1016%2FS1359-6446%2804%2903115-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrán, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, P.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cáceres, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Bustos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2262</span>– <span class="NLM_lpage">2264</span>, <span class="refDoi"> DOI: 10.1128/AAC.01423-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1128%2FAAC.01423-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=20160054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2262-2264&author=J.+Rullasauthor=J.+I.+Garc%C3%ADaauthor=M.+Beltr%C3%A1nauthor=P.-J.+Cardonaauthor=N.+C%C3%A1ceresauthor=J.+F.+Garc%C3%ADa-Bustosauthor=I.+Angulo-Barturen&title=Fast+standardized+therapeutic-efficacy+assay+for+drug+discovery+against+tuberculosis&doi=10.1128%2FAAC.01423-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span></div><div class="casAuthors">Rullas, Joaquin; Garcia, Juan Ignacio; Beltran, Manuela; Cardona, Pere-Joan; Caceres, Neus; Garcia-Bustos, Jose Francisco; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2262-2264</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Mycobacterium tuberculosis infection are essential tools in drug discovery.  Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice.  This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpajX5TwxQ_E7Vg90H21EOLACvtfcHk0lhOOAltVBZ7jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D&md5=c923fae175b34eab3778a0e4d8d51878</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FAAC.01423-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01423-09%26sid%3Dliteratum%253Aachs%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DJ.%2BI.%26aulast%3DBeltr%25C3%25A1n%26aufirst%3DM.%26aulast%3DCardona%26aufirst%3DP.-J.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DFast%2520standardized%2520therapeutic-efficacy%2520assay%2520for%2520drug%2520discovery%2520against%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2262%26epage%3D2264%26doi%3D10.1128%2FAAC.01423-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':[],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':[],'ref28':[],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renata A.G.  Reis</span>, <span class="hlFld-ContribAuthor ">Hao  Li</span>, <span class="hlFld-ContribAuthor ">Maxim  Johnson</span>, <span class="hlFld-ContribAuthor ">Pablo  Sobrado</span>. </span><span class="cited-content_cbyCitation_article-title">New frontiers in flavin-dependent monooxygenases. </span><span class="cited-content_cbyCitation_journal-name">Archives of Biochemistry and Biophysics</span><span> <strong>2021,</strong> <em>699 </em>, 108765. <a href="https://doi.org/10.1016/j.abb.2021.108765" title="DOI URL">https://doi.org/10.1016/j.abb.2021.108765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.abb.2021.108765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.abb.2021.108765%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Biochemistry%2520and%2520Biophysics%26atitle%3DNew%252Bfrontiers%252Bin%252Bflavin-dependent%252Bmonooxygenases%26aulast%3DReis%26aufirst%3DRenata%2BA.G.%26date%3D2021%26volume%3D699%26spage%3D108765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00003&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structural modifications around the hit.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00003&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/medium/jm0c00003_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Human Cl<sub>i</sub> vs measured PFI scatter plot: <i>X</i>-axis, measured PFI; <i>Y</i>-axis, human in vitro microsomal clearance. Numbers for each spot corresponds to compound numbers in the SAR tables. Color coding is as follows: green to orange is for compounds with an intracellular IC<sub>50</sub> in the range of 0.1–10 μM; orange to red is for compounds with IC<sub>50</sub> > 10–50 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.0c00003/20210410/images/large/jm0c00003_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00003&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13158" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13158" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Global
Tuberculosis Report 2019</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global%0ATuberculosis+Report+2019%3B+World+Health+Organization%3A+Geneva%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%250ATuberculosis%2520Report%25202019%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span> <i>WHO
Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+WHO%0ATreatment+Guidelines+for+Drug-Resistant+Tuberculosis%2C+2016+Update%3B+World+Health+Organization%3A+Geneva%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DWHO%250ATreatment%2520Guidelines%2520for%2520Drug-Resistant%2520Tuberculosis%252C%25202016%2520Update%26pub%3DWorld%2520Health%2520Organization%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span> <i>The
Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis.
Interim Policy Guidance</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The%0AUse+of+Delamanid+in+the+Treatment+of+Multidrug-Resistant+Tuberculosis.%0AInterim+Policy+Guidance%3B+World+Health+Organization%3A+Geneva%2C+2014."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%250AUse%2520of%2520Delamanid%2520in%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Tuberculosis.%250AInterim%2520Policy%2520Guidance%26pub%3DWorld%2520Health%2520Organization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span> <i>The
Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis:
Interim Policy Guidance</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The%0AUse+of+Bedaquiline+in+the+Treatment+of+Multidrug-Resistant+Tuberculosis%3A%0AInterim+Policy+Guidance%3B+World+Health+Organization%3A+Geneva%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DThe%250AUse%2520of%2520Bedaquiline%2520in%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Tuberculosis%253A%250AInterim%2520Policy%2520Guidance%26pub%3DWorld%2520Health%2520Organization%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoagland, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. E.</span></span> <span> </span><span class="NLM_article-title">New agents for the treatment of drug-resistant mycobacterium tuberculosis</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2016.04.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2Fj.addr.2016.04.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27151308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2016&pages=55-72&author=D.+T.+Hoaglandauthor=J.+Liuauthor=R.+B.+Leeauthor=R.+E.+Lee&title=New+agents+for+the+treatment+of+drug-resistant+mycobacterium+tuberculosis&doi=10.1016%2Fj.addr.2016.04.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">New agents for the treatment of drug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">Hoagland, Daniel T.; Liu, Jiuyu; Lee, Robin B.; Lee, Richard E.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-72</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inadequate dosing and incomplete treatment regimens, coupled with the ability of the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs, have fueled the rise of multidrug-resistant tuberculosis (MDR-TB).  Treatment of MDR-TB infections is a major clin. challenge that has few viable or effective solns.; therefore patients face a poor prognosis and years of treatment.  This review focuses on emerging drug classes that have the potential for treating MDR-TB and highlights their particular strengths as leads including their mode of action, in vivo efficacy, and key medicinal chem. properties.  Examples include the newly approved drugs bedaquiline and delaminid, and other agents in clin. and late preclin. development pipeline for the treatment of MDR-TB.  Herein, we discuss the challenges to developing drugs to treat tuberculosis and how the field has adapted to these difficulties, with an emphasis on drug discovery approaches that might produce more effective agents and treatment regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBEswjNcHj27Vg90H21EOLACvtfcHk0li78cXkuUJb0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSns7c%253D&md5=7c8ca15b9b493cceaf3d51d93b9afcec</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2016.04.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2016.04.026%26sid%3Dliteratum%253Aachs%26aulast%3DHoagland%26aufirst%3DD.%2BT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BE.%26atitle%3DNew%2520agents%2520for%2520the%2520treatment%2520of%2520drug-resistant%2520mycobacterium%2520tuberculosis%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2016%26volume%3D102%26spage%3D55%26epage%3D72%26doi%3D10.1016%2Fj.addr.2016.04.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dheda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divangahi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehme, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginsberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getahun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raviglione, M.</span></span> <span> </span><span class="NLM_article-title">Tuberculosis</span>. <i>Nature Reviews Disease Primers</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">16076</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2016.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrdp.2016.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27784885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=16076&author=M.+Paiauthor=M.+A.+Behrauthor=D.+Dowdyauthor=K.+Dhedaauthor=M.+Divangahiauthor=C.+C.+Boehmeauthor=A.+Ginsbergauthor=S.+Swaminathanauthor=M.+Spigelmanauthor=H.+Getahunauthor=D.+Menziesauthor=M.+Raviglione&title=Tuberculosis&doi=10.1038%2Fnrdp.2016.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tuberculosis</span></div><div class="casAuthors">Pai Madhukar; Behr Marcel A; Divangahi Maziar; Menzies Dick; Pai Madhukar; Dowdy David; Dheda Keertan; Boehme Catharina C; Ginsberg Ann; Swaminathan Soumya; Spigelman Melvin; Getahun Haileyesus; Raviglione Mario</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16076</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tuberculosis (TB) is an airborne infectious disease caused by organisms of the Mycobacterium tuberculosis complex.  Although primarily a pulmonary pathogen, M. tuberculosis can cause disease in almost any part of the body.  Infection with M. tuberculosis can evolve from containment in the host, in which the bacteria are isolated within granulomas (latent TB infection), to a contagious state, in which the patient will show symptoms that can include cough, fever, night sweats and weight loss.  Only active pulmonary TB is contagious.  In many low-income and middle-income countries, TB continues to be a major cause of morbidity and mortality, and drug-resistant TB is a major concern in many settings.  Although several new TB diagnostics have been developed, including rapid molecular tests, there is a need for simpler point-of-care tests.  Treatment usually requires a prolonged course of multiple antimicrobials, stimulating efforts to develop shorter drug regimens.  Although the Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, mainly to prevent life-threatening TB in infants and young children, it has been ineffective in controlling the global TB epidemic.  Thus, efforts are underway to develop newer vaccines with improved efficacy.  New tools as well as improved programme implementation and financing are necessary to end the global TB epidemic by 2035.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkhlsQg_ocTUPI-fCgwosgfW6udTcc2eZx5xyTFtyEt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngtVCgsw%253D%253D&md5=b2170e953514895635d3d13d8deefa24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2016.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2016.76%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DM.%26aulast%3DBehr%26aufirst%3DM.%2BA.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DDheda%26aufirst%3DK.%26aulast%3DDivangahi%26aufirst%3DM.%26aulast%3DBoehme%26aufirst%3DC.%2BC.%26aulast%3DGinsberg%26aufirst%3DA.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DSpigelman%26aufirst%3DM.%26aulast%3DGetahun%26aufirst%3DH.%26aulast%3DMenzies%26aufirst%3DD.%26aulast%3DRaviglione%26aufirst%3DM.%26atitle%3DTuberculosis%26jtitle%3DNature%2520Reviews%2520Disease%2520Primers%26date%3D2016%26volume%3D2%26spage%3D16076%26doi%3D10.1038%2Fnrdp.2016.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnoult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span> <span> </span><span class="NLM_article-title">The challenge of new drug discovery for tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">490</span>, <span class="refDoi"> DOI: 10.1038/nature09657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnature09657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21270886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2011&pages=483-490&author=A.+Koulauthor=E.+Arnoultauthor=N.+Lounisauthor=J.+Guillemontauthor=K.+Andries&title=The+challenge+of+new+drug+discovery+for+tuberculosis&doi=10.1038%2Fnature09657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The challenge of new drug discovery for tuberculosis</span></div><div class="casAuthors">Koul, Anil; Arnoult, Eric; Lounis, Nacer; Guillemont, Jerome; Andries, Koen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">7331</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tuberculosis (TB) is more prevalent in the world today than at any other time in human history.  Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance.  A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clin. development of new drugs.  The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new mol. scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control.  Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host.  In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9J_uIM64vSrVg90H21EOLACvtfcHk0lgi53IOf8Fwxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFShsrg%253D&md5=2c70f07fc0c88727f6b20d35f0c85695</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature09657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09657%26sid%3Dliteratum%253Aachs%26aulast%3DKoul%26aufirst%3DA.%26aulast%3DArnoult%26aufirst%3DE.%26aulast%3DLounis%26aufirst%3DN.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DAndries%26aufirst%3DK.%26atitle%3DThe%2520challenge%2520of%2520new%2520drug%2520discovery%2520for%2520tuberculosis%26jtitle%3DNature%26date%3D2011%26volume%3D469%26spage%3D483%26epage%3D490%26doi%3D10.1038%2Fnature09657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Payne, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwynn, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span> <span> </span><span class="NLM_article-title">Drugs for bad bugs: confronting the challenges of antibacterial discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1038/nrd2201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrd2201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=17159923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=29&author=D.+J.+Payneauthor=M.+N.+Gwynnauthor=D.+J.+Holmesauthor=D.+L.+Pompliano&title=Drugs+for+bad+bugs%3A+confronting+the+challenges+of+antibacterial+discovery&doi=10.1038%2Fnrd2201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs for bad bugs: confronting the challenges of antibacterial discovery</span></div><div class="casAuthors">Payne, David J.; Gwynn, Michael N.; Holmes, David J.; Pompliano, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-40</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets.  Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action.  Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH1tM2BSZbWLVg90H21EOLACvtfcHk0lgi53IOf8Fwxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfM&md5=18100253f9868af578ea621ab98a5c86</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2201%26sid%3Dliteratum%253Aachs%26aulast%3DPayne%26aufirst%3DD.%2BJ.%26aulast%3DGwynn%26aufirst%3DM.%2BN.%26aulast%3DHolmes%26aufirst%3DD.%2BJ.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26atitle%3DDrugs%2520for%2520bad%2520bugs%253A%2520confronting%2520the%2520challenges%2520of%2520antibacterial%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D29%26doi%3D10.1038%2Fnrd2201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, N. S.</span></span> <span> </span><span class="NLM_article-title">Hit generation in TB drug discovery: from genome to granuloma</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1887</span>– <span class="NLM_lpage">1916</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00602</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00602" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=1887-1916&author=T.+Yuanauthor=N.+S.+Sampson&title=Hit+generation+in+TB+drug+discovery%3A+from+genome+to+granuloma&doi=10.1021%2Facs.chemrev.7b00602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Hit Generation in TB Drug Discovery: From Genome to Granuloma</span></div><div class="casAuthors">Yuan, Tianao; Sampson, Nicole S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1887-1916</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB epidemic.  Recent efforts have focused on the development of whole-cell screening assays because biochem., target-based inhibitor screens during the last two decades have not delivered new TB drugs.  Mycobacterium tuberculosis (Mtb), the causative agent of TB, encounters diverse microenvironments and can be found in a variety of metabolic states in the human host.  Due to the complexity and heterogeneity of Mtb infection, no single model can fully recapitulate the in vivo conditions in which Mtb is found in TB patients, and there is no single "std." screening condition to generate hit compds. for TB drug development.  However, current screening assays have become more sophisticated as researchers attempt to mirror the complexity of TB disease in the lab.  In this review, we describe efforts using surrogates and engineered strains of Mtb to focus screens on specific targets.  We explain model culture systems ranging from carbon starvation to hypoxia, and combinations thereof, designed to represent the microenvironment which Mtb encounters in the human body.  We outline ongoing efforts to model Mtb infection in the lung granuloma.  We assess these different models, their ability to generate hit compds., and needs for further TB drug development, to provide direction for future TB drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzrykH7_zp77Vg90H21EOLACvtfcHk0ljORHC1_rfO4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCksr4%253D&md5=8ab51150e2eaeeb672ea666afb64ebf9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00602%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DT.%26aulast%3DSampson%26aufirst%3DN.%2BS.%26atitle%3DHit%2520generation%2520in%2520TB%2520drug%2520discovery%253A%2520from%2520genome%2520to%2520granuloma%26jtitle%3DChem.%2520Rev.%26date%3D2018%26volume%3D118%26spage%3D1887%26epage%3D1916%26doi%3D10.1021%2Facs.chemrev.7b00602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span> <span> </span><span class="NLM_article-title">The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">159</span>, <span class="refDoi"> DOI: 10.1038/nrmicro3200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrmicro3200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=24487820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Sntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=159&author=V.+Dartois&title=The+path+of+anti-tuberculosis+drugs%3A+from+blood+to+lesions+to+mycobacterial+cells&doi=10.1038%2Fnrmicro3200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells</span></div><div class="casAuthors">Dartois, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">159-167</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  For the successful treatment of pulmonary tuberculosis, drugs need to penetrate complex lung lesions and permeate the mycobacterial cell wall in order to reach their intracellular targets.  However, most currently used anti-tuberculosis drugs were introduced into clin. use without considering the pharmacokinetic and pharmacodynamic properties that influence drug distribution, and this has contributed to the long duration and limited success of current therapies.  In this Progress article, I describe new methods to quantify and image drug distribution in infected lung tissue and in mycobacterial cells, and I explore how this technol. could be used to design optimized multidrug regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_pBYMx4IImbVg90H21EOLACvtfcHk0ljORHC1_rfO4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Sntrs%253D&md5=fc2208aa14e3e937b230d0a7ae78940a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro3200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro3200%26sid%3Dliteratum%253Aachs%26aulast%3DDartois%26aufirst%3DV.%26atitle%3DThe%2520path%2520of%2520anti-tuberculosis%2520drugs%253A%2520from%2520blood%2520to%2520lesions%2520to%2520mycobacterial%2520cells%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2014%26volume%3D12%26spage%3D159%26doi%3D10.1038%2Fnrmicro3200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prideaux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Via, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarathy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  Iii</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartois, V.</span></span> <span> </span><span class="NLM_article-title">The association between sterilizing activity and drug distribution into tuberculosis lesions</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1038/nm.3937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnm.3937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=26343800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1223-1227&author=B.+Prideauxauthor=L.+E.+Viaauthor=M.+D.+Zimmermanauthor=S.+Eumauthor=J.+Sarathyauthor=P.+O%E2%80%99Brienauthor=C.+Chenauthor=F.+Kayaauthor=D.+M.+Weinerauthor=P.-Y.+Chenauthor=T.+Songauthor=M.+Leeauthor=T.+S.+Shimauthor=J.+S.+Choauthor=W.+Kimauthor=S.+N.+Choauthor=K.+N.+Olivierauthor=C.+E.+Barryauthor=V.+Dartois&title=The+association+between+sterilizing+activity+and+drug+distribution+into+tuberculosis+lesions&doi=10.1038%2Fnm.3937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The association between sterilizing activity and drug distribution into tuberculosis lesions</span></div><div class="casAuthors">Prideaux, Brendan; Via, Laura E.; Zimmerman, Matthew D.; Eum, Seokyong; Sarathy, Jansy; O'Brien, Paul; Chen, Chao; Kaya, Firat; Weiner, Danielle M.; Chen, Pei-Yu; Song, Taeksun; Lee, Myungsun; Shim, Tae Sun; Cho, Jeong Su; Kim, Wooshik; Cho, Sang Nae; Olivier, Kenneth N.; Barry, Clifton E., III; Dartois, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1223-1227</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Finding new treatment-shortening antibiotics to improve cure rates and curb the alarming emergence of drug resistance is the major objective of tuberculosis (TB) drug development.  Using a matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging suite in a biosafety containment facility, we show that the key sterilizing drugs rifampicin and pyrazinamide efficiently penetrate the sites of TB infection in lung lesions.  Rifampicin even accumulates in necrotic caseum, a crit. lesion site where persisting tubercle bacilli reside.  In contrast, moxifloxacin, which is active in vitro against a subpopulation of Mycobacterium tuberculosis that persists in specific niches under drug pressure and has achieved treatment shortening in mice, does not diffuse well in caseum, concordant with its failure to shorten therapy in recent clin. trials.  We suggest that such differential spatial distribution and kinetics of accumulation in lesions may create temporal and spatial windows of monotherapy in specific niches, allowing the gradual development of multidrug-resistant TB.  We propose an alternative working model to prioritize new antibiotic regimens based on quant. and spatial distribution of TB drugs in the major lesion types found in human lungs.  The finding that lesion penetration may contribute to treatment outcome has wide implications for TB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS0jbKV6VoIrVg90H21EOLACvtfcHk0lgPPkbyhVFL_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGntbnF&md5=b57f73461e02f4ee62ebf8e7579c4361</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm.3937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3937%26sid%3Dliteratum%253Aachs%26aulast%3DPrideaux%26aufirst%3DB.%26aulast%3DVia%26aufirst%3DL.%2BE.%26aulast%3DZimmerman%26aufirst%3DM.%2BD.%26aulast%3DEum%26aufirst%3DS.%26aulast%3DSarathy%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKaya%26aufirst%3DF.%26aulast%3DWeiner%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DP.-Y.%26aulast%3DSong%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DShim%26aufirst%3DT.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DCho%26aufirst%3DS.%2BN.%26aulast%3DOlivier%26aufirst%3DK.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DDartois%26aufirst%3DV.%26atitle%3DThe%2520association%2520between%2520sterilizing%2520activity%2520and%2520drug%2520distribution%2520into%2520tuberculosis%2520lesions%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D1223%26epage%3D1227%26doi%3D10.1038%2Fnm.3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Av-Gay, Y.</span></span> <span> </span><span class="NLM_article-title">New era of TB drug discovery and its impact on disease management</span>. <i>Curr. Treat. Options Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1007/s40506-016-0098-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1007%2Fs40506-016-0098-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=299-310&author=X.+Zhengauthor=Y.+Av-Gay&title=New+era+of+TB+drug+discovery+and+its+impact+on+disease+management&doi=10.1007%2Fs40506-016-0098-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs40506-016-0098-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40506-016-0098-0%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DAv-Gay%26aufirst%3DY.%26atitle%3DNew%2520era%2520of%2520TB%2520drug%2520discovery%2520and%2520its%2520impact%2520on%2520disease%2520management%26jtitle%3DCurr.%2520Treat.%2520Options%2520Infect.%2520Dis.%26date%3D2016%26volume%3D8%26spage%3D299%26epage%3D310%26doi%3D10.1007%2Fs40506-016-0098-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrentino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez del Rio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presa Matilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres Gomez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Hoyos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez Herran, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza Losana, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Av-Gay, Y.</span></span> <span> </span><span class="NLM_article-title">Development of an intracellular screen for new compounds able to inhibit mycobacterium tuberculosis growth in human macrophages</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1128/AAC.01920-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1128%2FAAC.01920-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=26503663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=640-645&author=F.+Sorrentinoauthor=R.+Gonzalez+del+Rioauthor=X.+Zhengauthor=J.+Presa+Matillaauthor=P.+Torres+Gomezauthor=M.+Martinez+Hoyosauthor=M.+E.+Perez+Herranauthor=A.+Mendoza+Losanaauthor=Y.+Av-Gay&title=Development+of+an+intracellular+screen+for+new+compounds+able+to+inhibit+mycobacterium+tuberculosis+growth+in+human+macrophages&doi=10.1128%2FAAC.01920-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an intracellular screen for new compounds able to inhibit Mycobacterium tuberculosis growth in human macrophages</span></div><div class="casAuthors">Sorrentino, Flavia; Gonzalez del Rio, Ruben; Zheng, Xingji; Matilla, Jesus Presa; Gomez, Pedro Torres; Hoyos, Maria Martinez; Herran, Maria Esther Perez; Losana, Alfonso Mendoza; Av-Gay, Yossef</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">640-645</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Here we describe the development and validation of an intracellular high-throughput screening assay for finding new antituberculosis compds. active in human macrophages.  The assay consists of a luciferase-based primary identification assay, followed by a green fluorescent protein-based secondary profiling assay.  Std. tuberculosis drugs and 158 previously recognized active antimycobacterial compds. were used to evaluate assay robustness.  Data show that the assay developed is a short and valuable tool for the discovery of new antimycobacterial compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE2XIe5jevhLVg90H21EOLACvtfcHk0lj593TIKsC5ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nF&md5=4ed12b5a9996d37db7a8d023ccabd48a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.01920-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01920-15%26sid%3Dliteratum%253Aachs%26aulast%3DSorrentino%26aufirst%3DF.%26aulast%3DGonzalez%2Bdel%2BRio%26aufirst%3DR.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DPresa%2BMatilla%26aufirst%3DJ.%26aulast%3DTorres%2BGomez%26aufirst%3DP.%26aulast%3DMartinez%2BHoyos%26aufirst%3DM.%26aulast%3DPerez%2BHerran%26aufirst%3DM.%2BE.%26aulast%3DMendoza%2BLosana%26aufirst%3DA.%26aulast%3DAv-Gay%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520an%2520intracellular%2520screen%2520for%2520new%2520compounds%2520able%2520to%2520inhibit%2520mycobacterium%2520tuberculosis%2520growth%2520in%2520human%2520macrophages%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D640%26epage%3D645%26doi%3D10.1128%2FAAC.01920-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.+S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lj593TIKsC5ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%2BS.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkening, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, A.</span></span> <span> </span><span class="NLM_article-title">Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1042</span>, <span class="refDoi"> DOI: 10.1124/dmd.31.8.1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.31.8.1035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=12867492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlvVOlsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=1035-1042&author=S.+Wilkeningauthor=F.+Stahlauthor=A.+Bader&title=Comparison+of+primary+human+hepatocytes+and+hepatoma+cell+line+HepG2+with+regard+to+their+biotransformation+properties&doi=10.1124%2Fdmd.31.8.1035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of primary human hepatocytes and hepatoma cell line HEPG2 with regard to their biotransformation properties</span></div><div class="casAuthors">Wilkening, Stefan; Stahl, Frank; Bader, Augustinus</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1035-1042</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Cultures of primary hepatocytes and hepatoma cell line HepG2 are frequently used in in vitro models for human biotransformation studies.  In this study, we characterized and compared the capacity of these model systems to indicate the presence of different classes of promutagens.  Genotoxic sensitivity, enzyme activity, and gene expression were monitored in response to treatment with food promutagens benzo[a]pyrene, dimethylnitrosamine (DMN), and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).  DNA damage could be detected reliably with the comet assay in primary human hepatocytes, which were maintained in sandwich culture.  All three promutagens caused DNA damage in primary cells, but in HepG2 no genotoxic effects of DMN and PhIP could be detected.  We supposed that the lack of specific enzymes accounts for their inability to process these promutagens.  Therefore, we quantified the expression of a broad range of genes coding for drug-metabolizing enzymes with real-time reverse transcription-polymerase chain reaction.  The genes code for cytochromes P 450 and, in addn., for a series of important phase II enzymes.  The expression level of these genes in human hepatocytes was similar to those previously reported for human liver samples.  On the other hand, expression levels in HepG2 differed significantly from that in human.  Activity and expression, esp. of phase I enzymes, were demonstrated to be extremely low in HepG2 cells.  Up-regulation of specific genes by test substances was similar in both cell types.  In conclusion, human hepatocytes are the preferred model for biotransformation in human liver, whereas HepG2 cells may be useful to study regulation of drug-metabolizing enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Qp8poi_lTbVg90H21EOLACvtfcHk0lj593TIKsC5ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlvVOlsLc%253D&md5=95037777c25df8b976f1b6ef4a40cac1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.8.1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.8.1035%26sid%3Dliteratum%253Aachs%26aulast%3DWilkening%26aufirst%3DS.%26aulast%3DStahl%26aufirst%3DF.%26aulast%3DBader%26aufirst%3DA.%26atitle%3DComparison%2520of%2520primary%2520human%2520hepatocytes%2520and%2520hepatoma%2520cell%2520line%2520HepG2%2520with%2520regard%2520to%2520their%2520biotransformation%2520properties%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D1035%26epage%3D1042%26doi%3D10.1124%2Fdmd.31.8.1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="note"><p class="first last">See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Supporting Information</a> for more details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osaki, H.</span></span> <span> </span><span class="NLM_article-title">In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">378</span>, <span class="refDoi"> DOI: 10.1002/bdd.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1002%2Fbdd.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27379984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtl2ls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=373-378&author=A.+Watanabeauthor=K.+Mayumiauthor=K.+Nishimuraauthor=H.+Osaki&title=In+vivo+use+of+the+CYP+inhibitor+1-aminobenzotriazole+to+increase+long-term+exposure+in+mice&doi=10.1002%2Fbdd.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo use of the CYP inhibitor 1-aminobenzotriazole to increase long-term exposure in mice</span></div><div class="casAuthors">Watanabe, Ayahisa; Mayumi, Kei; Nishimura, Kyohei; Osaki, Hiromi</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">373-378</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">1-Aminobenzotriazole (ABT) is a well-known in vivo nonspecific inhibitor of cytochrome P 450 (CYP) enzymes.  An effective dosing regimen of ABT for a multiple-administration study is needed to conduct pharmacol. studies for proof-of-concept, although it has been established for single-administration study, to characterize the pharmacokinetics of drug candidates.  This study demonstrated a suitable dosing vehicle of ABT for continuous administration and increased exposure to antipyrine, which is a nonspecific probe of CYP, using ABT for a long period in mice.  The dosing vehicle of ABT was 0.5% (w/v) hydroxypropyl methylcellulose and 0.5% (vol./vol.) Tween 80 in N,N-dimethylacetamide/20% hydroxypropyl-β-cyclodextrin aq. soln. (2:8, vol./vol.) based on the duration of apparent soly.  After implantation of an ALZET osmotic pump with ABT, the plasma concns. of ABT were maintained at more than 4.1 μg/mL over 336 h.  Compared with the vehicle group, the CLtot of antipyrine with ABT decreased to approx. one-fourth, and the BA of antipyrine with ABT increased up to 3-fold.  In addn., the enhancement of exposure of antipyrine by ABT was maintained over the 336 h.  The body wt., food consumption and hematol. parameters of mice did not change with ABT administration for 16 days.  These findings demonstrated that pretreatment of ABT can increase long-term exposure using continuous administration with the ALZET osmotic pump in mice with no overt toxicity.  It is concluded that the in vivo use of 1-aminobenzotriazole can be applied to pharmacol. studies for proof-of-concept, thus contributing to the selection of drug candidates at an early drug discovery stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH20CYqLyXE7Vg90H21EOLACvtfcHk0liwQIWLHwyiwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtl2ls7rL&md5=691b76090f9936b301ac70a911bdaae5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2020%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DMayumi%26aufirst%3DK.%26aulast%3DNishimura%26aufirst%3DK.%26aulast%3DOsaki%26aufirst%3DH.%26atitle%3DIn%2520vivo%2520use%2520of%2520the%2520CYP%2520inhibitor%25201-aminobenzotriazole%2520to%2520increase%2520long-term%2520exposure%2520in%2520mice%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2016%26volume%3D37%26spage%3D373%26epage%3D378%26doi%3D10.1002%2Fbdd.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span> <i>MetaSite</i>, version <span class="NLM_edition">6.0</span>; <span class="NLM_publisher-name">Molecular Discovery
Ltd.</span>; <a href="http://www.moldiscovery.com/software/metasite/" class="extLink">http://www.moldiscovery.com/software/metasite/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+MetaSite%2C+version+6.0%3B+Molecular+Discovery%0ALtd.%3B+http%3A%2F%2Fwww.moldiscovery.com%2Fsoftware%2Fmetasite%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMetaSite%26pub%3DMolecular%2520Discovery%250ALtd" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephs, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.-Z.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of 2-(Alkylthio)-1,3,4-Thiadiazoles and 2-(Alkylthio)-1,3-Benzothiazoles</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2770</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1021/tx3003998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx3003998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=2770-2779&author=Y.+Yangauthor=F.+Qiuauthor=J.+L.+Josephsauthor=W.+G.+Humphreysauthor=Y.-Z.+Shu&title=Bioactivation+of+2-%28Alkylthio%29-1%2C3%2C4-Thiadiazoles+and+2-%28Alkylthio%29-1%2C3-Benzothiazoles&doi=10.1021%2Ftx3003998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactivation of 2-(Alkylthio)-1,3,4-Thiadiazoles and 2-(Alkylthio)-1,3-Benzothiazoles</span></div><div class="casAuthors">Yang, Yanou; Qiu, Feng; Josephs, Jonathan L.; Humphreys, W. Griffith; Shu, Yue-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2770-2779</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Certain functional groups/structural motifs are known to generate chem. reactive metabolites that can covalently modify essential cellular macromols. and, therefore, have the potential to disrupt biol. function and elicit idiosyncratic adverse drug reactions.  In this report, we describe the bioactivation of 5-substituted 2-(alkylthio)-1,3,4-thiadiazoles and 2-(alkylthio)-1,3-benzothiazoles, which can be added to the growing list of structural alerts.  When 5-substituted 2-(methylthio)-1,3,4-thiadiazoles and 2-(methylthio)-1,3-benzothiazole were incubated with pooled human liver microsomes in the presence of NADPH and GSH, unusual GSH adducts were formed.  Characterization of these GSH adducts by high-resoln. mass spectrometry indicated the replacement of the methylthio- group by GSH, and NMR expts. ascertained the proposed structures.  On the basis of the metabolic profile change in incubation samples with/without GSH, we proposed that the GSH adduct formation involved two steps: (1) enzymic oxidn. of the alkylthio- group to form sulfoxide and sulfone and (2) nucleophilic displacement of the formed sulfoxide and sulfone by GSH.  The proposed mechanism was confirmed by the formation of the same GSH adduct from the incubation of synthetically prepd. sulfoxide and sulfone compds. in buffer.  We found the sulfur oxidn. step was significantly inhibited (80-100%) by preincubation with 1-aminobenzotriazole but was much less affected by thermo-inactivation (0-45%), suggesting that the sulfoxidn. step is primarily catalyzed by cytochrome P450s and not by flavin monooxygenases.  We also investigated the presence of this bioactivation pathway in more than a dozen compds. contg. 2-(alkylthio)-1,3,4-thiadiazole and 2-(alkylthio)-1,3-benzothiazoles.  The common GSH adduct formation pathway demonstrated by current studies raises a new structural alert and potential liability in drug safety when 2-alkylthio derivs. of 1,3-benzothiazoles and 1,3,4-thiadiazoles are incorporated in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXfJPsqwoIqbVg90H21EOLACvtfcHk0liwQIWLHwyiwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsrvI&md5=c78efd64b32baf4f65be8fe5b8cd0c09</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx3003998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx3003998%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DQiu%26aufirst%3DF.%26aulast%3DJosephs%26aufirst%3DJ.%2BL.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DShu%26aufirst%3DY.-Z.%26atitle%3DBioactivation%2520of%25202-%2528Alkylthio%2529-1%252C3%252C4-Thiadiazoles%2520and%25202-%2528Alkylthio%2529-1%252C3-Benzothiazoles%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2012%26volume%3D25%26spage%3D2770%26epage%3D2779%26doi%3D10.1021%2Ftx3003998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limberakis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolte, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Demonstration of the innate electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1470</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.052183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.113.052183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=23653442" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1470-1479&author=H.+Engauthor=R.+Sharmaauthor=T.+S.+McDonaldauthor=D.+J.+Edmondsauthor=J.-P.+Fortinauthor=X.+Liauthor=B.+D.+Stevensauthor=D.+A.+Griffithauthor=C.+Limberakisauthor=W.+M.+Nolteauthor=D.+A.+Priceauthor=M.+Jacksonauthor=A.+S.+Kalgutkar&title=Demonstration+of+the+innate+electrophilicity+of+4-%283-%28Benzyloxy%29phenyl%29-2-%28ethylsulfinyl%29-6-%28trifluoromethyl%29pyrimidine+%28BETP%29%2C+a+small-molecule+positive+allosteric+modulator+of+the+glucagon-like+peptide-1+receptor&doi=10.1124%2Fdmd.113.052183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Demonstration of the innate electrophilicity of 4-(3-(benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a small-molecule positive allosteric modulator of the glucagon-like peptide-1 receptor</span></div><div class="casAuthors">Eng, Heather; Sharma, Raman; McDonald, Thomas S.; Edmonds, David J.; Fortin, Jean-Philippe; Li, Xianping; Stevens, Benjamin D.; Griffith, David A.; Limberakis, Chris; Nolte, Whitney M.; Price, David A.; Jackson, Margaret; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1470-1479</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP) represents a novel small-mol. activator of the glucagon-like peptide-1 receptor (GLP-1R), and exhibits glucose-dependent insulin secretion in rats following i.v. (but not oral) administration.  To explore the quant. pharmacol. assocd. with GLP-1R agonism in preclin. species, the in vivo pharmacokinetics of BETP were examd. in rats after i.v. and oral dosing.  Failure to detect BETP in circulation after oral administration of a 10-mg/kg dose in rats was consistent with the lack of an insulinotropic effect of orally administered BETP in this species.  Likewise, systemic concns. of BETP in the rat upon i.v. administration (1 mg/kg) were minimal (and sporadic).  In vitro incubations in bovine serum albumin, plasma, and liver microsomes from rodents and humans indicated a facile degrdn. of BETP.  Failure to detect metabolites in plasma and liver microsomal incubations in the absence of NADP was suggestive of a covalent interaction between BETP and a protein amino acid residue(s) in these matrixes.  Incubations of BETP with glutathione (GSH) in buffer revealed a rapid nucleophilic displacement of the ethylsulfoxide functionality by GSH to yield adduct M1, which indicated that BETP was intrinsically electrophilic.  The structure of M1 was unambiguously identified by comparison of its chromatog. and mass spectral properties with an authentic std.  The GSH conjugate of BETP was also characterized in NADPH- and GSH-supplemented liver microsomes and in plasma samples from the pharmacokinetic studies.  Unlike BETP, M1 was inactive as an allosteric modulator of the GLP-1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDfkt1MNLwnLVg90H21EOLACvtfcHk0ljRyOYJXqGf1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjs7rK&md5=5394320704df49224ad4d28f1605c3f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.052183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.052183%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DH.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DMcDonald%26aufirst%3DT.%2BS.%26aulast%3DEdmonds%26aufirst%3DD.%2BJ.%26aulast%3DFortin%26aufirst%3DJ.-P.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DLimberakis%26aufirst%3DC.%26aulast%3DNolte%26aufirst%3DW.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDemonstration%2520of%2520the%2520innate%2520electrophilicity%2520of%25204-%25283-%2528Benzyloxy%2529phenyl%2529-2-%2528ethylsulfinyl%2529-6-%2528trifluoromethyl%2529pyrimidine%2520%2528BETP%2529%252C%2520a%2520small-molecule%2520positive%2520allosteric%2520modulator%2520of%2520the%2520glucagon-like%2520peptide-1%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D1470%26epage%3D1479%26doi%3D10.1124%2Fdmd.113.052183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goosen, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span> <span> </span><span class="NLM_article-title">Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.051839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.113.051839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=23610086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVajsbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1375-1388&author=A.+S.+Kalgutkarauthor=T.+F.+Ryderauthor=G.+S.+Walkerauthor=S.+T.+M.+Orrauthor=S.+Cabralauthor=T.+C.+Goosenauthor=K.+Laphamauthor=H.+Eng&title=Reactive+metabolite+trapping+studies+on+imidazo-+and+2-methylimidazo%5B2%2C1-b%5Dthiazole-based+inverse+agonists+of+the+ghrelin+receptor&doi=10.1124%2Fdmd.113.051839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Reactive metabolite trapping studies on imidazo- and 2-methylimidazo[2,1-b]thiazole-based inverse agonists of the ghrelin receptor</span></div><div class="casAuthors">Kalgutkar, Amit S.; Ryder, Tim F.; Walker, Gregory S.; Orr, Suvi T. M.; Cabral, Shawn; Goosen, Theunis C.; Lapham, Kimberly; Eng, Heather</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1375-1388</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The current study examd. the bioactivation potential of ghrelin receptor inverse agonists, 1-2-2-chloro-4-2H-1,2,3-triazol-2-yl benzyl-2,7-diazaspiro 3.5 nonan-7-yl-2-imidazo 2,1-b thiazol-6-yl ethanone (1) and 1-2-2-chloro-4-2H-1,2,3-triazol-2-yl benzyl-2,7-diazaspiro 3.5 nonan-7-yl-2-2-methylimidazo 2,1-b thiazol-6-yl ethanone (2), contg. a fused imidazo 2,1-b thiazole motif in the core structure.  Both compds. underwent oxidative metab. in NADPH- and glutathione-supplemented human liver microsomes to yield glutathione conjugates, which was consistent with their bioactivation to reactive species.  Mass spectral fragmentation and NMR anal. indicated that the site of attachment of the glutathionyl moiety in the thiol conjugates was on the thiazole ring within the bicycle.  Two glutathione conjugates were discerned with the imidazo 2,1-b thiazole deriv. 1.  One adduct was derived from the Michael addn. of glutathione to a putative S-oxide metabolite of 1, whereas, the second adduct was formed via the reaction of a second glutathione mol. with the initial glutathione-S-oxide adduct.  In the case of the 2-methylimidazo 2,1-b thiazole analog 2, glutathione conjugation occurred via an oxidative desulfation mechanism, possibly involving thiazole ring epoxidn. as the rate-limiting step.  Addnl. insights into the mechanism were obtained via 18O exchange and trapping studies with potassium cyanide.  The mechanistic insights into the bioactivation pathways of 1 and 2 allowed the deployment of a rational chem. intervention strategy that involved replacement of the thiazole ring with a 1,2,4-thiadiazole group to yield 2-2-chloro-4-2H-1,2,3-triazol-2-yl benzyl-2,7-diazaspiro 3.5 nonan-7-yl-2-2-methylimidazo 2,1-b 1,3,4 thiadiazol-6-yl ethanone (3).  These structural changes not only abrogated the bioactivation liability but also retained the attractive pharmacol. attributes of the prototype agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMoyDkpHUNgbVg90H21EOLACvtfcHk0ljRyOYJXqGf1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVajsbfI&md5=7d48d089b0cffbafbdbed4746f700367</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.051839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.051839%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DRyder%26aufirst%3DT.%2BF.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DCabral%26aufirst%3DS.%26aulast%3DGoosen%26aufirst%3DT.%2BC.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DEng%26aufirst%3DH.%26atitle%3DReactive%2520metabolite%2520trapping%2520studies%2520on%2520imidazo-%2520and%25202-methylimidazo%255B2%252C1-b%255Dthiazole-based%2520inverse%2520agonists%2520of%2520the%2520ghrelin%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D1375%26epage%3D1388%26doi%3D10.1124%2Fdmd.113.051839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boobis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laverty, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicoll-Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routledge, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span> <span> </span><span class="NLM_article-title">Managing the challenge of chemically reactive metabolites in drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">306</span>, <span class="refDoi"> DOI: 10.1038/nrd3408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1038%2Fnrd3408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21455238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=292-306&author=B.+K.+Parkauthor=A.+Boobisauthor=S.+Clarkeauthor=C.+E.+P.+Goldringauthor=D.+Jonesauthor=J.+G.+Kennaauthor=C.+Lambertauthor=H.+G.+Lavertyauthor=D.+J.+Naisbittauthor=S.+Nelsonauthor=D.+A.+Nicoll-Griffithauthor=R.+S.+Obachauthor=P.+Routledgeauthor=D.+A.+Smithauthor=D.+J.+Tweedieauthor=N.+Vermeulenauthor=D.+P.+Williamsauthor=I.+D.+Wilsonauthor=T.+A.+Baillie&title=Managing+the+challenge+of+chemically+reactive+metabolites+in+drug+development&doi=10.1038%2Fnrd3408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Managing the challenge of chemically reactive metabolites in drug development</span></div><div class="casAuthors">Park, B. Kevin; Boobis, Alan; Clarke, Stephen; Goldring, Chris E. P.; Jones, David; Kenna, J. Gerry; Lambert, Craig; Laverty, Hugh G.; Naisbitt, Dean J.; Nelson, Sidney; Nicoll-Griffith, Deborah A.; Obach, R. Scott; Routledge, Philip; Smith, Dennis A.; Tweedie, Donald J.; Vermeulen, Nico; Williams, Dominic P.; Wilson, Ian D.; Baillie, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">292-306</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The normal metab. of drugs can generate metabolites that have intrinsic chem. reactivity towards cellular mols., and therefore have the potential to alter biol. function and initiate serious adverse drug reactions.  Here, we present an assessment of the current approaches used for the evaluation of chem. reactive metabolites.  We also describe how these approaches are being used within the pharmaceutical industry to assess and minimize the potential of drug candidates to cause toxicity.  At early stages of drug discovery, iteration between medicinal chem. and drug metab. can eliminate perceived reactive metabolite-mediated chem. liabilities without compromising pharmacol. activity or the need for extensive safety evaluation beyond std. practices.  In the future, reactive metabolite evaluation may also be useful during clin. development for improving clin. risk assessment and risk management.  Currently, there remains a huge gap in our understanding of the basic mechanisms that underlie chem. stress-mediated adverse reactions in humans.  This Review summarizes our views on this complex topic, and includes insights into practices considered by the pharmaceutical industry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBv41vr7ZlNLVg90H21EOLACvtfcHk0ljmkf0-LxGQ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGnu78%253D&md5=8f6865f17bbe50b51aa4282379e82a08</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd3408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3408%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DBoobis%26aufirst%3DA.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKenna%26aufirst%3DJ.%2BG.%26aulast%3DLambert%26aufirst%3DC.%26aulast%3DLaverty%26aufirst%3DH.%2BG.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DS.%26aulast%3DNicoll-Griffith%26aufirst%3DD.%2BA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoutledge%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DVermeulen%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DD.%2BP.%26aulast%3DWilson%26aufirst%3DI.%2BD.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DManaging%2520the%2520challenge%2520of%2520chemically%2520reactive%2520metabolites%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D292%26epage%3D306%26doi%3D10.1038%2Fnrd3408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyaji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiosakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okudaira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1254</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.039180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1124%2Fdmd.111.039180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=21467212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1247-1254&author=S.+Nakayamaauthor=H.+Takakusaauthor=A.+Watanabeauthor=Y.+Miyajiauthor=W.+Suzukiauthor=D.+Sugiyamaauthor=K.+Shiosakaiauthor=K.+Hondaauthor=N.+Okudairaauthor=T.+Izumiauthor=O.+Okazaki&title=Combination+of+GSH+trapping+and+time-dependent+inhibition+assays+as+a+predictive+method+of+drugs+generating+highly+reactive+metabolites&doi=10.1124%2Fdmd.111.039180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites</span></div><div class="casAuthors">Nakayama, Shintaro; Takakusa, Hideo; Watanabe, Akiko; Miyaji, Yoshihiro; Suzuki, Wataru; Sugiyama, Daisuke; Shiosakai, Kazuhito; Honda, Kokichi; Okudaira, Noriko; Izumi, Takashi; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1247-1254</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions.  Because the CB assay is of low throughput and costly, a qual. trapping assay using agents such as [35S]GSH is often performed in the early stages of drug discovery.  However, trapping methods alone cannot replace the CB assay.  We hypothesized that the time-dependent inhibition (TDI) assay might be complementary to the [35S]GSH trapping assay in detecting RMs.  We performed CB assays, [35S]GSH trapping assays, and TDI assays for 42 structurally diverse compds.  First, we showed that the [35S]GSH trapping assay alone does not correlate with the extent of CB.  Four compds. that the [35S]GSH trapping assay failed to detect but that showed high extent of CB were inactivators of the enzyme in the TDI assay.  There was a tendency for compds. judged as pos. in the TDI assay to show a high degree of CB irresp. of the result of the [35S]GSH trapping assay.  Finally, to combine parameters from the two assays, we introduced intrinsic clearance to describe the formation of RMs (CLint, RMs).  The Spearman rank correlation coeff. between the extent of CB and CLint, RMs was 0.77 (p < 0.0001), which was better than that for the formation rates of [35S]GSH adducts.  Therefore, we demonstrated that a combination of the [35S]GSH trapping and TDI assays is an effective method for detecting compds. potentially capable of generating highly reactive metabolites in the early stages of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojK-Hmy3WcnLVg90H21EOLACvtfcHk0ljmkf0-LxGQ3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWksbY%253D&md5=93bb4dbc29ca3fa2d3d545a72b97ec30</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.039180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.039180%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DA.%26aulast%3DMiyaji%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DW.%26aulast%3DSugiyama%26aufirst%3DD.%26aulast%3DShiosakai%26aufirst%3DK.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DOkudaira%26aufirst%3DN.%26aulast%3DIzumi%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DCombination%2520of%2520GSH%2520trapping%2520and%2520time-dependent%2520inhibition%2520assays%2520as%2520a%2520predictive%2520method%2520of%2520drugs%2520generating%2520highly%2520reactive%2520metabolites%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1247%26epage%3D1254%26doi%3D10.1124%2Fdmd.111.039180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeBarber, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mdluli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">Ethionamide activation and sensitivity in multidrug-resistant mycobacterium tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">9677</span>– <span class="NLM_lpage">9682</span>, <span class="refDoi"> DOI: 10.1073/pnas.97.17.9677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1073%2Fpnas.97.17.9677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10944230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVent7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=9677-9682&author=A.+E.+DeBarberauthor=K.+Mdluliauthor=M.+Bosmanauthor=L.-G.+Bekkerauthor=C.+E.+Barry&title=Ethionamide+activation+and+sensitivity+in+multidrug-resistant+mycobacterium+tuberculosis&doi=10.1073%2Fpnas.97.17.9677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis</span></div><div class="casAuthors">DeBarber, Andrea E.; Mdluli, Khisimuzi; Bosman, Marlein; Bekker, Linda-Gail; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9677-9682</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ethionamide (ETA) is an important component of second-line therapy for the treatment of multidrug-resistant tuberculosis.  Synthesis of radiolabeled ETA and an examn. of drug metabolites formed by whole cells of Mycobacterium tuberculosis (MTb) have allowed the authors to demonstrate that ETA is activated by S-oxidn. before interacting with its cellular target.  ETA is metabolized by MTb to a 4-pyridylmethanol product remarkably similar in structure to that formed by the activation of isoniazid by the catalase-peroxidase KatG.  The authors demonstrated that overprodn. of Rv3855 (EtaR), a putative regulatory protein from MTb, confers ETA resistance whereas overprodn. of an adjacent, clustered monooxygenase (Rv3854c, EtaA) confers ETA hypersensitivity.  Prodn. of EtaA appears to be neg. regulated by EtaR and correlates directly with [14C]ETA metab., suggesting that EtaA is the activating enzyme responsible for thioamide oxidn. and subsequent toxicity.  Coding sequence mutations in EtaA were found in 11 of 11 multidrug-resistant MTb patient isolates from Cape Town, South Africa.  These isolates showed broad cross-resistance to thiocarbonyl contg. drugs including ETA, thiacetazone, and thiocarlide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNeMx28-Vc_bVg90H21EOLACvtfcHk0lhM05kiMNDznw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVent7s%253D&md5=3c024cae0889dd21ea67117fc1284f58</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.17.9677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.17.9677%26sid%3Dliteratum%253Aachs%26aulast%3DDeBarber%26aufirst%3DA.%2BE.%26aulast%3DMdluli%26aufirst%3DK.%26aulast%3DBosman%26aufirst%3DM.%26aulast%3DBekker%26aufirst%3DL.-G.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DEthionamide%2520activation%2520and%2520sensitivity%2520in%2520multidrug-resistant%2520mycobacterium%2520tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D9677%26epage%3D9682%26doi%3D10.1073%2Fpnas.97.17.9677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dover, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alahari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratraud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowruth, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besra, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, L.</span></span> <span> </span><span class="NLM_article-title">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1063</span>, <span class="refDoi"> DOI: 10.1128/AAC.01063-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1128%2FAAC.01063-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=17220416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=1055-1063&author=L.+G.+Doverauthor=A.+Alahariauthor=P.+Gratraudauthor=J.+M.+Gomesauthor=V.+Bhowruthauthor=R.+C.+Reynoldsauthor=G.+S.+Besraauthor=L.+Kremer&title=EthA%2C+a+common+activator+of+thiocarbamide-containing+drugs+acting+on+different+mycobacterial+targets&doi=10.1128%2FAAC.01063-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets</span></div><div class="casAuthors">Dover, Lynn G.; Alahari, Anuradha; Gratraud, Paul; Gomes, Jessica M.; Bhowruth, Veemal; Reynolds, Robert C.; Besra, Gurdyal S.; Kremer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1055-1063</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Many of the current antimycobacterial agents require some form of cellular activation unmasking reactive groups, which in turn will bind to their specific targets.  Therefore, understanding the mechanisms of activation of current antimycobacterials not only helps to decipher mechanisms of drug resistance but may also facilitate the development of alternative activation strategies or of analogs that do not require such processes.  Herein, through the use of genetically defined strains of Mycobacterium bovis BCG we provide evidence that EthA, previously shown to activate ethionamide, also converts isoxyl (ISO) and thiacetazone (TAC) into reactive species.  These results were further supported by the development of an in vitro assay using purified recombinant EthA, which allowed direct assessment of the metab. of ISO.  Interestingly, biochem. anal. of [14C]acetate-labeled cultures suggested that all of these EthA-activated drugs inhibit mycolic acid biosynthesis via different mechanisms through binding to specific targets.  This report is also the first description of the mol. mechanism of action of TAC, a thiosemicarbazone antimicrobial agent that is still used in the treatment of tuberculosis as a second-line drug in many developing countries.  Altogether, the results suggest that EthA is a common activator of thiocarbamide-contg. drugs.  The broad specificity of EthA can now be used to improve the activation process of these drugs, which may help overcome the toxicity problems assocd. with clin. thiocarbamide use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN_R6VIHikw7Vg90H21EOLACvtfcHk0lhM05kiMNDznw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12jsLY%253D&md5=e41cb13b90a0031fb69473bd1379c51a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1128%2FAAC.01063-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01063-06%26sid%3Dliteratum%253Aachs%26aulast%3DDover%26aufirst%3DL.%2BG.%26aulast%3DAlahari%26aufirst%3DA.%26aulast%3DGratraud%26aufirst%3DP.%26aulast%3DGomes%26aufirst%3DJ.%2BM.%26aulast%3DBhowruth%26aufirst%3DV.%26aulast%3DReynolds%26aufirst%3DR.%2BC.%26aulast%3DBesra%26aufirst%3DG.%2BS.%26aulast%3DKremer%26aufirst%3DL.%26atitle%3DEthA%252C%2520a%2520common%2520activator%2520of%2520thiocarbamide-containing%2520drugs%2520acting%2520on%2520different%2520mycobacterial%2520targets%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D1055%26epage%3D1063%26doi%3D10.1128%2FAAC.01063-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellington, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawate, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvis, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wivagg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazyanskaya, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nietupski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haseley, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, D. T.</span></span> <span> </span><span class="NLM_article-title">Baeyer-Villiger monooxygenases EthA and MymA are required for activation of replicating and non-replicating mycobacterium tuberculosis inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.05.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2Fj.chembiol.2016.05.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=27321573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWnsbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=666-677&author=S.+S.+Grantauthor=S.+Wellingtonauthor=T.+Kawateauthor=C.+A.+Desjardinsauthor=M.+R.+Silvisauthor=C.+Wivaggauthor=M.+Thompsonauthor=K.+Gordonauthor=E.+Kazyanskayaauthor=R.+Nietupskiauthor=N.+Haseleyauthor=N.+Iwaseauthor=A.+M.+Earlauthor=M.+Fitzgeraldauthor=D.+T.+Hung&title=Baeyer-Villiger+monooxygenases+EthA+and+MymA+are+required+for+activation+of+replicating+and+non-replicating+mycobacterium+tuberculosis+inhibitors&doi=10.1016%2Fj.chembiol.2016.05.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors</span></div><div class="casAuthors">Grant, Sarah Schmidt; Wellington, Samantha; Kawate, Tomohiko; Desjardins, Christopher A.; Silvis, Melanie R.; Wivagg, Carl; Thompson, Matthew; Gordon, Katherine; Kazyanskaya, Edward; Nietupski, Raymond; Haseley, Nathan; Iwase, Noriaki; Earl, Ashlee M.; Fitzgerald, Michael; Hung, Deborah T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">666-677</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Successful treatment of Mycobacterium tuberculosis infection typically requires a complex regimen administered over ≥6 mo.  Interestingly, many of the antibiotics used to treat M. tuberculosis are prodrugs that require intracellular activation.  Here, we describe 3 small mols., active against both replicating and non-replicating M. tuberculosis, that require activation by Baeyer-Villiger monooxygenases (BVMOs).  Two mols. require BVMO EthA (Rv3854c) for activation and the 3rd mol. requires the BVMO MymA (Rv3083).  While EthA is known to activate the antitubercular drug ethionamide, this is the 1st description of MymA as an activating enzyme of a prodrug.  Furthermore, we found that MymA also plays a role in activating ethionamide, with loss of MymA function resulting in ethionamide-resistant M. tuberculosis.  These findings suggest overlap in function and specificity of the BVMOs in M. tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIuztoncp3ybVg90H21EOLACvtfcHk0lgyGrSMtr8F_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWnsbzO&md5=d4403e9912b1dd7eb89d39d8b7825ba3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.05.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.05.011%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%2BS.%26aulast%3DWellington%26aufirst%3DS.%26aulast%3DKawate%26aufirst%3DT.%26aulast%3DDesjardins%26aufirst%3DC.%2BA.%26aulast%3DSilvis%26aufirst%3DM.%2BR.%26aulast%3DWivagg%26aufirst%3DC.%26aulast%3DThompson%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DKazyanskaya%26aufirst%3DE.%26aulast%3DNietupski%26aufirst%3DR.%26aulast%3DHaseley%26aufirst%3DN.%26aulast%3DIwase%26aufirst%3DN.%26aulast%3DEarl%26aufirst%3DA.%2BM.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DHung%26aufirst%3DD.%2BT.%26atitle%3DBaeyer-Villiger%2520monooxygenases%2520EthA%2520and%2520MymA%2520are%2520required%2520for%2520activation%2520of%2520replicating%2520and%2520non-replicating%2520mycobacterium%2520tuberculosis%2520inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D666%26epage%3D677%26doi%3D10.1016%2Fj.chembiol.2016.05.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">The library of mutant strains was kindly donated by the group of Dr. Deborah Hung. For details about the strains, see ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">An extended table with extracellular MIC, HepG2 tox, and aqueous solubility data for all the analogues synthesized is included in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, D. F. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, M.</span></span> <span> </span><span class="NLM_article-title">Compound lipophilicity for substrate binding to human P450s in drug metabolism</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">530</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03115-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1016%2FS1359-6446%2804%2903115-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=15183161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1ert78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=530-537&author=D.+F.+V.+Lewisauthor=M.+N.+Jacobsauthor=M.+Dickins&title=Compound+lipophilicity+for+substrate+binding+to+human+P450s+in+drug+metabolism&doi=10.1016%2FS1359-6446%2804%2903115-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Compound lipophilicity for substrate binding to human P450s in drug metabolism</span></div><div class="casAuthors">Lewis, David F. V.; Jacobs, Miriam N.; Dickins, Maurice</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">530-537</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Compd. lipophilicity is of key importance to P 450 binding affinity and enzyme selectivity.  Here, lipophilicity is discussed with ref. to the human drug-metabolizing P 450 enzymes of families CYP1, CYP2 and CYP3.  From an extensive compilation of log P values for P 450 substrates, and by anal. of relationships between partitioning energy and substrate-binding free energy, the relevance of lipophilicity and other factors pertaining to P 450 binding affinity is explained, leading to the formulation of lipophilicity relationships within substrates of each human P 450 enzyme involved in drug metab.  Furthermore, log P values for P 450 substrates appear to represent markers for enzyme selectivity.  Together with the important roles of hydrogen bonding and π-π stacking interaction energies, the desolvation of the P 450 active site makes a major contribution to the overall substrate-binding energy and, consequently, a good agreement with exptl. information is reported based on this anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-r8ssl6ll_bVg90H21EOLACvtfcHk0lgyGrSMtr8F_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1ert78%253D&md5=ae4f0a09265af25b77b505a1a47bbd0d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903115-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903115-0%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%26aufirst%3DD.%2BF.%2BV.%26aulast%3DJacobs%26aufirst%3DM.%2BN.%26aulast%3DDickins%26aufirst%3DM.%26atitle%3DCompound%2520lipophilicity%2520for%2520substrate%2520binding%2520to%2520human%2520P450s%2520in%2520drug%2520metabolism%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D530%26epage%3D537%26doi%3D10.1016%2FS1359-6446%2804%2903115-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rullas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrán, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardona, P.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cáceres, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Bustos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo-Barturen, I.</span></span> <span> </span><span class="NLM_article-title">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2262</span>– <span class="NLM_lpage">2264</span>, <span class="refDoi"> DOI: 10.1128/AAC.01423-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=10.1128%2FAAC.01423-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=20160054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=2262-2264&author=J.+Rullasauthor=J.+I.+Garc%C3%ADaauthor=M.+Beltr%C3%A1nauthor=P.-J.+Cardonaauthor=N.+C%C3%A1ceresauthor=J.+F.+Garc%C3%ADa-Bustosauthor=I.+Angulo-Barturen&title=Fast+standardized+therapeutic-efficacy+assay+for+drug+discovery+against+tuberculosis&doi=10.1128%2FAAC.01423-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis</span></div><div class="casAuthors">Rullas, Joaquin; Garcia, Juan Ignacio; Beltran, Manuela; Cardona, Pere-Joan; Caceres, Neus; Garcia-Bustos, Jose Francisco; Angulo-Barturen, Inigo</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2262-2264</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Murine models of Mycobacterium tuberculosis infection are essential tools in drug discovery.  Here we describe a fast standardized 9-day acute assay intended to measure the efficacy of drugs against M. tuberculosis growing in the lungs of immunocompetent mice.  This assay is highly reproducible, allows good throughput, and was validated for drug lead optimization using isoniazid, rifampin, ethambutol, pyrazinamide, linezolid, and moxifloxacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpajX5TwxQ_E7Vg90H21EOLACvtfcHk0lhOhywwWUM2zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFeltLo%253D&md5=c923fae175b34eab3778a0e4d8d51878</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FAAC.01423-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01423-09%26sid%3Dliteratum%253Aachs%26aulast%3DRullas%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa%26aufirst%3DJ.%2BI.%26aulast%3DBeltr%25C3%25A1n%26aufirst%3DM.%26aulast%3DCardona%26aufirst%3DP.-J.%26aulast%3DC%25C3%25A1ceres%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa-Bustos%26aufirst%3DJ.%2BF.%26aulast%3DAngulo-Barturen%26aufirst%3DI.%26atitle%3DFast%2520standardized%2520therapeutic-efficacy%2520assay%2520for%2520drug%2520discovery%2520against%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D2262%26epage%3D2264%26doi%3D10.1128%2FAAC.01423-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i82"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00003">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_76527"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00003?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00003</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings with associated biochemical and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_001.csv">CSV</a>)</p></li><li><p class="inline">Safety report, antimicrobial panel results, virtual site of metabolism prediction, GSH trapping experiments, and CYP450 inhibition assay for compound <b>1</b> as well as additional biochemical and biological data for compounds <b>2</b>–<b>49</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_001.csv">jm0c00003_si_001.csv (4.04 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00003/suppl_file/jm0c00003_si_002.pdf">jm0c00003_si_002.pdf (456.62 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00003&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-9%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00003%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00003" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b4c05a823d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
